Document:

<PAGE>

                                                                   EXHIBIT 10.47

                                  CONFIDENTIAL

NOTE: Certain portions of this Collaboration Agreement and its exhibits, which
are identified by the symbol "[* *]", have been omitted and filed separately
with the Securities and Exchange Commission pursuant to a confidential treatment
request.

                                DISCOVERWORKS(R)
                     DRUG DISCOVERY COLLABORATION AGREEMENT

THIS DISCOVERWORKS(R) DRUG DISCOVERY COLLABORATION AGREEMENT is made as of the
Effective Date by and between 3-Dimensional Pharmaceuticals, Inc., a Delaware
corporation having its principal place of business at Three Lower Makefield
Corporate Center, 1020 Stony Hill Road, Suite 300, Yardley, PA 19067, USA
("3DP"), and Janssen Pharmaceutica, N.V., having its place of business at
Turnhoutseweg 30, 2340 Beerse, Belgium and The R.W. Johnson Pharmaceutical
Research Institute, a division of Ortho-McNeil Pharmaceutical, Inc. having a
place of business at U.S. Route 202, Raritan, NJ 08869, USA (collectively, with
its Affiliates, referred to herein as "Janssen"). 3DP and Janssen may be
referred to herein as a "Party" or, collectively, as the "Parties." Reference to
a Party herein shall include its Affiliates (as hereinafter defined) unless
otherwise indicated.

WHEREAS, 3DP is engaged in discovery research for a variety of
biologically-active compounds and the development of technologies to facilitate
such research, and 3DP has developed and is patenting systems for identifying
and generating chemical compounds having desired pharmaceutical properties;

WHEREAS,  Janssen is engaged in research,  development and  commercialization of
biologically-active compounds for the treatment of human diseases; and

WHEREAS, 3DP and Janssen desire to enter into a research collaboration to allow
Janssen and 3DP to identify Prototype Compounds (as defined herein) active
against selected targets that may be developed and commercialized by Janssen.

NOW, THEREFORE, in consideration of the mutual promises and undertakings set
forth herein and other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, and intending to be legally bound
hereby, the Parties agree as follows:

                                    ARTICLE 1

                                   DEFINITIONS
<PAGE>

 The terms in this Agreement with initial letters capitalized, whether used in
the singular or the plural, shall have the meaning set forth below or, if not
listed below, the meaning designated in places throughout this Agreement.

         1.1      "Active Compound" means a compound(s) claimed by a Valid Claim
                  of a 3DP Patent, Joint Patent or Research Program Patent
                  Right.

         1.2      "Affiliate" means, with respect to either Party, any
                  corporation or other business entity, which controls, is
                  controlled by, or is under common control with such Party. A
                  corporation or other entity shall be regarded as in control of
                  another corporation or entity if it owns or directly or
                  indirectly controls at least fifty percent (50%) of the voting
                  stock or other ownership interest of the other corporation or
                  entity (or alternatively, such lesser percentage which is the
                  maximum allowed to be owned by a foreign corporation in a
                  particular jurisdiction), or if it possesses, directly or
                  indirectly, the power to direct or cause the direction of the
                  management and policies of the corporation or other entity or
                  the power to elect or appoint at least fifty percent (50%) of
                  the members of the governing body of the corporation or other
                  entity.

         1.3      "Agreement" means this DiscoverWorks(R) Drug Discovery
                  Collaboration Agreement, including its Schedules, as may be
                  amended from time to time.

         1.4      "Back-up Compound" means a compound selected from the Focused
                  Library which has activity against a Target, that is reserved
                  as a back-up for an Active Compound or Licensed Product having
                  activity against the same Target, and is not intended to be
                  developed or commercialized unless development and/or
                  commercialization of such Active Compound or Licensed Product
                  is terminated and such compound becomes a Replacement
                  Compound.

         1.5      "Combination Product" means a Licensed Product that includes
                  one or more active ingredients in addition to an Active
                  Compound.

         1.6      "Confidential Information" means all confidential and
                  proprietary technical and/or commercial information that has
                  or could have value or utility in a Party's business, or the
                  unauthorized disclosure of which could be detrimental to the
                  Party's interests, including information, inventions,
                  Know-how, data and materials relating to the Research Program
                  or to the Licensed Products, and shall include, without
                  limitation, research, technical, clinical development,
                  manufacturing, marketing, financial, personnel and other
                  business information and plans, whether in oral, written,
                  graphic or electronic form, except to the extent that it can
                  be established by the Receiving Party (as defined in Section
                  7.1) that such Confidential Information: (a) was already known
                  to the Receiving Party, other than under an obligation of
                  confidentiality from the Disclosing Party (as defined in
                  Section 7.1); (b) was generally available to the public or
                  otherwise part of the public domain at the time of its
                  disclosure to the Receiving Party; (c)

                                       2
<PAGE>

                  became generally available to the public or otherwise part of
                  the public domain after its disclosure and other than through
                  any act or omission of the Receiving Party in breach of this
                  Agreement; (d) was subsequently lawfully disclosed to the
                  Receiving Party by a Third Party; (e) can be shown by written
                  records to have been independently developed by or for the
                  Receiving Party without reference to the Confidential
                  Information received from the Disclosing Party and without
                  breach of any of the provisions of this Agreement; or (f) is
                  information that the Disclosing Party has specifically agreed
                  in writing that the Receiving Party may disclose.

         1.7      "Control" or "Controlled" means possession of the ability to
                  grant a license or sublicense of Patents, know-how or other
                  intangible rights as provided for herein without violating the
                  terms of any contract or other arrangements with any Third
                  Party.

         1.8      "DirectedDiversity(R)Technology" means the technology
                  described in: (a) the 3DP Patents identified in Schedule 1.8,
                                                                  ------------
                  and (b) associated proprietary 3DP know-how used to identify
                  Hits, Prototype Compounds, and Active Compounds.

         1.9      "DiscoverWorks(R) Technology" means 3DP's full panoply of drug
                  discovery and compound and library synthesis technologies,
                  including without limitation the technologies currently known
                  as DirectedDiversity(R) Technology, ThermoFluor(R) Technology,
                  3DP Synthetically Accessible Libraries and 3DP Probe
                  Libraries, notwithstanding that all such technologies and
                  resources may not be utilized under this Agreement.

         1.10     "Effective Date" means December 28, 2001.

         1.11     "Extended Research Term" means a period of time, mutually
                  agreed upon by the Parties, following conclusion of the Stage
                  A Term or Stage B Term or of an earlier Extended Research
                  Term, during which the Research Program is conducted. An
                  Extended Research Term may apply to either or both the Stage A
                  Term and the Stage B Term and is part of the Research Term.

         1.12     "Field" means the research, development and commercialization
                  of compounds for use in therapeutic, prophylactic and
                  diagnostic products in humans or animals. The Field shall
                  specifically exclude [*             *].

         1.13     "First Commercial Sale" means, with respect to a given
                  Licensed Product, the first shipment of Licensed Product for
                  use or consumption by the public of such Licensed Product in a
                  country after all required approvals, including marketing and
                  pricing approvals, have been granted by the applicable
                  governmental drug regulatory agency of such country.

                                       3
<PAGE>

         1.14     "Focused Library" means a library of compounds selected from
                  the 3DP Synthetically Accessible Library using
                  DirectedDiversity(R)Technology and synthesized by 3DP.

         1.15     "FTE" means a full time equivalent employee (i.e., one
                  full-time or multiple part-time employees aggregating to one
                  full-time employee) employed by 3DP and assigned to work on
                  the Research Program with such time and effort to constitute
                  one employee working on the Research Program on a full-time
                  basis consistent with normal business and scientific practice
                  (at least forty (40) hours per week of dedicated effort; on an
                  annual basis, at least forty (40) hours per week of dedicated
                  effort for at least forty-eight (48) weeks per year).

         1.16     "Generic Equivalent" means a pharmaceutical product that is
                  being sold in a country without infringing a claim of a Patent
                  Right covering a Licensed Product being sold hereunder by
                  Janssen, which would have infringed such claim of a Patent
                  Right, or which would have prevented a Third Party from
                  selling the same Active Compound that is part of the Licensed
                  Product, if such claim of a Patent Right were in force in that
                  country.

         1.17     "Hit" means a compound in the 3DP Probe Library having a
                  confirmed structure that (i) is identified from the screening
                  of a Target; (ii) modulates [*           *], as measured using
                  ThermoFluor(R) Technology, and (iii) passes the ThermoFluor(R)
                  validation tests set forth on Schedule 1.17.

         1.18     "IND" means an investigational new drug application filed with
                  the U.S. Food and Drug Administration or successor agency
                  ("FDA") as more fully defined in 21 C.F.R.ss.312.3, a CTX, or
                  their respective equivalents in any country.

         1.19     "Initiation of Prototype Compound Optimization" means the
                  receipt of written notice from Janssen to 3DP indicating that
                  Prototype Compound Optimization activities have been initiated
                  by Janssen for a Prototype Compound. Such notice shall, among
                  other things, specifically identify the Prototype Compound and
                  its Target, the project champion, and the site at which work
                  is being conducted.

         1.20     "Janssen Know-how" means any and all technical information,
                  inventions, developments, discoveries, software, know-how,
                  methods, techniques, formulae, data, processes and other
                  proprietary ideas, whether or not patentable or copyrightable,
                  that are first conceived, discovered, developed or reduced to
                  practice in the conduct of Prototype Compound Optimization or
                  the Janssen Research Program.

         1.21     "Janssen Patent" means those Patent Rights that claim
                  discoveries or inventions that (i) were conceived and/or
                  reduced to practice solely by Janssen employees or by a Third
                  Party acting under authority of Janssen prior to the Effective
                  Date; or (ii) were conceived and/or reduced to practice solely
                  by Janssen employees or by

                                       4
<PAGE>

                  a Third Party acting under authority of Janssen during the
                  Term but after the completion of the Research Program and the
                  [*              *] period following the Initiation of
                  Prototype Compound Optimization for each Prototype Compound,
                  on a compound-by-compound basis; and (iii) claiming a method,
                  apparatus, composition of matter, material, manufacture or
                  business method relating to Hits, Prototype Compounds, Active
                  Compound or Licensed Products.

         1.22     "Janssen Research Program" means activities of Janssen during
                  the Term that are intended to lead to the discovery of
                  compounds having activity against a Target, and the further
                  optimization, identification and/or discovery of such
                  compounds, excluding any activities of Janssen which occur
                  prior to the Effective Date or after the [* *] period
                  following the Initiation of Prototype Compound Optimization
                  for each Prototype Compound, on a compound-by-compound basis.

         1.23     "Joint Patent" means those Patent Rights that claim
                  discoveries or inventions that (i) were conceived and/or
                  reduced to practice jointly by Janssen and 3DP employees or by
                  a Third Party acting under authority of Janssen or 3DP during
                  the Term but after completion of the Research Program and the
                  [* *] period following the Initiation of Prototype Compound
                  Optimization for each Prototype Compound, on a
                  compound-by-compound basis; and (ii) claiming a method,
                  apparatus, composition of matter, material, manufacture or
                  business method relating to Hits, Prototype Compounds, Active
                  Compound or Licensed Products.

         1.24     "Joint Steering and Management Committee" or "JSMC" shall have
                  the meaning and roles ascribed to it in Article 4.

         1.25     "Know-how" means unpatented technical and other information,
                  including information comprising or relating to concepts,
                  discoveries, inventions, data, designs, formulae, ideas,
                  methods, models, assays, research plans, procedures, designs
                  for experiments and tests and results of experimentation and
                  testing (including results of research or development)
                  processes (including manufacturing processes, specifications
                  and techniques), laboratory records, chemical,
                  pharmacological, toxicological, clinical, analytical and
                  quality control data, trial data, case report forms, data
                  analyses, reports or summaries and information contained in
                  submissions to, and information from, ethical committees and
                  regulatory authorities.

         1.26     "Licensed Product" means a pharmaceutical product containing
                  an Active Compound, a Prototype Compound, a Replacement
                  Compound or a Back-Up Compound as an active ingredient.

                                       5
<PAGE>

         1.27     "Major Country" means the United States, Japan, the United
                  Kingdom, France, Germany, or Italy.

         1.28     "NDA" means a new drug application filed pursuant to 21 U.S.C.
                  Section 505(b)(1) including all documents, data and other
                  information concerning a Licensed Product which are necessary
                  for or included in, FDA approval to market a Licensed Product
                  and all supplements and amendments, including supplemental new
                  drug applications, that may be filed with respect to the
                  foregoing as more fully defined in 21 C.F.R. ss.314.50 et.
                  seq.

         1.29     "Net Sales" means the gross amounts invoiced by Janssen, its
                  Affiliates or sublicensees for sales of Licensed Product in
                  finished package form (ready for use by the ultimate consumer)
                  in the Territory to a Third Party, including, but not limited
                  to, sales to wholesalers or other customers typical in each
                  country in bona fide, arm's length transactions. In the event
                  Janssen does not sell directly to such customers in one or
                  more countries, electing instead to utilize another party as a
                  distributor to those customers, it is understood that Net
                  Sales shall include sales by the distributor rather than
                  Janssen's sales to the distributor. In determining Net Sales,
                  certain deductions may be taken against the gross amount
                  invoiced. These allowable deductions are:

                  1.29.1   (i) discounts, including cash discounts, discounts to
                           managed care or similar organizations or government
                           organizations, administrative fees paid to pharmacy
                           benefits managers; (ii) rebates paid or credited,
                           including government rebates such as Medicaid
                           chargebacks or rebates; (iii) retroactive price
                           reductions or allowances actually allowed or granted
                           from the billed amount; and (iv) commercially
                           reasonably promotional allowances actually granted to
                           customers as reflected on the same invoice as for the
                           sale of Licensed Product;

                  1.29.2   credits or allowances actually granted upon claims,
                           rejections or returns of such sales of Licensed
                           Products, including government mandated recalls and
                           recalls that Janssen reasonably believes are in the
                           best interest of the consumer, it being understood
                           that if the recalled Licensed Product is resupplied,
                           Net Sales shall be calculated based on the resupplied
                           quantities at the price previously charged, provided
                           that the cause of the recall was not due to the
                           negligence of Janssen;

                  1.29.3   taxes, duties or other governmental charges levied on
                           or measured by the billing amount when included in
                           billing, as adjusted for rebates, charge-backs and
                           refunds; and

                  1.29.4   freight, postage, shipping and insurance charges to
                           the extent included on the same invoice by Janssen or
                           its Affiliates or sublicensee for delivery of such
                           Licensed Products.

                                       6
<PAGE>

                  In the case of discounts on packages of products or services
                  which include Licensed Product in those countries of the
                  Territory in which such is legally permissible ("Packages"),
                  the discount applied to Licensed Product within the Package
                  shall be no greater than the discount determined by
                  discounting the list price of the Licensed Product in the
                  Package by the average percentage discount of list prices of
                  all products of Janssen in the same Package, calculated as
                  follows:

                        Average percentage              (     A  )
                            Discount on a        =      ( 1- --- )  x  100
                         Particular Package             (     B  )

                  where A equals the total discounted value of a particular
                  Package of products, and B equals the sum of the undiscounted
                  value of the same Package of products. Janssen shall provide
                  3DP with reasonable documentation supporting the percentage
                  discounts with respect to each product within such Package.

                  A "sale" of a Licensed Product is deemed to occur upon the
                  invoicing, or if no invoice is issued, upon the earlier of
                  shipment or transfer of title in the Licensed Product to a
                  Third Party.

                  With respect to Combination Products, Net Sales for such
                  Combination Product sold by Janssen shall be determined by the
                  Parties to this Agreement in good faith based on the relative
                  value of the Active Compound and the additional active
                  ingredients that are included in the Combination Product.

         1.30     "Patent Rights" means all U. S. patent applications or issued
                  patents, including, but not limited to, provisionals,
                  divisionals, continuations, continuations-in-part, reissues,
                  reexaminations and extensions derived therefrom, such as
                  patent term restorations, supplementary protection
                  certificates, etc., as well as all foreign patents (including
                  PCTs) and foreign patent counterparts to the foregoing.

         1.31     "Prototype Compound" means a compound discovered using
                  information obtained from a Hit in the course of Prototype
                  Compound Generation, as described in Section 2.2, having a
                  dissociation constant [* *] as determined in a dose response
                  experiment and which demonstrates a desired activity against a
                  Target in a molecular or cellular functional assay. Prototype
                  Compounds will have pharmaceutically acceptable properties as
                  determined by the JSMC prior to initiation of Prototype
                  Compound Generation and [* *]. Prototype Compounds will be
                  identified as Prototype Compounds by the JSMC within [* *] of
                  delivery of data [* *]. For purposes of clarity, the Janssen
                  may, at its discretion, select a compound as a Prototype
                  Compound even if such compound does not meet the criteria set
                  forth above.

                                       7
<PAGE>

         1.32     "Prototype Compound Generation" means a program for
                  discovering Prototype Compounds using information obtained
                  from Hits, and iterative rounds of chemistry and the 3DP
                  Synthetically Accessible Library to make Focused Libraries for
                  rescreening using ThermoFluor(R) Technology against such
                  Target as more fully described in Section 2.2.

         1.33     "Prototype Compound Optimization" means a program conducted by
                  Janssen for further optimizing, identifying and/or developing
                  a Prototype Compound or a compound discovered in the course of
                  the Janssen Research Program, to improve the
                  structure-activity relationships, potency, selectivity,
                  pharmacokinetics, pharmacodynamics and acute safety of such
                  Prototype Compound or such compound discovered in the course
                  of the Janssen Research Program, to identify an Active
                  Compound.

         1.34     "Replacement Compound" shall have the meaning attributed
                  thereto in Section 5.8.

         1.35     "Replacement Target" shall have the meaning attributed thereto
                  in Section 2.3.

         1.36     "Research Plan" means the description of the research
                  activities of the Parties for particular Targets in the
                  performance of the Research Program, including an allocation
                  of FTEs to be used for various tasks and a timeline for such
                  tasks. A draft of the Research Plan is attached hereto as
                  Schedule 1.36.
                  -------------

         1.37     "Research Program" means research activities of the Parties
                  during the Research Term, as described in Article 2, that are
                  intended to lead to the discovery of Hits and Prototype
                  Compounds, excluding Prototype Compound Optimization.

         1.38     "Research Program Know-how" means Know-how conceived or
                  developed during the conduct of the Research Program.

         1.39     "Research Program Patent Rights" means those Patent Rights
                  that claim discoveries or inventions that were conceived
                  and/or reduced to practice by Janssen or 3DP or jointly by
                  Janssen and 3DP or by a Third Party acting under authority of
                  Janssen or 3DP in the course of the Research Program or a
                  Janssen Research Program and during the [*    *]  period
                  following the Initiation of Prototype Compound Optimization
                  for each Prototype Compound on a compound-by-compound basis
                  and relating to the Research Program or Janssen Research
                  Program.

         1.40     "Research Term" shall have the meaning attributed thereto in
                  Section 10.1.

         1.41     "Stage A" means the research activities undertaken by the
                  Parties pursuant to Article 2 as part of the Research Program
                  with respect to the first and second Targets to be provided by
                  Janssen to 3DP.

                                       8
<PAGE>

         1.42     "Stage A Commencement Date" means the Effective Date.

         1.43     "Stage A Term" means the period beginning on the Stage A
                  Commencement Date through the first anniversary thereof,
                  during which Stage A of the Research Program is conducted.

         1.44     "Stage B" means the research activities undertaken by the
                  Parties pursuant to Article 2 as part of the Research Program
                  with respect to the third and fourth Targets to be provided by
                  Janssen to 3DP.

         1.45     "Stage B Commencement Date" means the date on which Janssen
                  provides written notice of the third and fourth Targets to
                  3DP.

         1.46     "Stage B Term" means the period beginning on the Stage B
                  Commencement Date through the first anniversary thereof,
                  during which Stage B of the Research Program is conducted.

         1.47     "Target" means a protein against which Hits are identified and
                  Prototype Compounds are to be optimized in the Research
                  Program. Targets, as defined herein, shall also include
                  Replacement Targets once such targets become Targets pursuant
                  to Section 2.3.

         1.48     "Term" shall have the meaning ascribed thereto in Section
                  10.2.

         1.49     "Territory" means the entire world.

         1.50     "ThermoFluor(R) Technology" means the technology described in:
                  (a) the 3DP Patents identified in Schedule 1.50, and (b)
                                                    -------------
                  associated proprietary 3DP Know-how used to evaluate ligand
                  binding parameters of Hits, Prototype Compounds, and Active
                  Compounds.

         1.51     "Third Party" means an individual, corporation or other entity
                  other than a Party or any of its Affiliates.

         1.52     "3DP Patent" means those Patent Rights that claim discoveries
                  or inventions that (i) were conceived and/or reduced to
                  practice solely by 3DP employees or by a Third Party acting
                  under authority of 3DP prior to the Effective Date; or (ii)
                  were conceived and/or reduced to practice solely by 3DP
                  employees or by a Third Party acting under authority of 3DP
                  during the Term, but after completion of the Research Program
                  and the [* *] period following the Initiation of Prototype
                  Compound Optimization for each Prototype Compound, on a
                  compound-by-compound basis; and (iii) claiming a method,
                  apparatus, composition of matter, material, manufacture or
                  business method relating to Hits, Prototype Compounds, Active
                  Compound or Licensed Products.

                                       9
<PAGE>

         1.53     "3DP Probe Library" means the sample compound library or any
                  subset thereof, comprised of proprietary and non-proprietary
                  compounds which are owned or Controlled by 3DP or to the
                  extent not encumbered by a bona fide third party interest,
                  that have been synthesized for the purposes of fulfilling
                  3DP's obligations under this Agreement, which is used for the
                  screening of Targets using ThermoFluor(R) Technology for the
                  purpose of identification of Hits, Prototype Compounds, or
                  Active Compounds. While the individual non-proprietary
                  compounds in the 3DP Probe Library are not proprietary, the
                  collection itself, and the list, as a whole, of
                  non-proprietary compounds included in the collection, are the
                  "Confidential Information" of 3DP.

         1.54     "3DP Synthetically Accessible Library" means 3DP's virtual
                  compound library as it exists from time to time from which 3DP
                  Probe Libraries have been selected, and from which Focused
                  Libraries will be selected.

         1.55     "Valid Claim" means (a) a claim of an issued and unexpired
                  patent included within the Patent Rights, which has not been
                  held permanently revoked, unenforceable or invalid by a
                  decision of a court or other governmental agency of competent
                  jurisdiction, unappealable or unappealed within the time
                  allowed for appeal, and which has not been admitted to be
                  invalid or unenforceable through reissue or disclaimer or
                  otherwise, or (b) a claim of a pending patent application
                  included within the Patent Rights, which claim was filed in
                  good faith and has not been abandoned or finally disallowed
                  without the possibility of appeal or refiling of such
                  application; provided, however, if a claim of a pending
                  application included within the Patent Rights has not issued
                  within six (6) years after the filing date from which such
                  claim takes priority, such claim of a pending application
                  shall no longer be a Valid Claim for purposes of this
                  definition until such patent application issues.

                                    ARTICLE 2

                                RESEARCH PROGRAM

         2.1      Supply of Targets. Janssen shall supply 3DP with four (4)
                  Targets, the first and second of which are identified in
                  Schedule 2.1 attached hereto, in quantities and of quality
                  ------------
                  sufficient to perform the Research Program pursuant to the
                  Research Plan. The third and fourth Targets shall be provided
                  to 3DP by Janssen no later than [* *], or as otherwise agreed
                  by the Parties. All such Targets shall be supplied to 3DP in
                  the form of proteins.

         2.2      Prototype Compound Generation. Depending on the nature and
                  source of each Target, 3DP will have the following
                  obligations. 3DP shall initially screen the Target against a
                  screening library, selected by 3DP from the 3DP Probe Library
                  and totaling approximately one hundred thousand (100,000)
                  compounds per Target. If such initial screening produces no
                  Hits, the JSMC may ask 3DP to

                                       10
<PAGE>

                  perform a secondary screen of a reasonable number of
                  additional compounds from the 3DP Probe Library and 3DP will
                  undertake such secondary screen. If the initial screening or
                  the secondary screening produces Hits, 3DP will undertake
                  rounds of iterative chemistry. Each round will include the
                  synthesis of Focused Libraries containing up to [* *] but not
                  less than [* *] compounds (unless such compounds are subject
                  to the limitations set forth in Schedule 2.2 or such other
                                                  ------------
                  maximum and minimum compound numbers as the Parties may agree
                  upon) per round. 3DP shall continue to perform iterative
                  rounds of chemistry until the first to occur of the following:

                  2.2.1    a Prototype Compound is identified in accordance with
                           Section 1.28; or

                  2.2.2    a maximum of [* *] total rounds of iterative
                           chemistry are performed to generate Focused Libraries
                           from the 3DP Synthetically Accessible Library; or

                  2.2.3    a maximum of [* *] compounds contained in Focused
                           Libraries are synthesized and screened using
                           DiscoverWorks(R) Technology from the 3DP
                           Synthetically Accessible Library.

         2.3      Replacement Targets.

                  2.3.1    If neither initial screening nor the secondary
                           screening of the compounds from the 3DP Probe Library
                           produces any Hits against that Target, then Janssen
                           may identify, subject to approval by 3DP and the
                           JSMC, a replacement Target ("Replacement Target")
                           against which 3DP will conduct Prototype Compound
                           Generation pursuant to Section 2.2 for the remainder
                           of the applicable Stage A Term or Stage B Term.

                  2.3.2    If Prototype Compound Generation of such Replacement
                           Target is incomplete at the end of the applicable
                           Stage A Term or Stage B Term, then at Janssen's
                           request, 3DP will continue and complete the Prototype
                           Compound Generation pursuant to Section 2.2 for such
                           Replacement Target at the same FTE rate of
                           compensation paid to 3DP as recited in Section 5.2.

                  2.3.3    Janssen may select a total of up to [* *] Replacement
                           Targets pursuant to the provisions of this Section
                           2.3.

                  2.3.4    Any Replacement Targets identified by Janssen may be
                           disapproved by 3DP only (i) in order to avoid
                           potential conflicts with respect to prior contractual
                           obligations and current internal 3DP programs, (ii)
                           for lack of suitability with ThermoFluor(R)
                           Technology, (iii) because 3DP reasonably believes
                           that use of such Replacement Target would infringe a
                           valid and enforceable third party patent, or (iv)
                           because the Target is for the primary

                                       11
<PAGE>

                           purpose of identifying drugs specifically intended
                           for [*     *].

         2.4      Prototype Compounds. Upon identification of a Prototype
                  Compound in accordance with Section 1.28, (a) the Prototype
                  Compound, along with all Back-Up Compounds shall be licensed
                  to Janssen for Prototype Compound Optimization and further
                  development and commercialization as provided in Section 6.4
                  herein and (b) 3DP shall provide Janssen with the structure
                  and protocol for synthesis of such Prototype Compound within
                  [* *] of the JSMC identifying it as a Prototype Compound.
                  Janssen shall promptly inform 3DP upon Initiation of Prototype
                  Compound Optimization.

         2.5      Back-up Compounds. On a Target-by-Target basis, upon
                  identification of a Prototype Compound, all the Compounds in
                  the Focused Libraries having activity against such Target
                  equivalent or better than the activity needed to be considered
                  a Hit against that Target shall constitute Back-Up Compounds.
                  On the first anniversary of initiation of Prototype Compound
                  Optimization for a Prototype Compound that has activity
                  against a Target, Janssen shall identify a total of up to
                  [* *] compounds from the Focused Libraries having activity
                  against the same Target to be designated as Back-up Compounds.
                  On the second anniversary of initiation of Prototype Compound
                  Optimization for such Prototype Compound, Janssen shall
                  identify a total of up to [* *] compounds from the [* *]
                  compounds previously identified and having activity against
                  the same Target to be designated Back-up Compounds. If a
                  Back-up Compound is selected for development as a Replacement
                  Compound, the [* *] period following the initiation of
                  Prototype Compound Optimization for each Prototype Compound on
                  a compound-by-compound basis during which Janssen Know-how
                  shall be disclosed by Janssen to 3DP for 3DP to prepare, file,
                  prosecute and maintain Research Program Patent Rights pursuant
                  to Article 8, will be deemed to have restarted on the date of
                  notification of such selection.

         2.6      No Grant of License to DiscoverWorks(R) Technology.
                  Notwithstanding any provision to the contrary in this
                  Agreement, no license to any portion of the DiscoverWorks(R)
                  Technology, including any related Know-how, is hereby granted
                  by 3DP to Janssen under this Agreement or otherwise.

                                   ARTICLE 3

                        RESEARCH AND DEVELOPMENT EFFORTS

         3.1      Research Efforts. Each Party shall use commercially reasonable
                  efforts to perform its responsibilities and fulfill its
                  obligations under this Agreement. As used herein, the term
                  "commercially reasonable efforts" will mean efforts

                                       12
<PAGE>

                  consistent with such Party's normal scientific and business
                  practice, as applied to other programs of similar scientific
                  and commercial potential.

         3.2      Allocation of FTEs. 3DP shall dedicate, and Janssen shall
                  fund, [* *] FTEs to Stage A of the Research Program for the
                  Stage A Term and [* *] FTEs to Stage B of the Research Program
                  for the Stage B Term, unless otherwise agreed by the Parties
                  in writing.

         3.3      Disclosure of Research Program Results. The JSMC will provide
                  quarterly written reports to the Parties presenting a
                  meaningful summary of the work performed on the Research
                  Program and Prototype Compound Optimization. In addition, on
                  reasonable request by Janssen or 3DP, 3DP or Janssen will make
                  presentations to the JSMC of its activities under this
                  Agreement to inform the JSMC of the details of the work done
                  under this Agreement during the Research Term and the [* *]
                  period following the Initiation of Prototype Compound
                  Optimization for each Prototype Compound, on a
                  compound-by-compound basis. Know-how and other information
                  regarding the Research Program or Prototype Compound
                  Optimization disclosed by one Party to the other Party
                  pursuant hereto may be used only in accordance with the rights
                  granted under this Agreement. Within thirty (30) days
                  following the end of each calendar quarter, the Parties shall
                  each exchange and provide to the JSMC chairperson and
                  secretary a written report summarizing in reasonable detail
                  the work performed by it under the Research Program or
                  Prototype Compound Optimization during the preceding calendar
                  quarter.

         3.4      Prototype Compound Optimization Continuing Report
                  Responsibility. For each compound identified as a Prototype
                  Compound or Active Compound, Janssen shall, until the issuance
                  of the last Research Program Patent Right, provide a report of
                  its activities, and/or those of its Affiliates and
                  sublicensees, toward the development, use and/or
                  commercialization of such Prototype Compound or Active
                  Compound. Such report relating to Prototype Compound
                  Optimization shall be submitted to 3DP semi-annually and shall
                  set forth in reasonable detail, with supporting data, the
                  results of work performed on such compound, including, without
                  limitation, all material information and data generated during
                  such period not previously provided to 3DP pursuant to Section
                  8.3, reasonably necessary to enable 3DP to prepare, file,
                  prosecute and maintain Research Program Patent Rights. If no
                  results of work performed on such compound have been obtained
                  by Janssen during the six-month period after the preceding
                  semi-annual report, Janssen will so inform 3DP. In no event
                  shall Janssen provide such a report relating to Prototype
                  Compound Optimization less frequently than semi-annually.
                  After achievement of the milestone in Section 5.7.2 for an
                  Active Compound, Janssen will thereafter provide to 3DP
                  reports relating to such Active Compound annually. Janssen
                  will provide timely notice, in good faith, of its decision to
                  discontinue its and/or its Affiliates' and

                                       13
<PAGE>

                  sublicensees' activities toward the development, use and/or
                  commercialization of a Prototype Compound, Active Compound
                  and/or Licensed Product.

         3.5      Material Transfer. In order to facilitate the Research
                  Program, either Party (a "Supplying Party") may provide to the
                  other Party (a "Receiving Party") certain information
                  (including chemical structures), biological materials or
                  chemical compounds, including without limitation any compounds
                  from the 3DP Synthetically Accessible Library, 3DP Probe
                  Library or Focused Library (collectively, the "Substances")
                  owned by or licensed to the Supplying Party (other than under
                  this Agreement) and available for use by either Party in
                  furtherance of the Research Program. Except as otherwise
                  provided under this Agreement, all information or Substances
                  delivered to the Receiving Party shall remain the sole
                  property of the Supplying Party, shall be used only in
                  furtherance of the Research Program and shall be solely under
                  the control of the Receiving Party, shall not be used or
                  delivered to or for the benefit of any Third Party without the
                  prior written consent of the Supplying Party, and shall not be
                  used in research or testing involving human subjects except
                  pursuant to an approved Janssen clinical trial. Because not
                  all of their characteristics may be known, the Substances
                  supplied under this Section 3.6 must be used with prudence and
                  appropriate caution in any experimental work. THE SUBSTANCES
                  ARE PROVIDED "AS IS" AND WITHOUT ANY REPRESENTATION OR
                  WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY
                  IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY
                  PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE
                  SUBSTANCES WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER
                  PROPRIETARY RIGHTS OF ANY THIRD PARTY.

         3.6      Insurance. Each party shall maintain appropriate insurance
                  with respect to its activities hereunder, in amounts customary
                  in the pharmaceutical and biotechnology industries.

         3.7      Liability. Each Party shall be responsible for, and hereby
                  assumes, any and all risks of personal injury or property
                  damage attributable to the gross negligent or willful acts or
                  omissions, during the term of the Research Program, of that
                  Party or its Affiliates, and their respective directors,
                  officers, employees and agents.

                                   ARTICLE 4

                           RESEARCH PROGRAM GOVERNANCE

         4.1      Joint Steering and Management Committee. 3DP and Janssen agree
                  to establish a Joint Steering and Management Committee (the
                  "JSMC"), and shall each designate three members selected by
                  their respective R&D management to form the JSMC. The
                  chairperson of the JSMC shall be selected by Janssen. 3DP

                                       14
<PAGE>

                  shall select the secretary to the JSMC. Each Party may replace
                  its representatives at any time, upon notice to the other
                  Party. Any member of the JSMC may designate a substitute to
                  attend and perform the functions of that member at any meeting
                  of the JSMC. The JSMC shall review the Research Plan for the
                  Stage A Term within 30 days after the Effective Date.
                  Thereafter, the Research Plan shall be updated by the JSMC in
                  writing as changes are made to the Research Program on at
                  least an annual basis.

         4.2      Responsibilities of the JSMC. The JSMC shall be responsible
                  for:

                  4.2.1    Adopting, reviewing and amending the Research Plan to
                           implement the Research Program;

                  4.2.2    Overseeing the progress of research in the Research
                           Program;

                  4.2.3    Monitoring Prototype Compound Optimization and the
                           Janssen Research Program and providing a forum for
                           meetings and updates relating to Prototype Compound
                           Optimization and the Janssen Research Program until
                           the issuance of the last Research Program Patent
                           Right;

                  4.2.4    Allocation of funded FTEs across the Targets, and
                           within each Target;

                  4.2.5    Reviewing results from the screening of the 3DP Probe
                           Library and Focused Libraries in connection with
                           selecting the additional compounds from the 3DP Probe
                           Library to be screened by 3DP or synthesized by 3DP,
                           and the identification of Hits and Prototype
                           Compounds;

                  4.2.6    Defining quality criteria for identification of Hits
                           and Prototype Compounds pursuant to Sections 1.29 and
                           1.16; such criteria to be defined within sixty (60)
                           days after the Effective Date; and

                  4.2.7    Reviewing and approving publications and other public
                           disclosures related to the subject matter of the
                           Research Program.

         4.3      JSMC Meetings. During the Research Term, the JSMC shall meet
                  in person or by teleconference on a calendar quarter basis
                  (provided that at least one meeting per year shall be in
                  person) or more frequently as necessary and as may be agreed
                  upon, with each Party bearing all travel and related costs for
                  its representatives. After the end of the Research Term, but
                  during the [* *] period following the initiation of Prototype
                  Compound Optimization for each Prototype Compound, on a
                  compound-by-compound basis, the JSMC shall meet in person or
                  by teleconference at least semi-annually. Thereafter, the JSMC
                  shall meet on an ad hoc basis as needed to perform the
                  responsibilities designated to the JSMC. In addition to
                  periodic meetings, the members of the JSMC shall communicate
                  regularly by telephone, electronic mail, facsimile, or other
                  method, as deemed necessary or appropriate.

                                       15
<PAGE>

         4.4      JSMC Decision-Making Process. Each Party shall have one vote
                  on all matters decided by the JSMC, and decisions by the JSMC
                  shall be made by unanimous vote of the parties. The Parties
                  shall attempt to resolve any disagreement between the Parties
                  within the JSMC using the objectives and principles of this
                  Agreement as the basis for settling such disputes. Any
                  disagreement that cannot be resolved by a vote of the JSMC
                  shall be subject to the procedures set forth in Article 13.

         4.5      Minutes of JSMC Meetings. Within two (2) weeks after each JSMC
                  meeting, the secretary of the JSMC shall prepare and
                  distribute minutes of the meeting, which shall provide a
                  description in reasonable detail of the discussions had at the
                  meeting and a list of any actions, decisions or determinations
                  approved by the JSMC. The JSMC secretary shall be responsible
                  for circulation of all draft and final minutes. Draft minutes
                  shall be first circulated to the chairperson, edited by the
                  chairperson and then circulated in final draft form to all
                  members of the JSMC sufficiently in advance of the next
                  meeting to allow adequate review and comment prior to the
                  meeting. Minutes shall be approved or disapproved, and revised
                  as necessary, at the next meeting of the JSMC. Final minutes
                  shall be distributed to the members of the JSMC.

         4.6      Management of Matters Outside the Jurisdiction of the JSMC.
                  Matters outside the scope of the Research Program and internal
                  to each Party are not under the purview of the JSMC. Such
                  matters include, but are not limited to the following:
                  internal personnel policies and programs; budgeting, finance,
                  commercial and marketing strategies; Prototype Compound
                  Optimization; and development and commercialization decisions.
                  However, the Parties may, at their sole discretion,
                  communicate with each other on those matters which, while
                  outside the scope of the Research Program, influence the
                  conduct or term of the Research Program or the development or
                  commercialization of any Hit, Prototype Compound, or Active
                  Compound.

                                   ARTICLE 5

                                 FINANCIAL TERMS

         5.1      Technology Access Fee. Janssen agrees to pay a nonrefundable
                  technology access fee of [* *] within thirty (30) days after
                  the Effective Date.

         5.2      FTE Reimbursement Fees.

                  5.2.1    Janssen agrees to pay 3DP for [* *] Stage A FTEs at a
                           rate of [* *] per FTE per year. Such funding shall be
                           payable by Janssen to 3DP in a single nonrefundable
                           payment of [* *] by same day wire transfer and shall
                           be paid concurrently with the Technology Access Fee.

                                       16
<PAGE>

                  5.2.2    Janssen agrees to pay 3DP for [* *] Stage B FTEs [*
                           *] per FTE per year. Such funding shall be payable by
                           Janssen to 3DP in a single nonrefundable payment of
                           [* *] by same day wire transfer and shall be paid
                           concurrently with the Technology Access Fee.

         5.3      Costs. Except as otherwise provided in this Agreement, or as
                  may be agreed from time to time by the Parties in writing, 3DP
                  and Janssen will each bear all of its own expenses incurred in
                  connection with the Research Program including but not limited
                  to any capital expenses for equipment to carry out the
                  Research Program.

         5.4      Extended Term Fees. The level of reimbursement for FTEs in any
                  Extended Research Term shall be negotiated in good faith by
                  the Parties.

         5.5      Research Audit. 3DP shall maintain complete and accurate
                  records tracking the number of FTEs carrying out the Research
                  Program. During the Research Term and for one year thereafter,
                  upon Janssen's reasonable request, 3DP shall make such records
                  available no more than twice a year during normal business
                  hours for examination at Janssen 's expense for the sole
                  purpose of verifying for Janssen whether or not 3DP is using
                  the average required number of FTEs to carry out the Research
                  Program as specified in the Research Plan. Should it be
                  determined that 3DP has used fewer than the required FTEs
                  during any period of the Research Term, Janssen shall receive
                  a credit for the lost FTE time against any future payments
                  owed to 3DP (or if the Parties mutually agree, the lost FTE
                  time will be made up in subsequent quarters); or if no future
                  payments will be owed by Janssen to 3DP, a payment shall be
                  made by 3DP to Janssen for the lost FTE time.

         5.6      Fees for Early Termination of the Research Program. If Janssen
                  terminates the Research Program without cause, pursuant to the
                  provisions of Section 10.3, prior to the end of the Research
                  Term, Janssen agrees to pay to 3DP a termination fee equal to
                  [* *].

         5.7      Milestone Payments. The following milestones shall become due
                  and payable by Janssen to 3DP within sixty (60) days after
                  accomplishment of the following milestones:

                  5.7.1    Upon the identification by the JSMC of the first
                           Prototype Compound for each Target: [* *];

                  5.7.2    Upon submission of an IND and expiration of the
                           thirty (30) day waiting period without disapproval by
                           the FDA or its foreign counterpart for each Active
                           Compound: [* *]; and

                                       17
<PAGE>

                  5.7.3    Upon filing and acceptance by the FDA of an NDA for
                           each Active Compound: [* *].

         5.8      Milestone Payment Credit. In the event that any milestone
                  payment is made pursuant to Section 5.7 with respect to a
                  Prototype Compound or Active Compound selected for development
                  (an "Original Compound"), where, after the payment of any such
                  milestones, such development terminates and, at any time after
                  such termination, a Back-up Compound is selected for
                  development (a "Replacement Compound"), then Janssen shall be
                  entitled to a credit against milestone payments due with
                  respect to the Replacement Compound, in the amount equal to
                  all milestone payments actually paid with respect to the
                  Original Compound prior to termination of development of such
                  Original Compound.

         5.9      Milestone Press Release. Within ten (10) days of the
                  achievement of the milestone(s) set forth in Section 5.7, 3DP
                  shall, at its discretion and subject to Janssen's prior
                  written approval (such approval not to be unreasonably
                  withheld or delayed) issue a press release announcing, by way
                  of example, the achievement of a milestone, the identification
                  of a Prototype Compound (excluding any structural
                  information), and such other information as mutually agreed by
                  the Parties.

         5.10     Royalty Rate. Janssen shall pay 3DP a royalty of [* *] on
                  annual Net Sales.

         5.11     Royalty Rate Reduction.

                  5.11.1   Generic Equivalent. If, in any quarterly royalty
                           reporting period, (i) a third Party commences selling
                           a product which is a Generic Equivalent of the
                           Licensed Product in a country in the Territory and
                           (ii) such Unlicensed Unit Sales (as defined below)
                           amount to the following percentages of Janssen's Unit
                           Sales of the Licensed Product in such country in the
                           same royalty reporting period, the royalty rate on
                           Net Sales shall be reduced in such country in
                           accordance with the percentages below and such lower
                           royalty rate shall then apply on the Net Sales in
                           such country as long as the Unlicensed Unit Sales
                           amount to the particular percentage of Janssen's Unit
                           Sales of the Licensed Product in such country in the
                           same royalty reporting period.

                           Unlicensed Unit Sales         Royalty Rate Reduction*

                           (as a % of Janssen Unit Sales)   (% of Royalty Rate)
                           ------------------------------    -------------------

                           [*                   *]           [*               *]

                           [*                   *]           [*               *]

                                       18
<PAGE>

                           [*                   *]           [*               *]

                           * A royalty rate reduction will, however, only be
                           applicable if Janssen also experiences a decrease in
                           Net Sales of the applicable Licensed Product in that
                           country from the Net Sales of the applicable Licensed
                           Product in the same royalty reporting period in the
                           previous calendar year in the same country.

                           For purposes of this Section 5.11.1, (i) "Unlicensed
                           Unit Sales" and "Janssen Unit Sales" shall be deemed
                           to mean the total grams of the Active Compound
                           contained in the Third Party product (irrespective of
                           dosage form) and the Licensed Product (irrespective
                           of dosage form), respectively, as reflected on the
                           label of each such Licensed Product and Third Party
                           product; and (ii) Unlicensed Unit Sales shall be
                           determined by the sales reports of IMS America Ltd.
                           of Plymouth Meeting, Pennsylvania ("IMS") or any
                           successor to IMS or any other independent sales
                           auditing firm selected by Janssen and reasonably
                           acceptable to 3DP. Janssen shall bear all costs of
                           providing 3DP with such information. If Janssen is
                           entitled to a royalty reduction based on Unlicensed
                           Unit Sales pursuant to this Section 5.11.1 for any
                           royalty reporting period, Janssen shall submit the
                           sales report of IMS or such other independent firm,
                           as applicable, for the relevant royalty reporting
                           period to 3DP, together with Janssen 's or its
                           Affiliates' or sublicensees' sales report for the
                           relevant royalty reporting period. Such sales reports
                           for each royalty reporting period in which Janssen is
                           entitled to such royalty reduction shall be submitted
                           with the royalty report for such royalty reporting
                           period submitted pursuant to Section 5.15.

                  5.11.2   Third Party Patents. If Patent Rights of a Third
                           Party should exist in any country during the Term
                           which are required to manufacture, use sell the
                           Licensed Product, and if it should prove in Janssen's
                           reasonable judgment (as supported by an opinion from
                           outside patent counsel which counsel is acceptable to
                           both Parties) impractical or impossible for Janssen,
                           its Affiliates or its sublicensee to continue the
                           activity or activities licensed hereunder without
                           obtaining a royalty bearing license from such Third
                           Party under such Patent Rights in said country, then
                           Janssen shall be entitled to a credit against the
                           royalty payments due hereunder of an amount equal to
                           the royalty paid to such Third Party, not to exceed
                           [* *] of the royalty rate due under this Agreement,
                           arising from the manufacture, use or sale of the
                           Licensed Product in said country.

                  5.11.3   Compulsory License. If at any time and from time to
                           time a Third Party in any country shall, under the
                           right of a compulsory license granted or ordered to
                           be granted by a competent governmental authority,

                                       19
<PAGE>

                           manufacture, use or sell any Licensed Product, with
                           respect to which royalties would be payable pursuant
                           to Section 5.10 hereof, then Janssen may reduce the
                           royalty on sales in such country of such Licensed
                           Product according to the rates specified in Section
                           5.11.1.

         5.12     Royalty Period. The royalty payments set forth in Section 5.9
                  shall be payable for each Licensed Product on a
                  product-by-product and country-by-country basis from the time
                  of First Commercial Sale of Licensed Product in such country
                  until the later of: (a) [* *] from the time of First
                  Commercial Sale of Licensed Product in such country; or (b)
                  until the last-to-expire or -lapse of Patent Rights containing
                  a Valid Claim with respect to the Active Compound (including
                  without limitation a Replacement Compound) which is an
                  ingredient of such Licensed Product in such country.

         5.13     Royalty Conditions. No royalties shall be due upon the sale or
                  other transfer among Janssen, its Affiliates, licensees or
                  sublicensees, but in such cases the royalty shall be due and
                  calculated upon Janssen's or its Affiliate's, licensee's or
                  sublicensee's Net Sales of Licensed Product to the first
                  independent Third Party.

         5.14     Mode of Payment. All payments to 3DP hereunder shall be made
                  by wire transfer of United States Dollars in the requisite
                  amount to the account designated by 3DP which is attached
                  hereto as Schedule 5.14; provided, however, that any notice by
                            -------------
                  3DP of a change in such account shall not be effective until
                  thirty (30) days after receipt thereof by Janssen. Payments
                  shall be free and clear of any taxes due by Janssen (other
                  than withholding and other taxes imposed on 3DP), fees or
                  charges, to the extent applicable. For purposes of computing
                  royalty payments for Net Sales made outside of the United
                  States, such royalties shall be converted into U.S. Dollars,
                  by applying the rate of exchange as used by Janssen's global
                  accounting system which reflects the average exchange rate for
                  the applicable payment period.

         5.15     Quarterly Royalty Reports. During the Term and commencing with
                  the First Commercial Sale of each Licensed Product, Janssen
                  shall furnish or cause to be furnished to 3DP on a quarterly
                  basis, a written report or reports covering each quarter (each
                  such quarter being sometimes referred to herein as a
                  "reporting period") showing:

                  5.15.1   Gross invoiced sales and total deductions used to
                           calculate Net Sales of each Licensed Product sold by
                           Janssen and its sublicensees during the reporting
                           period on a country-by-country basis. For the United
                           States only, twice per calendar year, Janssen shall
                           provide to 3DP a report showing all itemized
                           deductions from gross sales to Net Sales. In any
                           Major Country or country which represents ten percent
                           (10%) or more of world wide gross invoiced sales
                           (other than the United States), to the extent that
                           there are significant variances in total deductions
                           from gross

                                       20
<PAGE>

                           invoiced sales to Net Sales from one quarter to
                           another, Janssen shall, at 3DP's reasonable request,
                           provide a reasonably detailed explanation as to such
                           increase.

                  5.15.2   The royalties, payable in U.S. Dollars, which shall
                           have accrued hereunder in respect of such Net Sales.

                  5.15.3   The exchange rates used, if any, in converting into
                           U.S. Dollars, from the currencies in which sales were
                           made.

                  5.15.4   Dispositions of such Licensed Product other than
                           pursuant to sale for cash, if such data is normally
                           reported in royalty reports of other licensed
                           products.

                  5.15.5   Any withholding taxes required to be paid from such
                           royalties.

         5.16     Royalty Payment Due Date; Accrual. Royalties which have
                  accrued during any month and are required to be shown on a
                  final quarterly sales report provided for hereunder shall be
                  due and payable on the date such final quarterly sales report
                  is due. In addition, at the end of each calendar year in which
                  royalties are paid hereunder, Janssen agrees to reconcile
                  estimated or accrued rebates and discounts taken during such
                  calendar year in accordance with its standard reconciliation
                  practices and make any necessary adjustment in the next
                  calendar quarter in which royalties are due and payable.

         5.17     Royalty Report Timing. Janssen shall provide flash sales
                  reports to 3DP [* *] after the close of each reporting period,
                  and final reports shall be due [* *] following the close of
                  each reporting period.

         5.18     Currency Exchange. In the case of sales of any Licensed
                  Product outside the United States, royalty payments by Janssen
                  to 3DP shall be converted to U.S. Dollars in accordance with
                  Janssen's current customary and usual procedures for
                  calculating same which are the following: the rate of currency
                  conversion shall be calculated using a simple monthly period
                  average of the end "spot rates" provided by Brown Brothers
                  Harriman, 59 Wall Street, NY, NY 10005, for each quarter, or
                  if such rate is not available, the spot rate as published by a
                  leading United States commercial bank for such accounting
                  period. This method of conversion is consistent with Janssen's
                  current accounting methods. Janssen shall give 3DP prompt
                  written notice of any changes to Janssen's customary and usual
                  procedures for currency conversion, which shall only apply
                  after such notice has been delivered and provided that such
                  changes continue to maintain a set methodology for currency
                  conversion.

                                       21
<PAGE>

         5.19     Records Retention. With respect to any products for which
                  royalties are due pursuant to this Agreement, Janssen and its
                  Affiliates and any licensees or sublicensees shall keep
                  records, for two (2) years, of such Net Sales in sufficient
                  detail to confirm the accuracy of the royalty calculations
                  hereunder. At the request of 3DP, Janssen shall permit an
                  independent certified accountant of nationally recognized
                  standing appointed by 3DP and reasonably acceptable to
                  Janssen, during normal business hours and upon reasonable
                  notice, to examine these records solely to the extent
                  necessary to verify such calculations. Such investigation
                  shall be at the expense of 3DP unless it reveals a discrepancy
                  in Janssen's favor of more than [* *], in which event it shall
                  be at Janssen's expense.

         5.20     Taxes. The Party receiving royalties and other payments under
                  this Agreement shall pay any and all taxes levied on account
                  of such payment. If any taxes are required to be withheld by
                  the paying Party, it shall: (a) deduct such taxes from the
                  remitting payment, (b) pay the taxes, in a timely manner, to
                  the proper taxing authority, and (c) send proof of payment to
                  the other Party and certify its receipt by the taxing
                  authority within sixty (60) days following such payment.

                                   ARTICLE 6

                       OWNERSHIP; GRANT OF LICENSE RIGHTS

         6.1      Ownership of Libraries. 3DP shall retain its ownership rights
                  to the compounds in the 3DP Probe Library and the 3DP
                  Synthetically Accessible Library and in any Focused Library
                  developed by 3DP pursuant to this Agreement.

         6.2      No Reverse Engineering. Janssen shall not, and shall not cause
                  or assist any Third Party to, use any data or information
                  derived from the Research Program or the 3DP Probe Library or
                  the 3DP Synthetically Accessible Library to design, create or
                  supplement a compound library.

         6.3      Ownership of Targets. Janssen shall retain any ownership
                  rights Janssen may have in any Targets Janssen provides to 3DP
                  pursuant to this Agreement, and 3DP shall have a right to use
                  such Targets solely for the purpose of performing its
                  obligations under the Research Program pursuant to the terms
                  of this Agreement. During the Research Term [* *], 3DP
                  shall not use Targets in any work it conducts with Third
                  Parties. During the Research Term [* *], 3DP shall not enter
                  into a drug discovery or development agreement with any Third
                  Party on the same Target or Targets.

         6.4      Ownership of Hits and Prototype Compounds; Janssen Exclusive
                  License. 3DP shall retain any proprietary rights, title and
                  interest in and appurtenant to Hits, Prototype Compounds and
                  any other compounds in the Focused Library; provided, however,
                  that Janssen shall have an exclusive, worldwide license under

                                       22
<PAGE>

                  3DP Patents, Joint Patents and Research Program Patent Rights
                  (even as to 3DP), with the right to sublicense, to conduct
                  research, develop, make, have made, use, sell, have sold,
                  offer for sale or import Prototype Compounds, Replacement
                  Compounds, Active Compounds, Back-Up Compound or Licensed
                  Products in the Field. Notwithstanding the foregoing, 3DP
                  shall retain the right to use any Prototype Compounds, Back-up
                  Compounds, Replacement Compounds, Active Compounds, or any
                  other compounds in the Focused Library that are used in
                  Licensed Products to conduct research; provided, however, that
                  3DP shall not publish results of such research and shall not
                  provide Active Compounds, Prototype Compounds, Replacement
                  Compounds, or Back-Up Compounds to any Third Party during the
                  Term [* *].

                                   ARTICLE 7

                            CONFIDENTIAL INFORMATION

         7.1      Confidentiality Obligations. The Parties agree that, for the
                  Term and for five (5) years thereafter, either Party (a
                  "Receiving Party") that receives Confidential Information from
                  the other Party (a "Disclosing Party") shall keep, and shall
                  endeavor to ensure that its officers, directors and employees
                  keep, confidential and shall not publish or otherwise disclose
                  and shall not use for any purpose (except as expressly
                  permitted hereunder) any Confidential Information furnished to
                  it by the Disclosing Party pursuant to this Agreement
                  (including without limitation, Know-how). The obligations of
                  confidentiality and non-use set forth in this Section 7.1
                  shall also apply to biological material and chemical compounds
                  and associated information (including, without limitation,
                  Know-how) disclosed by one Party to the other prior to or
                  during the Term; provided however, that such obligation of
                  confidentiality and non-use shall not apply to Janssen with
                  respect to compounds that are assigned to Janssen or
                  exclusively licensed to Janssen by 3DP.

         7.2      Written Assurances and Permitted Uses of Confidential
                  Information.

                  7.2.1    Each Party shall inform its employees and consultants
                           who perform work on the Research Program, of the
                           obligations of confidentiality specified in Section
                           7.1 and all such persons shall be bound by the terms
                           of confidentiality set forth therein.

                  7.2.2    The Receiving Party may disclose the Disclosing
                           Party's Confidential Information to the extent the
                           Receiving Party is compelled to disclose such
                           information by a judicial or administrative authority
                           of competent jurisdiction, including but not limited
                           to submitting information to tax authorities or
                           complying with any discovery or similar request for
                           production of documents in litigation or similar
                           alternative dispute resolution proceedings; provided
                           however, that in such case the Receiving

                                       23
<PAGE>

                           Party shall give notice, in a timely fashion, to the
                           Disclosing Party so that the Disclosing Party may
                           seek a protective order or other remedy from said
                           authority. In any event, the Receiving Party shall
                           disclose only that portion of the Confidential
                           Information that, in the opinion of its legal
                           counsel, is legally required to be disclosed and will
                           exercise reasonable efforts to ensure that any such
                           information so disclosed will be accorded
                           confidential treatment by said court or tribunal.

                  7.2.3    To the extent it is reasonably necessary or
                           appropriate to fulfill its obligations and exercise
                           its rights under this Agreement, either Party may
                           disclose Confidential Information to its Affiliates
                           on a need-to-know basis on condition that such
                           Affiliates agree to keep the Confidential Information
                           confidential for the same time periods and to the
                           same extent as such Party is required to keep the
                           Confidential Information confidential under this
                           Agreement, and to any regulatory authorities to the
                           extent reasonably necessary to obtain regulatory
                           approvals.

                  7.2.4    To the extent that it is reasonably necessary or
                           appropriate to fulfill its obligations, either Party
                           may disclose Confidential Information to the U.S.
                           Patent and Trademark Office or any foreign
                           counterparts thereof, in order to comply with the
                           rules governing disclosure of material information
                           during patent examination.

                  7.2.5    The existence and the terms and conditions of this
                           Agreement which the Parties have not specifically
                           agreed to disclose pursuant to this Section 7.2 shall
                           be treated by each Party as Confidential Information
                           of the other Party.

         7.3      Permitted Disclosures for Business Development Purposes.
                  Notwithstanding the foregoing or any other provision in this
                  Agreement to the contrary, 3DP may disclose statistics and
                  masked informational data for presentations to investors or to
                  scientific audiences, based on the research data produced
                  pursuant to the activities under this Agreement, including
                  without limitation, success rates; and excluding Confidential
                  Information identifying, for example, specific Prototype
                  Compounds, Active Compounds, Targets, Hits, Back-Up Compounds,
                  Replacement Compounds, Research Program Patent Rights,
                  chemical names, chemical structures and their activities.

         7.4      Notification. Both Parties recognize that each may wish to
                  publish the results of their work relating to the Research
                  Program. However, both Parties also recognize the importance
                  of acquiring patent protection on Licensed Products.
                  Consequently, 3DP shall not make any publication relating to
                  any Prototype Compound, Replacement Compound, Active Compound
                  or Licensed Product without the prior written permission of
                  Janssen and any proposed publication by either Party relating
                  to the Research Program or Prototype Compound

                                       24
<PAGE>

                  Optimization shall comply with this Article 7. At least sixty
                  (60) days before a manuscript is to be submitted to a
                  publisher, the publishing Party will provide the JSMC with a
                  copy of the manuscript. If the publishing Party wishes to make
                  an oral presentation, it will provide the JSMC with a copy of
                  the abstract (if one is submitted) at least sixty (60) days
                  before it is to be submitted. The publishing Party will also
                  provide to the JSMC a copy of the text of the presentation,
                  including all slides, posters and any other visual aids, at
                  least sixty (60) days before the presentation is made.

         7.5      Review of Proposed Publications. The JSMC will review the
                  manuscript, abstract, text or any other material provided
                  under Section 7.4 to determine if patentable subject matter is
                  disclosed. The JSMC will notify the publishing Party within
                  sixty (60) days of receipt of the proposed publication if the
                  JSMC determines that patentable subject matter is or may be
                  disclosed, or if the JSMC believes Confidential Information or
                  proprietary information is or may be disclosed. If it is
                  determined by the JSMC that patent applications should be
                  filed, the publishing Party shall delay its publication or
                  presentation for a period not to exceed ninety (90) days from
                  the JSMC's notification to the publishing Party to allow time
                  for the filing of patent applications covering patentable
                  subject matter. In the event that the delay needed to complete
                  the filing of any necessary patent application will exceed the
                  ninety (90)-day period, the Parties will discuss the need for
                  obtaining an extension of the publication delay beyond the
                  ninety (90)-day period. If it is determined by the JSMC that
                  confidential or proprietary information is being disclosed,
                  the JSMC will attempt to arrive at an agreement on mutually
                  acceptable modifications to the proposed publication to avoid
                  such disclosure. The publishing Party of any manuscript, text
                  or oral presentation will acknowledge the other Party for its
                  contribution to the material being published or presented and
                  to the Research Program.

                                   ARTICLE 8

                     PATENT RIGHTS AND INTELLECTUAL PROPERTY

         8.1      Ownership; Inventions. Inventorship for patentable inventions
                  conceived and reduced to practice during the course of the
                  performance of activities pursuant to this Agreement shall be
                  determined in accordance with U.S. patent laws for determining
                  inventorship. Janssen Patents shall be owned by Janssen, 3DP
                  Patents shall be owned by 3DP, and Joint Patents shall be
                  jointly owned by the Parties. Research Program Patent Rights
                  shall be owned by 3DP, regardless of inventorship, and Janssen
                  agrees to assign to 3DP its rights in any Research Program
                  Patent Rights having Janssen employees as sole or joint
                  inventors. In the event of a dispute regarding inventorship,
                  if the parties are unable to resolve such inventorship
                  dispute, the Parties shall establish a procedure to resolve
                  such dispute, which may include engaging a Third Party patent
                  attorney jointly selected by the Parties to resolve such
                  dispute. Each Party will cooperate with the other to

                                       25
<PAGE>

                  the extent reasonably necessary to execute assignments and
                  other documentation as may be required.

         8.2      Disclosure of Patentable Inventions. Each Party shall promptly
                  provide to the other any invention disclosure submitted in the
                  normal course of business and disclosing an invention arising
                  during the Research Program and [* *] period following the
                  Initiation of Prototype Compound Optimization for each
                  Prototype Compound, on a compound-by-compound basis, and
                  relating to Hits, Prototype Compounds, Active Compounds,
                  Back-Up Compounds or Replacement Compounds.

         8.3      Disclosure of Janssen Know-how. During the [* *] period
                  following the initiation of Prototype Compound Optimization
                  for each Prototype Compound on a compound-by-compound basis,
                  Janssen shall promptly provide 3DP with complete written
                  disclosures of any potentially patentable technology derived
                  from the Research Program, the Janssen Research Program and/or
                  Prototype Compound Optimization.

         8.4      3DP Patentable Inventions and Know-How.

                  8.4.1    3DP Patent Prosecution.

                           (a)      Selection of Outside Counsel. Before
                                    retaining any law firm and/or patent
                                    attorney for the preparation and prosecution
                                    of any patent applications which are
                                    Research Program Patent Rights, 3DP shall
                                    inform Janssen of the identity of such law
                                    firm and/or patent attorney it desires to
                                    employ and the Parties will discuss such
                                    firm and/or attorney. 3DP will consider any
                                    suggestions from Janssen regarding the
                                    selection of a law firm and/or patent
                                    attorney for handling preparation,
                                    prosecution and maintenance of Research
                                    Program Patent Rights and Janssen may
                                    disapprove any law firm and/or patent
                                    attorney proposed by 3DP, such approval not
                                    to be unreasonably withheld or delayed.

                           (b)      Prosecution and Maintenance. During the
                                    Term, 3DP shall prepare, file, prosecute and
                                    maintain 3DP Patents (at 3DP's sole expense)
                                    and Research Program Patent Rights (at
                                    Janssen's sole expense) and use reasonable
                                    efforts to initially file all such patent
                                    applications in the United States. For
                                    Research Program Patent Rights, Janssen
                                    shall provide a list of countries in which
                                    such patent applications shall be filed
                                    reasonably in advance of 3DP's estimated
                                    filing date. 3DP shall file such patent
                                    applications in each indicated country.

                                       26
<PAGE>

                           (c)      Discontinuance. If 3DP does not intend to
                                    file for patent protection or does not wish
                                    to continue preparation, prosecution or
                                    maintenance of Research Program Patent
                                    Rights, then it shall give at least
                                    forty-five (45) days advance notice to
                                    Janssen, and in no event less than a
                                    reasonable period of time for Janssen to act
                                    in its stead. In such case, Janssen may
                                    elect at its sole discretion to continue
                                    preparation, filing and prosecution or
                                    maintenance of the discontinued patent at
                                    its sole expense. 3DP shall execute such
                                    documents and perform such acts as may be
                                    reasonably necessary for Janssen to file or
                                    to continue prosecution or maintenance of
                                    such patent. Discontinuance may be elected
                                    on a country-by-country basis or for a
                                    patent application or patent series in
                                    total.

                  8.4.2    Cooperation. 3DP shall consult with Janssen and shall
                           keep Janssen continuously informed of all material
                           matters relating to the preparation, filing,
                           prosecution and maintenance of Research Program
                           Patent Rights covered by this Agreement, including,
                           but not limited to, disclosing to Janssen the
                           complete text of all such Research Program Patent
                           Rights. In addition, 3DP shall provide Janssen with
                           copies of all material correspondence with the
                           applicable patent office.

         8.5      Janssen Patentable Inventions and Know-How.

                  8.5.1    Janssen Patent Prosecution.

                           (a)      Prosecution and Maintenance. During the
                                    Term, Janssen shall, at its own expense,
                                    prepare, file, prosecute and maintain
                                    Janssen Patents and use reasonable efforts
                                    to file initially all such patent
                                    applications in countries in which Janssen
                                    would file patent applications in its normal
                                    business practice for comparable technology.

                           (b)      Discontinuance. If Janssen does not intend
                                    to file for Patent protection or does not
                                    wish to continue preparation, prosecution or
                                    maintenance of a Janssen Patent, then it
                                    shall give at least forty-five (45) days
                                    advance notice to 3DP, and in no event less
                                    than a reasonable period of time for 3DP to
                                    act in its stead. In such case, 3DP may
                                    elect at its sole discretion to continue
                                    preparation, filing and prosecution or
                                    maintenance of the discontinued patent at
                                    its sole expense. Janssen shall execute such
                                    documents and perform such acts as may be
                                    reasonably necessary for 3DP to file or to
                                    continue prosecution or maintenance of such
                                    patent. Discontinuance may be elected on a
                                    country-by-country basis or for a patent
                                    application or patent series in total.

                                       27
<PAGE>

                  8.5.2    Cooperation. Janssen shall consult with 3DP and shall
                           keep 3DP continuously informed of all material
                           matters relating to the preparation, filing,
                           prosecution and maintenance of Janssen Patents
                           covered by this Agreement, including, but not limited
                           to, disclosing to 3DP the complete text of all such
                           Janssen Patents.

         8.6      Joint Patents

                  8.6.1    The Parties shall jointly determine whether to
                           prepare, file, prosecute and maintain any Joint
                           Patents. Janssen shall act as the lead Party for the
                           prosecution and maintenance of such Joint Patents.

                  8.6.2    Janssen shall keep 3DP apprised of the status of each
                           Joint Patent and shall seek the advice of 3DP with
                           respect to patent strategy and drafting applications
                           and shall give reasonable consideration to any
                           suggestions or recommendations of 3DP concerning the
                           preparation, filing, prosecution, maintenance and
                           defense thereof. Each Party shall be responsible for
                           50% of the cost of such filings.

                  8.6.3    The Parties shall cooperate reasonably in the
                           prosecution of all Joint Patents and shall share all
                           material information relating thereto, including all
                           material communications from patent offices, promptly
                           after receipt of such information.

                  8.6.4    If, during the term of this Agreement, Janssen
                           intends to allow any Joint Patent to lapse or to
                           abandon any such Joint Patent, Janssen shall,
                           whenever practicable, notify 3DP of such intention at
                           least sixty (60) days prior to the date upon which
                           such Joint Patent shall lapse or become abandoned but
                           in no event less than a reasonably sufficient time to
                           prevent such lapse or abandonment, and 3DP shall
                           thereupon have the right, but not the obligation, to
                           assume responsibility for the prosecution,
                           maintenance and defense thereof and all expenses
                           related thereto.

         8.7      Assistance. Each Party hereby agrees:

                  8.7.1    to make its employees, agents and consultants
                           reasonably available to the other Party (or the other
                           Party's authorized attorneys, agents or
                           representatives), to the extent reasonably necessary
                           to enable the Prosecuting Party to undertake
                           preparation, filing, prosecution and maintenance of
                           its Patent Rights;

                  8.7.2    to cooperate, if necessary and appropriate, with the
                           other Party in gaining patent term extensions
                           wherever applicable to Patent Rights; and

                                       28
<PAGE>

                  8.7.3    to endeavor in good faith to coordinate its efforts
                           with the other Party to minimize or avoid
                           interference with the preparation, filing,
                           prosecution and maintenance of the other Party's
                           Patent Rights.

         8.8      Initial Filing if Made Outside of the United States. The
                  Parties agree to use reasonable efforts to ensure that any
                  Patent Rights filed outside of the United States prior to a
                  U.S. filing will be in a form sufficient to establish the date
                  of original filing as a priority date for the purposes of a
                  subsequent U.S. filing.

         8.9      Infringement Claims by Third Parties.

                  8.9.1    Notice. If the manufacture, use or sale of an Active
                           Compound or any Licensed Product results in a claim
                           or a threatened claim by a Third Party against a
                           Party hereto for patent infringement or for inducing
                           or contributing to patent infringement ("Infringement
                           Claim"), the Party first having notice of an
                           Infringement Claim shall promptly notify the other in
                           writing. The notice shall set forth the facts of the
                           Infringement Claim in reasonable detail.

                  8.9.2    Defense. Janssen shall have the right but not the
                           obligation to defend any suit resulting from an
                           Infringement Claim at its expense. 3DP shall
                           cooperate and assist Janssen in any such litigation
                           at Janssen's expense. In the event Janssen declines
                           to take steps with respect to such infringement
                           within [* *] following notice of such infringement,
                           3DP shall have the right to do so at its expense.

                  8.9.3    Settlement. In the event that the manufacture, use or
                           sale of the Active Compound or the Licensed Product
                           in a country would infringe Third Party Patent Rights
                           and a license to such Third Party Patent Rights is
                           available, and Janssen in its sole discretion seeks
                           such a license, the Parties agree:

                           (a)      Subject to Section 5.11.2, Janssen shall be
                                    responsible for all costs associated with
                                    acquiring such Third Party license; and

                           (b)      Janssen shall use reasonable efforts to
                                    obtain required licenses under the Third
                                    Party Patents, with a right to sublicense to
                                    3DP.

         8.10     Patent Assignment. Neither Party may assign its interest in
                  rights under Research Program Patent Rights or any Patent
                  Rights claiming an Active Compound or Licensed Product, except
                  with the prior written consent of the other Party, such
                  consent not to be unreasonably withheld or delayed; provided,
                  however, that either Party may assign such rights without
                  consent of the other Party to a permitted assignee under this
                  Agreement.

         8.11     Infringement Claims Against Third Parties.

                                       29
<PAGE>

                  8.11.1   Cooperation. 3DP and Janssen each agree to take
                           reasonable actions to protect 3DP Patents, Janssen
                           Patents, Joint Patents or Research Program Patent
                           Rights from infringement. If one Party brings any
                           such action or proceeding, the other Party may be
                           joined as a Party plaintiff if necessary for the
                           action or proceeding to proceed and, in case of
                           joining, the other Party agrees to give the first
                           Party reasonable assistance and authority to file and
                           to prosecute such suit. The other Party shall be
                           reimbursed for any costs associated with its
                           participation.

                  8.11.2   Notice. If any 3DP Patent, Janssen Patent, Joint
                           Patents and/or Research Program Patent Rights is
                           infringed by a Third Party in any country in
                           connection with the manufacture, use and/or sale of
                           an Active Compound or Licensed Product in such
                           country, the Party to this Agreement first having
                           knowledge of such infringement, or knowledge of a
                           reasonable probability of such infringement, shall
                           promptly notify the other in writing. The notice
                           shall set forth the known facts of such infringement
                           in reasonable detail.

                  8.11.3   Institution of Proceedings.

                           (a)      3DP shall have the primary right, but not
                                    the obligation, to institute, prosecute and
                                    control with its own counsel, any action or
                                    proceeding with respect to infringement of a
                                    3DP Patent or Research Program Patent
                                    Rights. Janssen shall have the right, at its
                                    own expense, to be represented in such
                                    action by its own counsel; provided,
                                    however, no settlement may be entered into
                                    by 3DP without the written consent of
                                    Janssen, which consent shall not be
                                    unreasonably withheld or delayed, if such
                                    settlement would have a material adverse
                                    effect on Janssen's interests.

                           (b)      With respect to Joint Patents, Janssen shall
                                    have the primary right, but not the
                                    obligation, to institute, prosecute and
                                    control any action or proceeding with
                                    respect to infringement of such Joint
                                    Patents, by counsel of its own choice and at
                                    its own expense; provided, however, 3DP may
                                    participate in such proceedings, represented
                                    by counsel of its own choice and at its own
                                    expense, no settlement may be entered into
                                    by Janssen without the written consent of
                                    3DP, which consent shall not be unreasonably
                                    withheld or delayed.

                           (c)      Janssen shall have the sole right to enforce
                                    any rights under the Janssen Patents at its
                                    own expense.

                  8.11.4   Failure to Institute Proceedings. If the Party having
                           the primary right to institute proceedings under
                           Section 8.11.3 (hereinafter referred to as the

                                       30
<PAGE>

                           "First Prosecuting Party") fails to institute,
                           prosecute or control such action or prosecution
                           within a period of one hundred eighty (180) days
                           after receiving notice of the infringement from the
                           other Party (hereinafter referred to as the "Second
                           Prosecuting Party"), then the Second Prosecuting
                           Party shall have the right to bring and control any
                           such action by counsel of its own choice, and the
                           First Prosecuting Party shall have the right, at its
                           own expense, to be represented in any such action by
                           counsel of its own choice. The First Prosecuting
                           Party shall cooperate with the Second Prosecuting
                           Party in such effort, including being joined as a
                           party to such action if necessary.

                  8.11.5   Costs. The Party bringing suit under this Article
                           shall bear all costs of the suit and shall retain any
                           damages or other monetary awards recovered.

                  8.11.6   Settlement. The parties shall keep each other
                           informed of the status of and of their respective
                           activities regarding any litigation or settlement
                           thereof concerning Licensed Products in the Field. A
                           settlement or consent judgment or other voluntary
                           final disposition of a suit brought by a Party under
                           this Section 8.11 may be entered without the consent
                           of the other Party; provided such settlement, consent
                           judgment or other disposition does not admit the
                           invalidity or unenforceability of any Patent Rights;
                           and provided further, that any rights to continue the
                           infringing activity in such settlement, consent
                           judgment or other disposition shall be limited to the
                           product or activity that was the subject of the suit.

         8.12     Notices Relating to the Act. 3DP shall notify Janssen of the
                  issuance of each U.S. patent included among the 3DP Patents,
                  Research Program Patent Rights and Joint Patents wherein 3DP
                  is the filing Party, giving the date of issue and patent
                  number for each such patent. 3DP and Janssen each shall
                  immediately give notice to the other of any certification
                  filed under the "U.S. Drug Price Competition and Patent Term
                  Restoration Act of 1984" (hereinafter the "Act"), including,
                  but not necessarily limited to, notices pursuant toss.ss.101
                  and 103 of the Act from persons who have filed an abbreviated
                  NDA ("ANDA") or a "paper" NDA claiming that 3DP Patents,
                  Janssen Patents, Joint Patents or Research Program Patent
                  Rights are invalid or that infringement will not arise from
                  the manufacture, use or sale of any Active Compound or
                  Licensed Product by a Third Party.

                  8.12.1   If Janssen decides not to bring infringement
                           proceedings against the entity making such a
                           certification, Janssen shall give notice to 3DP of
                           its decision not to bring suit within twenty-one (21)
                           days after receipt of notice of such certification.

                  8.12.2   3DP may then, but is not required to, bring suit
                           against the party that filed the certification.

                                       31
<PAGE>

                  8.12.3   Any suit by Janssen or 3DP shall either be in the
                           name of Janssen or in the name of 3DP, or jointly in
                           the name of Janssen and 3DP, as may be required by
                           law.

                  8.12.4   For purposes of this Section, the Party not bringing
                           suit shall execute such legal papers necessary for
                           the prosecution of such suit as may be reasonably
                           requested by the Party bringing suit.

         8.13     Patent Term Extensions. 3DP hereby authorizes Janssen to (a)
                  provide in any NDA a list of patents which includes 3DP
                  Patents, Joint Patents and Research Program Patent Rights
                  owned by 3DP that relate to such Licensed Product and such
                  other information as Janssen believes is appropriate; (b)
                  commence suit for infringement of 3DP Patents, Joint Patents
                  and Research Program Patent Rights underss.271(e) (2) of Title
                  35 of the United States Code; and (c) exercise any rights that
                  may be exercisable by 3DP as patent owner under the Act,
                  including without limitation, applying for an extension of the
                  term of any patent included in 3DP Patents, Joint Patents and
                  Research Program Patent Rights. In the event that applicable
                  law in any country provides for the extension of the term of
                  any patent included among Research Program Patent Rights owned
                  by 3DP, such as under the Act, the Supplementary Certificate
                  of Protection of the Member States of the European Union and
                  other similar measures in any other country, 3DP shall apply
                  for and use its reasonable efforts to obtain such an extension
                  or, should the law require Janssen to so apply, 3DP hereby
                  gives permission to Janssen to do so. Janssen and 3DP agree to
                  cooperate with one another in obtaining such extension. 3DP
                  agrees to cooperate with Janssen or its sublicensee, as
                  applicable, in the exercise of the authorization granted
                  herein and shall execute such documents and take such
                  additional action as Janssen may reasonably request in
                  connection therewith, including, if necessary, permitting
                  itself to be joined as a Party in any suit for infringement
                  brought by Janssen hereunder.

                                   ARTICLE 9

                                 INDEMNIFICATION

         9.1      Indemnification by Janssen. Janssen shall indemnify, defend
                  and hold 3DP and its agents, employees and directors (the "3DP
                  Indemnitees") harmless from and against any and all liability,
                  damage, loss, cost or expense (including reasonable attorneys'
                  fees) arising out of Third Party claims or lawsuits related to
                  (a) Janssen's performance of its obligations under this
                  Agreement; or (b) patent infringement related to 3DP's use of
                  the Targets pursuant to this Agreement; or (c) patent
                  infringement or product liability for bodily injury and/or
                  property damage related to Janssen's development activities
                  with compounds identified under the Research Program and/or
                  with Licensed Products; or (d) the manufacture, use or sale of
                  Licensed Products by Janssen, sublicensees, distributors and
                  agents, except to the extent such claims or suits result from
                  the

                                       32
<PAGE>

                  breach of any of the provisions of this Agreement, gross
                  negligence or willful misconduct of the 3DP Indemnitees. Upon
                  the assertion of any such claim or suit, the 3DP Indemnitees
                  shall promptly notify Janssen thereof and shall permit Janssen
                  to assume direction and control of the defense of the claim
                  (including the selection of counsel and the right to settle it
                  at the sole discretion of Janssen, provided that such
                  settlement does not impose any material obligation on the 3DP
                  Indemnitees), and shall cooperate as requested (at the expense
                  of Janssen) in the defense of the claim.

         9.2      Indemnification By 3DP. 3DP shall indemnify, defend and hold
                  Janssen and its agents, employees and directors (the "Janssen
                  Indemnitees") harmless from and against any and all liability,
                  damage, loss, cost or expense (including reasonable attorneys'
                  fees) arising out of Third Party claims or lawsuits related to
                  3DP's performance of its obligations under this Agreement,
                  except to the extent that such claims or suits result from the
                  breach of any of the provisions of this Agreement, gross
                  negligence or willful misconduct of the Janssen Indemnitees.
                  Upon the assertion of any such claim or suit, the Janssen
                  Indemnitees shall promptly notify 3DP thereof and shall permit
                  3DP to assume direction and control of the defense of the
                  claim (including the selection of counsel and the right to
                  settle it at the sole discretion of 3DP, provided that such
                  settlement does not impose any material obligation on the
                  Janssen Indemnitees), and shall cooperate as requested (at the
                  expense of 3DP) in the defense of the claim.

                                   ARTICLE 10

                              TERM AND TERMINATION

         10.1     Term of Research Program. The Research Program shall commence
                  upon the Effective Date, and unless earlier terminated as
                  provided herein, shall expire on the last to expire of the
                  Stage A Term or the Stage B Term or any Extended Research Term
                  (the "Research Term").

         10.2     Term of Agreement. This Agreement shall commence upon the
                  Effective Date and shall terminate: (a) thirty (30) days after
                  notice, in good faith, by one Party to the other Party,
                  following the termination or expiration of the Research Term,
                  if no compound, which was identified as a Prototype Compound,
                  is being optimized, developed, commercialized and/or sold by
                  Janssen or 3DP, or (b) upon the identification and
                  commercialization of one or more Licensed Products, upon
                  expiration of Janssen's obligation to pay royalties hereunder
                  (the "Term").

         10.3     Termination of the Research Program Without Cause. Subject to
                  the provisions of Section 5.6, Janssen may terminate the
                  Research Program upon ninety (90)-days advance written notice
                  during the Research Term provided, however, [* *].

                                       33
<PAGE>

         10.4     Breach. The failure by a Party to comply with any of the
                  material obligations contained in this Agreement shall entitle
                  the other Party to give notice to have the default cured. If
                  such default is not cured within sixty (60) days after the
                  receipt of such notice, or diligent steps are not taken to
                  cure if by its nature such default cannot be cured within
                  sixty (60) days, the notifying Party shall be entitled,
                  without prejudice to any of its other rights conferred to it
                  by this Agreement, and in addition to any other remedies that
                  may be available to it, to terminate the Research Program
                  and/or this Agreement; provided, however, that such right to
                  terminate shall be stayed in the event that, during such sixty
                  (60)-day period, the Party alleged to have been in default
                  shall have: (a) initiated arbitration in accordance with
                  Article 13, below, with respect to the alleged default, and
                  (b) diligently and in good faith cooperated in the prompt
                  resolution of such arbitration proceedings.

         10.5     No Waiver. The right of a Party to terminate the Research
                  Program and/or this Agreement, as provided in this Article 10,
                  shall not be affected in any way by its waiver or failure to
                  take action with respect to any prior default.

         10.6     Insolvency or Bankruptcy.

                  10.6.1   Either Party may, in addition to any other remedies
                           available by law or in equity, terminate the Research
                           Program and/or this Agreement by written notice to
                           the other Party in the event the latter Party shall
                           have become insolvent or bankrupt, or shall have an
                           assignment for the benefit of its creditors, or there
                           shall have been appointed a trustee or receiver of
                           the other Party or for all or a substantial part of
                           its property or any case or proceeding shall have
                           been commenced or other action taken by or against
                           the other Party in bankruptcy or seeking
                           reorganization, liquidation, dissolution, winding-up,
                           arrangement or readjustment of its debts or any other
                           relief under any bankruptcy, insolvency,
                           reorganization or other similar act or law of any
                           jurisdiction now or hereafter in effect, or there
                           shall have been issued a warrant of attachment,
                           execution, distraint or similar process against any
                           substantial part of the property of the other Party,
                           and any such event shall have continued for ninety
                           (90) days undismissed, unbonded and undischarged.

                  10.6.2   All rights and licenses granted under or pursuant to
                           this Agreement by Janssen or 3DP are, and shall
                           otherwise be deemed to be, for purposes of Section
                           365(n) of the U.S. Bankruptcy Code, licenses of right
                           to "Intellectual Property" as defined under Section
                           101 of the U.S. Bankruptcy Code. The Parties agree
                           that the Parties as licensees of such rights under
                           this Agreement, shall retain and may fully exercise
                           all of their rights and elections under the U.S.
                           Bankruptcy Code. The Parties further agree that, in
                           the event of the commencement of a bankruptcy
                           proceeding by or against either Party under the U.S.
                           Bankruptcy Code, the Party

                                       34
<PAGE>

                           hereto which is not a party to such proceeding shall
                           be entitled to a complete duplicate of (or complete
                           access to, as appropriate) any such intellectual
                           property and all embodiments of such intellectual
                           property, and same, if not already in their
                           possession, shall be promptly delivered to them (a)
                           upon any such commencement of a bankruptcy proceeding
                           upon their written request therefor, unless the Party
                           subject to such proceedings elects to continue to
                           perform all of their obligations under this
                           Agreement, or (b) if not delivered under (a) above,
                           upon the rejection of this Agreement by or on behalf
                           of the Party subject to such proceeding upon written
                           request therefor by a nonsubject party.

         10.7     Consequences of Termination of the Research Program.

                  10.7.1   In the event of termination of the Research Program
                           by Janssen pursuant to the provisions of Sections
                           10.4 or 10.6, 3DP shall (i) promptly transfer to
                           Janssen copies, whether in written or electronic
                           form, of all data, reports, records and materials
                           (including any Research Program Know-how) in 3DP's
                           possession or control which relate to the Research
                           Program; (ii) return to Janssen all relevant records
                           and materials, whether in written or electronic form,
                           in 3DP's possession or control containing
                           Confidential Information of Janssen; and (iii)
                           furnish to Janssen all unused Substances provided to
                           3DP by Janssen in connection with the Research
                           Program. Thereafter, Janssen shall have no further
                           obligation to fund the Research Program, but the
                           remainder of the Agreement shall, including without
                           limitation, Janssen's rights to continue Prototype
                           Compound Optimization for those Prototype Compounds
                           identified as such pursuant to Section 1.29, remain
                           in force and effect until expiration of the term of
                           the Agreement, unless it is sooner terminated as
                           provided in this Agreement.

                  10.7.2   In the event of termination of the Research Program
                           by 3DP pursuant to the provisions of 10.4 or 10.6, or
                           if Janssen terminates the Research Program pursuant
                           to the provisions of Section 10.3, Janssen shall (i)
                           promptly transfer to 3DP copies, whether in written
                           or electronic form, of all data, reports, records and
                           materials (including any Research Program Know-how)
                           in Janssen's possession or control which relate to
                           the Research Program; (ii) return to 3DP all relevant
                           records and materials, whether in written or
                           electronic form, in Janssen's possession or control
                           containing Confidential Information of 3DP; and (iii)
                           furnish to 3DP all unused Substances, if any,
                           provided to Janssen by 3DP in connection with the
                           Research Program. Thereafter, the remainder of the
                           Agreement shall remain in force and effect until
                           expiration of the term of the Agreement, unless it is
                           sooner terminated as provided in this Agreement.

                                       35
<PAGE>

                  10.7.3   Either Party's termination of the Research Program
                           pursuant to Section 10.3, 10.4 and/or 10.6 shall be
                           without prejudice to, and shall not affect, any of
                           the Parties' respective rights and obligations under
                           this Agreement that do not specifically relate to the
                           Research Program. Without limiting the generality of
                           the foregoing, Janssen's rights to exploit the
                           Licensed Products under any Research Program Patent
                           Rights and Research Program Know-how, if such
                           licenses are in operation, in accordance with the
                           terms of this Agreement, shall not be affected by any
                           such termination.

         10.8     Consequences of Termination of this Agreement. Upon
                  termination of this Agreement, all remaining records and
                  materials in a Party's possession or control containing the
                  other Party's Confidential Information and to which the former
                  Party does not retain rights hereunder shall promptly be
                  returned, except that one (1) copy shall be retained by legal
                  counsel for the former Party.

         10.9     Survival of Obligations. The termination or expiration of this
                  Agreement shall not relieve the Parties of any obligations
                  accruing prior to such termination, and any such termination
                  shall be without prejudice to the rights of either Party
                  against the other. The provisions of Sections 3.7, 5.15, 5.16,
                  6.1, 6.2, 6.3, 8.1, 10.8, 14.1, 14.14, 14.15 and Articles 1,
                  7, 9 and 13 shall survive any termination of this Agreement.

                                   ARTICLE 11

         DEVELOPMENT, REGULATORY AND COMMERCIALIZATION RESPONSIBILITIES

         11.1     Commercial Responsibilities. Janssen agrees to use
                  commercially reasonable efforts consistent with its normal
                  business practices, and in no event less than efforts standard
                  in the pharmaceutical industry, to develop and commercialize
                  Licensed Products. Such efforts shall be efforts consistent
                  with efforts used by Janssen (in each case comparable efforts
                  will be measured against such efforts used by Janssen for
                  marketing in the country where the commercialization takes
                  place for that Licensed Product) in commercializing its own
                  products that are similar with regard to, for example, market
                  potential, price per treatment, patient population, and
                  competitive position. Janssen shall use commercially
                  reasonable efforts consistent with its normal business
                  practices to effect the commercial launch of Licensed Products
                  in the Major Countries within [* *] of Regulatory Approval in
                  such Major Countries.

         11.2     Janssen's Marketing Obligations For Licensed Product. All
                  business decisions, including, without limitation, the design,
                  sale, price and promotion of Licensed Products under this
                  Agreement and the decisions whether to market any particular
                  Licensed Product shall be within the sole discretion of
                  Janssen.

                                       36
<PAGE>

         11.3     Janssen Responsibilities. Janssen shall be responsible for all
                  development, regulatory filings and related submissions that
                  are made in connection with the commercialization of Licensed
                  Products developed by Janssen and all commercialization
                  activities with respect to Licensed Products, and shall do so
                  at Janssen's sole discretion and expense. The JSMC will
                  provide annual written reports to the Parties presenting a
                  meaningful summary of the development and commercialization
                  activities undertaken for each Licensed Product for the Term.

                                   ARTICLE 12

                         REPRESENTATIONS AND WARRANTIES

         12.1     Authority. Each Party represents and warrants that as of the
                  Effective Date it has the full right, power and authority to
                  enter into this Agreement and that this Agreement has been
                  duly executed by such Party and constitutes a legal, valid and
                  binding obligation of such Party, enforceable in accordance
                  with its terms.

         12.2     No Conflicts. Each Party represents and warrants that the
                  execution, delivery and performance of this Agreement does not
                  conflict with, or constitute a breach or default under, any of
                  its charter or organizational documents, any law, order,
                  judgment or governmental rule or regulation applicable to it,
                  or any material agreement, contract, commitment or instrument
                  to which it is a party.

         12.3     No Existing Third Party Rights. Each Party represents and
                  warrants that its obligations under this Agreement are not
                  encumbered by any rights granted by such Party to any Third
                  Parties that are or may be inconsistent with the rights and
                  licenses granted in this Agreement.

         12.4     Permitted Use of Targets. Janssen represents and warrants that
                  it has the legal right to use and permit 3DP to use all
                  Targets provided to 3DP for Research Program activities under
                  this Agreement.

         12.5     Continuing Representations. The representations and warranties
                  of each Party contained in this Article 12 shall survive the
                  execution and delivery of this Agreement and shall remain true
                  and correct at all times during the Term with the same effect
                  as if made on and as of such later date.

         12.6     Disclaimer of Warranties. 3DP MAKES NO REPRESENTATIONS AND
                  EXTENDS NO WARRANTIES OR CONDITIONS OF ANY KIND, EITHER
                  EXPRESS OR IMPLIED, WITH RESPECT TO THE 3DP DISCOVERWORKS(R)
                  TECHNOLOGY, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF
                  MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. IN
                  PARTICULAR, 3DP OFFERS NO REPRESENTATION OR WARRANTY THAT THE
                  USE OF ALL OR ANY PART OF THE 3DP DISCOVERWORKS(R) TECHNOLOGY
                  UNDER THIS

                                       37
<PAGE>

                  AGREEMENT WILL RESULT IN THE DISCOVERY OR THE SUCCESSFUL
                  COMMERCIALIZATION OF A LICENSED PRODUCT FOR USE AGAINST THE
                  TARGET IN THE FIELD.

         12.7     No Infringement. To the best of its knowledge as of the
                  Effective Date, 3DP represents and warrants that the use of
                  the DirectedDiversity(R)Technology and
                  ThermoFluor(R)Technology does not infringe any Patent Rights
                  of a Third Party.

         12.8     Infectious Disease Targets. Janssen covenants that the Targets
                  and Replacement Targets that are provided by Janssen for
                  screening pursuant to this Agreement are not provided for the
                  primary purpose of identifying [* *].

                                   ARTICLE 13

                               DISPUTE RESOLUTION

         13.1     Any dispute concerning or arising out of this Agreement or
                  concerning the existence or validity hereof shall be
                  determined by the following procedure:

                  13.1.1   Dispute Resolution and Arbitration. In the case of
                           any disputes between the Parties arising from this
                           Agreement, and in case this Agreement does not
                           provide a solution for how to resolve such disputes,
                           the Parties shall discuss and negotiate in good faith
                           a solution acceptable to both Parties and in the
                           spirit of this Agreement. If after negotiating in
                           good faith pursuant to the foregoing sentence, the
                           Parties fail to reach agreement within sixty (60)
                           days, then the Chief Executive Officer of 3DP and the
                           Chairman Research & Development Pharmaceuticals shall
                           discuss in good faith an appropriate resolution to
                           the dispute. If these executives fail, after good
                           faith discussions, to reach an amicable agreement
                           within sixty (60) days, then either Party may upon
                           written notice to the other submit the dispute to
                           binding arbitration pursuant to Section 13.2.

         13.2     Arbitration. Any claim, dispute or controversy arising out of
                  or in connection with or relating to this Agreement,
                  (including, without limitation, disputes with respect to the
                  rights and obligations of the Parties following termination)
                  not settled by the procedures set forth in Section 13.1 above
                  or the breach or alleged breach of a material provision of
                  this Agreement shall be adjudicated by arbitration in
                  accordance with the Arbitration Proceedings as set forth in
                  Schedule 13.2 attached hereto.

                                   ARTICLE 14

                            MISCELLANEOUS PROVISIONS

         14.1     Entire Agreement. This Agreement and each of the Schedules
                  hereto constitute and contain the entire understanding and
                  agreement of the Parties respecting the

                                       38
<PAGE>

                  subject matter of this Agreement and cancels and supersedes
                  any and all prior negotiations, correspondence, understandings
                  and agreements between the Parties, whether oral or written,
                  regarding such subject matter.

         14.2     Further Actions. Each Party agrees to execute, acknowledge and
                  deliver such further instruments and to do all such other acts
                  as may be necessary or appropriate in order to carry out the
                  purposes and intent of this Agreement.

         14.3     Binding Effect. This Agreement and the rights granted herein
                  shall be binding upon and shall inure to the benefit of 3DP,
                  Janssen and their successors and permitted assigns.

         14.4     Assignment. Neither Party may assign this Agreement without
                  the prior written consent of the other Party; provided,
                  however, that either Party may assign this Agreement without
                  the prior written consent of the other Party in connection
                  with the sale or transfer of substantially all of its assets
                  that relate to this Agreement, or in the event of its merger
                  or consolidation or change of control or similar transaction.
                  Any permitted assignee shall assume all obligations of its
                  assignor under this Agreement.

         14.5     No Implied Licenses. No rights to any other patents, Know-how
                  or technical information, or other intellectual property
                  rights, other than as explicitly identified herein, are
                  granted or deemed granted by this Agreement. No right, express
                  or implied, is granted by this Agreement to a Party to use in
                  any manner the name or any other trade name or trademark of
                  the other Party in connection with the performance of this
                  Agreement.

         14.6     No Waiver. No waiver, modification or amendment of any
                  provision of this Agreement shall be valid or effective unless
                  made in writing and signed by a duly authorized officer of
                  each Party. The failure of either Party to assert a right
                  hereunder or to insist upon compliance with any term or
                  condition of this Agreement shall not constitute a waiver of
                  that right or excuse a similar subsequent failure to perform
                  any such term or condition.

         14.7     Force Majeure. The failure of a Party to perform any
                  obligation under this Agreement by reason of acts of God, acts
                  of governments, riots, wars, strikes, accidents or
                  deficiencies in materials or transportation or other causes of
                  a similar magnitude beyond its control shall not be deemed to
                  be a breach of this Agreement.

         14.8     Independent Contractors. Both Parties are independent
                  contractors under this Agreement. Nothing contained in this
                  Agreement is intended nor is to be construed so as to
                  constitute 3DP or Janssen as partners or joint venturers with
                  respect to this Agreement. Neither Party shall have any
                  express or implied right or authority to assume or create any
                  obligations on behalf of or in the name of the

                                       39
<PAGE>

                  other Party or to bind the other Party to any other contract,
                  agreement or undertaking with any Third Party.

         14.9     Notices and Deliveries. Any formal notices, request, delivery,
                  approval or consent required or permitted to be given under
                  this Agreement shall be in writing and shall be deemed to have
                  been sufficiently given when it is received, whether delivered
                  in person, transmitted by facsimile with contemporaneous
                  confirmation, delivered by registered letter (or its
                  equivalent) or delivered by overnight courier service (receipt
                  required), to the Party to which it is directed at its address
                  shown below or such other address as such Party shall have
                  last given by notice to the other Parties.
<TABLE>

                  <S>                                             <C>
                  If to Janssen:                                  with a copy to:

                  Johnson & Johnson Pharmaceutical                Johnson & Johnson
                  Research & Development, LLC                     One Johnson & Johnson Plaza
                  U.S. Route 202                                  New Brunswick, New Jersey 08933
                  Raritan, NJ  08869

                  ATTN: Chairman                                  ATTN: Chief Patent Counsel
                  FAX: 908-707-1895                               FAX:  732-524-2138

                  If to 3DP:                                      with a copy to:

                  3-Dimensional Pharmaceuticals, Inc.             Morgan, Lewis & Bockius LLP
                  Three Lower Makefield Corporate Center          1701 Market Street
                  1020 Stony Hill Road, Suite 300                 Philadelphia, PA 19103
                  Yardley, PA  19067
                  ATTN:  Chief Executive Officer                  ATTN:  Manya S. Deehr, Esq.
                  FAX:  267-757-7248                              FAX:  215-963-5299

</TABLE>

         14.10    Public Announcements. On or shortly after the Effective Date,
                  3DP shall issue a press release with respect to entering into
                  this Agreement in the form attached hereto as Schedule 14.10.
                                                                --------------

         14.11    Headings. The captions to the sections and articles in this
                  Agreement are not a part of this Agreement, and are included
                  merely for convenience of reference only and shall not affect
                  its meaning or interpretation.

         14.12    Severability. In the event that any provision of this
                  Agreement shall, for any reason, be held to be invalid or
                  unenforceable in any respect, such invalidity or
                  unenforceability shall not affect any other provision hereof,
                  and this Agreement shall be construed as if such invalid or
                  unenforceable provision had not been included herein.

                                       40
<PAGE>

         14.13    No Consequential Damages. IN NO EVENT SHALL EITHER PARTY OR
                  ANY OF ITS RESPECTIVE AFFILIATES BE LIABLE TO THE OTHER PARTY
                  OR ANY OF ITS AFFILIATES FOR SPECIAL, INDIRECT, INCIDENTAL OR
                  CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT,
                  NEGLIGENCE, STRICT LIABILITY OR OTHERWISE, INCLUDING, BUT NOT
                  LIMITED TO, LOSS OF PROFITS OR REVENUE, OR CLAIMS OF CUSTOMERS
                  OF ANY OF THEM OR OTHER THIRD PARTIES FOR SUCH OR OTHER
                  DAMAGES.

         14.14    Applicable Law. This Agreement shall be governed by and
                  interpreted in accordance with the laws of the State of
                  Delaware without reference to its conflicts of laws
                  provisions.

         14.15    Advice of Counsel. Janssen and 3DP have each consulted with
                  counsel of their choice regarding this Agreement, and each
                  acknowledges and agrees that this Agreement shall not be
                  deemed to have been drafted by one Party or another and will
                  be construed accordingly.

         14.16    Counterparts. This Agreement may be executed in counterparts,
                  or facsimile versions, each of which shall be deemed to be an
                  original, and both of which together shall be deemed to be one
                  and the same agreement.

                                       41
<PAGE>

         IN WITNESS WHEREOF, the Parties have caused this Agreement to be
executed by their respective duly authorized officers as of the date first above
written, each copy of which -shall for all purposes be deemed to be an original.

3-DIMENSIONAL PHARMACEUTICALS, INC.          JANSSEN PHARMACEUTICA, N.V.

By:      __________________________          By:      __________________________

Name:    David C. U'Prichard, Ph.D.          Name:    __________________________

Title:   Chief Executive Officer             Title:   __________________________

                                             THE R.W. JOHNSON
                                             PHARMACEUTICAL RESEARCH
                                             INSTITUTE, a division of
                                             Ortho-McNeil Pharmaceutical, Inc.

                                             By:      __________________________

                                             Name:    __________________________

                                             Title:   __________________________

                                       42
<PAGE>

                                  Schedule 1.8

                          DIRECTED DIVERSITY(R) PATENTS

--------------------------------------------------------------------------------

    TITLE      COUNTRY      SERIAL    FILING     PATENT       ISSUE DATE
                            NUMBER    DATE       NUMBER

--------------------------------------------------------------------------------

               [* The entire table, consisting of 1 page, has been
            omitted pursuant to a confidential treatment request *]

                                       43
<PAGE>

                                  Schedule 1.17

                         THERMOFLUOR(R) VALIDATION TESTS

[*               *]

[*               *]

[* 1 entire page has been omitted pursuant to a confidential treatment
request *]

                                       44
<PAGE>

                                  Schedule 1.36

                                  RESEARCH PLAN

                  [* 1 entire page has been omitted pursuant to
                      a confidential treatment request *]

                                       45
<PAGE>

                                  Schedule 1.50

                             THERMOFLUOR(R) PATENTS

--------------------------------------------------------------------------------

       TITLE         COUNTRY      SERIAL    FILING    PATENT     ISSUE DATE
                                  NUMBER     DATE     NUMBER
--------------------------------------------------------------------------------

               [* The entire table, consisting of 1 page, has been
            omitted pursuant to a confidential treatment request *]

                                       46
<PAGE>

                                  Schedule 2.1

                                     TARGETS

TARGET 1:         [*                *]

[*                                                            *]

TARGET 2:         [*                *]

[*                                                            *]

  [* 2 pages have been omitted pursuant to a confidential treatment request *]

                                       47
<PAGE>

                                  Schedule 2.2

                  [* 1 entire page has been omitted pursuant to
                      a confidential treatment request *]

                                       48
<PAGE>

                                  Schedule 5.14

                                WIRE INSTRUCTIONS

                  [* 1 entire page has been omitted pursuant to
                      a confidential treatment request *]

                                       49
<PAGE>

                                  Schedule 13.2

                             ARBITRATION PROCEEDINGS

         1.1  (a) Any dispute, controversy or claim arising out of or related to
                  this Agreement, or the interpretation, application, breach,
                  termination or validity thereof, including any claim of
                  inducement by fraud or otherwise, which claim would, but for
                  this provision, be submitted to arbitration shall, before
                  submission to arbitration, first be mediated through
                  non-binding mediation in accordance with the Model Procedures
                  for the Mediation of Business Disputes promulgated by the CPR
                  Institute for Dispute Resolution, or successor ("CPR") then in
                  effect, except where those rules conflict with these
                  provisions, in which case these provisions control. The
                  mediation shall be conducted in Wilmington, Delaware and shall
                  be attended by a senior executive with authority to resolve
                  the dispute from each of the operating companies that are
                  Parties.

              (b) The mediator shall be neutral, independent, disinterested and
                  shall be selected from a professional mediation firm such as
                  ADR Associates or JAMS/ENDISPUTE or CPR.

              (c) The parties shall promptly confer in an effort to select a
                  mediator by agreement. In the absence of such an agreement
                  within 10 days of initiation of the mediation, the mediator
                  shall be selected by CPR as follows: CPR shall provide the
                  parties with a list of at least 15 names. Each party shall
                  exercise challenges for cause, two peremptory challenges, and
                  rank the remaining candidates within 5 working days of
                  receiving the CPR list. The parties may together interview the
                  three top-ranked candidates for no more than one hour each
                  and, after the interviews, may each exercise one peremptory
                  challenge. The mediator shall be the remaining candidate with
                  the highest aggregate ranking.

              (d) The mediator shall confer with the parties to design
                  procedures to conclude the mediation within no more than 45
                  days after initiation. Under no circumstances may the
                  commencement of arbitration under Section 1.2 hereof be
                  delayed more than 45 days by the mediation process specified
                  herein absent contrary agreement of the parties.

              (e) Each party agrees not to use the period or pendency of the
                  mediation to disadvantage the other party procedurally or
                  otherwise. No statements made by either side during the
                  mediation may be used by the other or referred to during any
                  subsequent proceedings.

              (f) Each party has the right to pursue provisional relief from any
                  court, such as attachment, preliminary injunction, replevin,
                  etc., to avoid irreparable harm,

                                       50
<PAGE>

                  maintain the status quo, or preserve the subject matter of the
                               ------ ---
                  arbitration, even though mediation has not been commenced or
                  completed.

         1.2  (a) Following the mediation procedures set forth in Section 1.1,
                  any dispute, claim or controversy arising from or related in
                  any way to this Agreement or the interpretation, application,
                  breach, termination or validity thereof, including any claim
                  of inducement of this Agreement by fraud or otherwise, will be
                  submitted for resolution to arbitration pursuant to the rules
                  then pertaining of CPR, except where those rules conflict with
                  these provisions, in which case these provisions control. The
                  arbitration will be held in Wilmington, Delaware.

              (b) The panel shall consist of three arbitrators chosen from the
                  CPR Panels of Distinguished Neutrals (or, by agreement, from
                  another provider of arbitrators) each of whom is a lawyer with
                  at least 15 years experience with a law firm or corporate law
                  department of over 25 lawyers or was a judge of a court of
                  general jurisdiction. In the event the aggregate damages
                  sought by the claimant are stated to be less than $5 million,
                  and the aggregate damages sought by the counterclaimant are
                  stated to be less than $5 million, and neither side seeks
                  equitable relief, then a single arbitrator shall be chosen,
                  having the same qualifications and experience specified above.
                  Each arbitrator shall be neutral, independent, disinterested,
                  impartial and shall abide by The Code of Ethics for
                  Arbitrators in Commercial Disputes approved by the AAA. There
                  shall be no ex parte communications with an arbitrator either
                              -- -----
                  before or during the arbitration, relating to the dispute or
                  the issues involved in the dispute or the arbitrator's views
                  on any such issues.

              (c) The parties agree to cooperate (1) to attempt to select the
                  arbitrator(s) by agreement within 45 days of initiation of the
                  arbitration, including jointly interviewing the final
                  candidates, (2) to meet with the arbitrator(s) within 45 days
                  of selection and (3) to agree at that meeting or before upon
                  procedures for discovery and as to the conduct of the hearing
                  which will result in the hearing being concluded within no
                  more than 9 months after selection of the arbitrator(s) and in
                  the award being rendered within 60 days of the conclusion of
                  the hearings, or of any post-hearing briefing, which briefing
                  will be completed by both sides within 45 days after the
                  conclusion of the hearings.

              (d) In the event the parties cannot agree upon selection of the
                  arbitrator(s), CPR will select arbitrator(s) as follows: CPR
                  shall provide the parties with a list of no less than 25
                  proposed arbitrators (15 if a single arbitrator is to be
                  selected) having the credentials referenced above. Within 25
                  days of receiving such list, the parties shall rank at least
                  65% of the proposed arbitrators on the initial CPR list, after
                  exercising cause challenges. The parties may then interview
                  the five candidates (three if a single arbitrator is to be
                  selected) with the highest combined rankings for no more than
                  one hour each and, following the interviews, may exercise one
                  peremptory challenge each. The panel will consist of the
                  remaining three

                                       51
<PAGE>

                  candidates (or one, if one arbitrator is to be selected) with
                  the highest combined rankings.

                  In the event these procedures fail to result in selection of
                  the required number of arbitrators, CPR shall select the
                  appropriate number of arbitrators from among the members of
                  the various CPR Panels of Distinguished Neutrals, allowing
                  each side challenges for cause and three peremptory challenges
                  each.

              (e) In the event the parties cannot agree upon procedures for
                  discovery and conduct of the hearing meeting the schedule set
                  forth in Section 1.2(c) above, then the arbitrator(s) shall
                  set dates for the hearing, any post-hearing briefing, and the
                  issuance of the award in accord with the Section 1.2(c)
                  schedule. The arbitrator(s) shall provide for discovery
                  according to those time limits, giving recognition to the
                  understanding of the parties that they contemplate reasonable
                  discovery, including document demands and depositions, but
                  that such discovery be limited so that the Section 1.2(c)
                  schedule may be met without difficulty. In no event will the
                  arbitrator(s), absent agreement of the parties, allow more
                  than a total of ten days for the hearing or permit either side
                  to obtain more than a total of 40 hours of deposition
                  testimony from all witnesses, including both fact and expert
                  witnesses, or serve more than 20 individual requests for
                  documents, including subparts, or 20 individual requests for
                  admission or interrogatories, including subparts. Multiple
                  hearing days will be scheduled consecutively to the greatest
                  extent possible.

              (f) The arbitrator(s) must render their award by application of
                  the substantive law of the State of Delaware and are not free
                  to apply "amiable compositeur" or "natural justice and
                  equity." The arbitrator(s) shall render a written opinion
                  setting forth findings of fact and conclusions of law with the
                  reasons therefor stated. A transcript of the evidence adduced
                  at the hearing shall be made and shall, upon request, be made
                  available to either party. The arbitrator(s) shall have power
                  to exclude evidence on grounds of hearsay, prejudice beyond
                  its probative value, redundancy, or irrelevance and no award
                  shall be overturned by reason of such ruling on evidence. To
                  the extent possible, the arbitration hearings and award will
                  be maintained in confidence.

              (g) The United States District Court for the District in which the
                  arbitration is held may enter judgment upon any award. In the
                  event the panel's award exceeds $5 million in monetary damages
                  or includes or consists of equitable relief, or rejects a
                  claim in excess of that amount or for that relief, then the
                  court shall vacate, modify or correct any award (including
                  remanding to the arbitrators for further proceedings) where
                  the arbitrators' findings of fact are clearly erroneous,
                  and/or where the arbitrators' conclusions of law are
                  erroneous; in other words, the court will undertake the same
                  review as if it were a federal appellate court reviewing a
                  district court's findings of fact and conclusions of law
                  rendered after a bench trial. An award for less than $5
                  million in damages and not including equitable relief,

                                       52
<PAGE>

                  or which neither rejects a claim in excess of that amount or
                  for that relief, may be vacated, modified or corrected only
                  pursuant to the Federal Arbitration Act. The parties consent
                  to the jurisdiction of the above-specified Court for the
                  enforcement of these provisions, the review specified herein,
                  and the entry of judgment on any award. In the event such
                  Court lacks jurisdiction, then any court having jurisdiction
                  of this matter may enter judgment upon any award and provide
                  the same relief, and undertake the same review, as specified
                  herein.

              (h) In the event the expanded judicial review provided for under
                  Section 1.2(g) above is not available from the court as a
                  matter of law, the party unable to obtain such review may
                  instead obtain review of the arbitrators' award or decision by
                  a single appellate arbitrator (the "Appeal Arbitrator")
                  selected from the CPR list of distinguished neutrals and
                  pursuant to selection procedures specified in Section 1.2(d)
                  above. If CPR cannot provide such services, the parties will
                  together select another provider of arbitration services that
                  can. No Appeal Arbitrator shall be selected unless he or she
                  can commit to rendering a decision within forty-five days
                  following oral argument as provided in this paragraph. Any
                  such review must be initiated within thirty (30) days
                  following the date the court declines the expanded review
                  specified in Section 1.2(g) above. In the event timely review
                  is sought, the Appeal Arbitrator will make the same review of
                  the arbitration panel's ruling and its bases that the U.S.
                  Court of Appeals of the Circuit where the arbitration hearings
                  are held would make of findings of fact and conclusions of law
                  rendered by a district court after a bench trial and then
                  modify, vacate or affirm the arbitration panel's award or
                  decision accordingly, or remand to the panel for further
                  proceedings. The Appeal Arbitrator will consider only the
                  arbitration panel's findings of fact and conclusions of law,
                  pertinent portions of the hearing transcript and evidentiary
                  record as submitted by the parties, opening and reply briefs
                  of the party pursuing the review, and the answering brief of
                  the opposing party, plus a total of no more than four (4)
                  hours of oral argument evenly divided between the parties. The
                  party seeking review must submit its opening brief and any
                  reply brief within seventy-five (75) and one hundred thirty
                  (130) days, respectively, following the date the court
                  declines the expanded review specified in Section 1.2(g);
                  whereas, the opposing party must submit its responsive brief
                  within one hundred ten (110) days of that date. Oral argument
                  shall take place within five (5) months after the court
                  declines the expanded review specified in Section 1.2(g), and
                  the Appeal Arbitrator shall render a decision within
                  forty-five (45) days following oral argument. That decision
                  will be final and not subject to further review, except
                  pursuant to the Federal Arbitration Act.

              (i) Each party has the right before or, if the arbitrator(s)
                  cannot hear the matter within an acceptable period, during the
                  arbitration to seek and obtain from the appropriate court
                  provisional remedies such as attachment, preliminary
                  injunction, replevin, etc. to avoid irreparable harm, maintain
                  the status quo, or preserve the subject matter of the
                  arbitration.

                                       53
<PAGE>

              (j) EACH PARTY HERETO WAIVES ITS RIGHT TO TRIAL OF ANY ISSUE BY
                  JURY.

              (k) EACH PARTY HERETO WAIVES ANY CLAIM TO PUNITIVE, EXEMPLARY OR
                  MULTIPLIED DAMAGES FROM THE OTHER.

              (l) EACH PARTY HERETO WAIVES ANY CLAIM OF CONSEQUENTIAL DAMAGES
                  FROM THE OTHER.

              (m) EACH PARTY HERETO WAIVES ANY CLAIM FOR ATTORNEYS' FEES AND
                  COSTS AND PREJUDGMENT INTEREST FROM THE OTHER.

                                       54
<PAGE>

                                 SCHEDULE 14.10

                                  PRESS RELEASE

FOR IMMEDIATE RELEASE

<TABLE>
<CAPTION>

Corporate Contact                   Media Inquiries                 Investor Inquiries
-----------------                   ---------------                 ------------------
<S>                                 <C>                             <C>
3-Dimensional Pharmaceuticals       Noonan/Russo Communications     Rx Communications
Scott Horvitz                       Glenn Silver                    Melody Carey
VP, Finance and Administration      212-696-4455, ext. 271          917-322-2571
267-757-7208                        g.silver@noonanrusso.com        mcarey@rxir.com
horvitz@3dp.com                     ------------------------
---------------
</TABLE>

          3-DIMENSIONAL PHARMACEUTICALS ANNOUNCES DISCOVERWORKS(R)DRUG
            DISCOVERY ALLIANCE WITH JOHNSON & JOHNSON PHARMACEUTICAL
                             RESEARCH & DEVELOPMENT

Yardley, PA, January 7, 2002 - 3-Dimensional Pharmaceuticals, Inc. (Nasdaq:DDDP)
(3DP) today announced a drug discovery alliance that will apply 3DP's
proprietary technologies to discover and optimize small molecule drug leads
directed to genomics targets identified by Johnson & Johnson Pharmaceutical
Research & Development, L.L.C.

Under terms of the agreement, 3DP will receive an upfront technology access fee
and committed research funding during the research collaboration period. 3DP is
also eligible to receive milestone payments and royalties on any sales of
resulting products.

3DP (http://www.3dp.com) is an integrated bio-pharmaceuticals company dedicated
to revolutionizing small molecule drug discovery and development. 3DP's
proprietary platform, DiscoverWorks, can be applied to virtually any potential
drug target. It produces drug candidates suitable for faster development , with
fewer resources and a higher probability of success than using conventional drug
discovery methods. 3DP is developing its own drug pipeline and collaborates with
other pharmaceutical companies in discovery and development.

                                      ###

Statements in this press release that are not strictly historical are "forward
looking" statements which involve a high degree of risk and uncertainty. Such
statements are only predictions, and the actual events of results may differ
materially from those projected in such forward-looking statements. Factors that
could cause or contribute to differences include, but are not limited to, risks
associated with our new and uncertain technologies, clinical trials and product
development, the long and arduous process of obtaining regulatory approval, our
dependence on existing strategic alliances and new collaborations, our
dependence on patents and proprietary rights, our ability to protect and enforce
our patents and proprietary rights, the development and availability of
competitive products or technologies, our ability to attract and retain talented
employees and our ability to manage our expansion as a company increasingly
focused on internal product research and development.

                                       55<PAGE>

                                                                   Exhibit 10.48

                               LICENSE AGREEMENT

                                GLAXOSMITHKLINE

                                      AND

                      3-DIMENSIONAL PHARMACEUTICALS, INC.

Note:  Certain portions of this License Agreement and its exhibits, which
----
are identified by the symbol "[*    *]", have been omitted and filed separately
with the Securities and Exchange Commission pursuant to a confidential treatment
request.
<PAGE>

                               LICENSE AGREEMENT
                               -----------------

     THIS LICENSE AGREEMENT (hereinafter "AGREEMENT"), made as of the _____ day
of January, 2002, between SmithKline Beecham Corporation, a Pennsylvania
corporation having a place of business at One Franklin Plaza, Philadelphia, PA
19101 ("SBC") and Glaxo Group Limited, a company incorporated in England and
Wales, having an office at Greenford Road, Greenford, Middlesex, UB6 OHE, United
Kingdom ("GGL" and, together with SBC, GlaxoSmithKline or "GSK") and 3-
Dimensional Pharmaceuticals, Inc., a Delaware corporation having a place of
business at Three Lower Makefield Corporate Center, 1020 Stony Hill Road,
Yardley, PA 19067 (herein referred to as "3DP"),

                                WITNESSETH THAT:
                                ----------------

     WHEREAS, GSK is the owner of all right, title and interest in certain
patents, identified in Appendix B hereto, and know-how, relating to two
thrombopoietin peptide mimetics known internally at GSK as AF13948 and AF15705,
as well as to certain PEGylated forms of these compounds known internally at GSK
as GW350805 and GW395058, respectively;

     WHEREAS GSK was developing, but has discontinued development of, GW350805
and W395058; and

     WHEREAS, 3DP desires to obtain an exclusive license, and GSK is willing to
grant an exclusive license to develop and commercialize such compounds on the
terms and conditions set forth herein.

     NOW, THEREFORE, in consideration of the covenants and obligations expressed
herein, and intending to be legally bound, and otherwise to be bound by proper
and reasonable conduct, the parties agree as follows:

1.   DEFINITIONS
     -----------

     1.01 "AFFILIATE" shall mean any corporation or other entity that controls,
is controlled by or is under common control with a party to this Agreement. A
corporation or other entity, as applicable, shall be regarded as in control of
another corporation or other entity if it owns or directly or indirectly
controls at least fifty percent (50%) of the voting stock of the other
corporation or (a) in the absence of the ownership of at least fifty percent
(50%) of the voting stock of a corporation or (b) in the case of a non-corporate
entity, if it possesses, directly or indirectly, the power to direct or cause
the direction of the management and policies of such corporation or non-
corporate entity, as applicable.

                                    Page 1
<PAGE>

     1.02 "EFFECTIVE DATE" shall mean the date as of which this Agreement is
effective and shall be the date of this Agreement first written above.

     1.03 "FIELD" shall the mean the development, manufacture and sale of
products that are peptides or modified peptides, including but not limited to
PRODUCTS, that exhibit activity mimetic to thrombopoietin and that [*        *];
excluding however for all purposes the development, manufacture and sale of
products that [*        *], including but not limited to PRODUCTS,
[*         *].

     1.04 "KNOW-HOW" shall mean the technical information and know-how that is
owned or controlled by GSK as of the EFFECTIVE DATE and that is necessary or
useful for the development, manufacturing or regulatory approval of a PRODUCT
and shall include, without limitation, biological, chemical, pharmacological,
toxicological, clinical, assay, control and manufacturing data and any other
information specifically relating to a PRODUCT. A non-comprehensive list of
documentation encompassed within KNOW-HOW is set forth on Appendix A attached
hereto, which may be amended from time to time by mutual agreement of the
parties. In addition, if in the course of providing the services described in
Appendix E, GSK develops additional information or know-how that is necessary or
useful for the development, manufacturing or regulatory approval of a PRODUCT,
KNOW-HOW shall also include such additional information and know-how. For the
avoidance of doubt, it is understood and agreed that LICENSOR shall have no
obligation to complete or finalize any draft reports or collections of data that
may be included within KNOW-HOW.

     1.05 "LICENSEE" shall mean 3DP.

     1.06 "LICENSOR" shall mean GSK.

     1.07 "NDA" shall mean an application for marketing approval of a
pharmaceutical product in any country of the world.

     1.08 "PATENTS" shall mean the patents and patent applications that are
owned by LICENSOR as of the EFFECTIVE DATE, or to which LICENSOR otherwise has
the right to grant licenses as of the EFFECTIVE DATE and that generically or
specifically claim a PRODUCT or compositions thereof, methods of manufacturing a
PRODUCT or compositions thereof, or methods of using a PRODUCT or compositions
thereof. Also included within the definition of PATENTS are all continuations,
continuations-in-part, divisions, patents of addition, utility models, reissues,
renewals, extensions and supplementary patent certificates derived from or based
on such patents and patent applications. The list of U.S. and PCT patent
applications and patents encompassed within PATENTS as of the EFFECTIVE DATE is
set forth in Appendix B attached hereto. Promptly following the EFFECTIVE DATE,
LICENSOR shall amend Appendix B to include all patent applications and patents
encompassed within PATENTS. In addition, PATENTS shall also include patents and
patent applications filed in

                                    Page 2
<PAGE>

accordance with Section 7.01 as well as all continuations, continuations-in-
part, divisions, patents of addition, utility models, reissues, renewals,
extensions and supplementary patent certificates derived from or based on such
patents and patent applications.

     1.09 "PRODUCT" shall mean any of AF15705, AF13948, GW350805 and GW395058,
each of which is more fully described on Appendix C, including alternative
PEGylated or otherwise-modified forms thereof and including pharmaceutical
compositions comprising such compounds or modified forms thereof, as well as any
derivatives thereof that are discovered or developed by LICENSEE during the term
of this AGREEMENT. "PRODUCTS" shall mean all of AF15705, AF13948, GW350805 and
GW395058 and all alternative PEGylated or otherwise-modified forms thereof and
including pharmaceutical compositions comprising such compounds or modified
forms thereof, as well as any derivatives thereof that are discovered or
developed by LICENSEE during the term of this AGREEMENT.

     1.10 "TERRITORY" shall mean all the countries and territories in the world.

     1.11 "THIRD PARTY(IES)" shall mean any party other than a party to this
Agreement or an AFFILIATE of either party.

2.  GRANT
    -----
     2.01 LICENSOR hereby grants to LICENSEE an exclusive license, with the
right to grant sublicenses, under the PATENTS and KNOW-HOW to make, have made,
use, offer to sell, sell and import products in the FIELD in the TERRITORY,
subject to the terms and conditions of this Agreement.

3.  PAYMENTS AND ROYALTIES
    ----------------------
     3.01 In consideration for the exclusive license to PATENTS and KNOW-HOW
granted to LICENSEE by LICENSOR under this Agreement, LICENSEE shall make the
following stock issuances to LICENSOR (to be split equally between each GSK
entity comprising LICENSOR) in accordance with the Stock Purchase Agreement
attached hereto as Appendix D:

          1.  500,000 shares of Common Stock of LICENSEE to be issued
within five (5) business days after the EFFECTIVE DATE;

          2.  [*                *] shares of Common Stock of LICENSEE to be
issued within ten (10 days of the effective date of [*              *], i.e.,
within ten (10) days of the date on which LICENSEE [*            *]or to an
analogous agency under the laws and regulations of any other country;

          3.  [*                *] shares of Common Stock of LICENSEE to be
issued within ten (10) days of [*                       *];

                                    Page 3
<PAGE>

          4.  [*                *] shares of Common Stock of LICENSEE to be
issued within ten (10) days of [*                       *];

          5.  [*                *] shares of Common Stock of LICENSEE to be
issued with ten (10) days of [*                 *].

        [*                                              *]

     3.02 The stock issuances specified in Section 3.01 shall be the sole
consideration for all rights granted to LICENSEE hereunder and for all
obligations assumed by LICENSOR hereunder.

     3.03 LICENSEE shall give LICENSOR prompt written notice of occurrence of
each of the development milestones identified in Section 3.01(2),(3),(4), and
(5).

4.   DEVELOPMENT AND REGISTRATION
     ----------------------------

     4.01 As of the EFFECTIVE DATE, LICENSEE shall have full control and
authority over, and shall be solely responsible for PRODUCTS, including but not
limited to the development, registration, manufacture and commercialization of
PRODUCTS in the TERRITORY.  LICENSEE will exercise its reasonable efforts and
diligence in developing and commercializing a PRODUCT in accordance with its
business, legal, medical and scientific judgment, and in undertaking
investigations and actions required to obtain appropriate governmental approvals
to market a PRODUCT in the TERRITORY.  All such activity shall be undertaken at
LICENSEE's expense.

     4.02 LICENSEE shall keep LICENSOR informed in writing, on an annual basis,
of the status of the development of PRODUCTS throughout the TERRITORY.

     4.03 Except as specified in Appendix E and in Section 4.04, LICENSOR shall
have no obligation to provide any support to LICENSEE, whether financially,
internal resource or otherwise, for the development and commercialization of
PRODUCTS under the terms of this Agreement or otherwise.

     4.04 Except to the extent transferred to LICENSEE pursuant to this
Agreement, LICENSOR shall maintain its data, records, reports, and other
information relating to the research and development of PRODUCTS to the same
extent, and with the same level of care, as it would for other pharmaceutical
products that it discovers, develops and directly commercializes, provided that
such data, records, reports, and other information are in its possession or
control as of the EFFECTIVE DATE.

5.   SUPPLY, DISTRIBUTION AND LABELING
     ---------------------------------

                                    Page 4
<PAGE>

     5.01 LICENSEE shall be solely responsible for providing its clinical,
promotional and commercial requirements of PRODUCTS throughout the TERRITORY.

     5.02 LICENSEE shall be solely responsible for the distribution in the
TERRITORY of PRODUCTS.

     5.03 At Licensee's discretion, PRODUCTS sold by LICENSEE or its permitted
sublicensees in the TERRITORY may bear a legend on its packaging stating that
such PRODUCT is sold under a license from LICENSOR and/or bearing the patent
numbers of patents claiming the PRODUCT that have been granted in the country of
sale; provided that the exact content of such legend must be approved by
LICENSOR prior to commercial launch in the TERRITORY if LICENSEE elects to use
such legends.  LICENSOR shall bear no responsibility for any limitation on
damages recoverable from an infringer in an infringement suit as provided for
under Section 7.05 herein if LICENSEE elects under this Section 5.03 to omit the
US patent numbers of patents claiming the PRODUCT.

6.   EXCHANGE OF INFORMATION, TRANSITIONAL SERVICES, AND CONFIDENTIALITY
     -------------------------------------------------------------------

     6.01 LICENSOR shall compile and transfer to LICENSEE, KNOW-HOW, including
but not limited to the documentation listed on Appendix A, and shall otherwise
provide certain transitional services, all as described in Appendix E.  The
obligation to transfer KNOW-HOW extends only to KNOW-HOW known to GSK as of
EFFECTIVE DATE or developed by GSK prior to acceptance of an IND for a PRODUCT.

     6.02 During the term of this Agreement and for five (5) years thereafter,
irrespective of any termination earlier than the expiration of the term of this
Agreement, LICENSOR shall not use or reveal or disclose to THIRD PARTIES any
confidential information received from LICENSEE without first obtaining the
written consent of LICENSEE, except as may be required to be disclosed to a
governmental agency, in which case LICENSOR shall give LICENSEE prior notice of
the details of such disclosure and of the requirements therefor.  This
confidentiality obligation shall not apply to such information which is or
becomes a matter of public knowledge, or is already in the possession of
LICENSOR, or is disclosed to LICENSOR by a THIRD PARTY having the right to do
so, or is subsequently and independently developed by employees of LICENSOR or
AFFILIATES thereof who had no knowledge of the confidential information
disclosed.  LICENSOR shall take reasonable measures to assure that no
unauthorized use or disclosure is made by others to whom access to such
information is granted.

     6.03 During the term of this Agreement and for five (5) years thereafter,
irrespective of any termination earlier than the expiration of the term of this
Agreement, LICENSEE shall not use or reveal or disclose to THIRD PARTIES any
confidential information received from

                                    Page 5
<PAGE>

LICENSOR in accordance with this Agreement or under the Confidential Information
Agreement between LICENSOR and LICENSEE dated June 16, 2001, without first
obtaining the written consent of LICENSOR. This confidentiality obligation shall
not apply to KNOW-HOW or to such information which is or becomes a matter of
public knowledge, or is already in the possession of LICENSEE, or is disclosed
to LICENSEE by a THIRD PARTY having the right to do so, or is subsequently and
independently developed by employees of LICENSEE or AFFILIATES thereof who had
no knowledge of the confidential information disclosed. LICENSEE shall take
reasonable measures to assure that no unauthorized use or disclosure is made by
others to whom access to such information is granted.

     6.04 Either party to this Agreement may release the announcement attached
hereto as Appendix F.  Otherwise, no public announcement or other disclosure to
THIRD PARTIES concerning the existence of or terms of this Agreement shall be
made, either directly or indirectly, by any party to this Agreement, except as
may be legally required or as may be required for recording purposes, without
first obtaining the written approval of the other party and agreement upon the
nature and text of such announcement or disclosure; provided however, that in
the event of any disclosure required by law or required for recording purposes,
the disclosing party shall notify the other party prior to any such disclosure
and reasonably cooperate with any requests to limit or otherwise protect any
such disclosures.

     The above notwithstanding, without the prior consent of LICENSOR, LICENSEE
may disclose to third parties information concerning the development and
commercialization of PRODUCTS provided that it shall not disclose the terms of
this Agreement, except to the extent already disclosed by the announcement
attached as Appendix F, without the prior written consent of LICENSOR.

     A party desiring to make any other public announcement or other disclosure
shall inform the other party of the proposed announcement or disclosure in
reasonably sufficient time prior to release, and shall provide the other party
with a written copy thereof, in order to allow such other party to comment upon
such announcement or disclosure.

     6.05 LICENSOR shall not submit for written or oral publication any
manuscript, abstract or the like which includes data or other information
relating to either PRODUCT without first obtaining the prior written consent of
LICENSEE.

     6.06 Nothing in this Agreement shall be construed as preventing or in any
way inhibiting LICENSEE from complying with statutory and regulatory
requirements governing the development, manufacture, use and sale or other
distribution of PRODUCTS in any manner that it reasonably deems appropriate,
including, for example, by disclosing to regulatory authorities confidential or
other information received from LICENSOR or THIRD PARTIES.

                                    Page 6
<PAGE>

     6.07 All confidential information disclosed by one party to the other shall
remain the intellectual property of the disclosing party.  In the event that a
court or other legal or administrative tribunal, directly or through an
appointed master, trustee or receiver, assumes partial or complete control over
the assets of a party to this Agreement based on the insolvency or bankruptcy of
such party, the bankrupt or insolvent party shall promptly notify the court or
other tribunal (i) that confidential information received from the other party
under this Agreement remains the property of the other party and (ii) of the
confidentiality obligations under this Agreement.  In addition, the bankrupt or
insolvent party shall, to the extent permitted by law, take all steps necessary
or desirable to maintain the confidentiality of the other party's confidential
information and to ensure that the court, other tribunal or appointee maintains
such information in confidence in accordance with the terms of this Agreement.

7.   PATENT PROSECUTION AND LITIGATION
     ----------------------------------

     7.01 Each party shall have and retain sole and exclusive title to all
inventions, discoveries and know-how which are made, conceived, reduced to
practice or generated solely by its employees, agents, or other persons acting
under its authority in the course of or as a result of the performance of
activities under this Agreement.  Each party shall own a fifty percent (50%)
undivided interest in all such inventions, discoveries and know-how made,
conceived, reduced to practice or generated jointly by employees, agents, or
other persons acting under the authority of both parties in the course of or as
a result of the performance of activities under this Agreement.  For the
avoidance of doubt, it is understood and agreed that LICENSOR is not obligated
to, and has no intent of being involved at all with LICENSEE in the development
or commercialization of PRODUCT under this Agreement, and that the
responsibility for the development and commercialization of PRODUCT rests solely
with LICENSEE, except as provided in Appendix E and in Section 4.04.  LICENSOR
shall have the right to file, prosecute and maintain patent applications and
patents directed to inventions and discoveries that are owned in whole by
LICENSOR in accordance with this Section 7.01.  LICENSEE shall have the right to
file, prosecute and maintain patent applications and patents directed to
inventions and discoveries that are owned in whole by LICENSEE in accordance
with this Section 7.01.  Both parties shall have the right to file, prosecute
and maintain patent applications and patents directed to inventions and
discoveries that are jointly owned by LICENSEE and by LICENSOR in accordance
with this Section 7.01 and the parties shall agree upon which of them shall take
the lead in filing, prosecuting and maintaining such patent applications at the
equal expense of both parties.  If either party declines to exercise its rights
to file, prosecute and maintain patent applications or patents hereunder, the
other party shall have the right to file, prosecute and maintain such patent
applications and patents at its own expense.

                                    Page 7
<PAGE>

     7.02 LICENSOR shall disclose to LICENSEE the complete texts of all patents
and patent applications that are PATENTS as well as of all correspondence to or
from the U.S. Patent and Trademark Office, and other patent offices around the
world, relating to such patents and patent applications, as well as all
information received concerning the institution or possible institution of any
interference, opposition, re-examination, reissue, revocation, nullification or
any official proceeding involving a PATENT anywhere in the TERRITORY.  All such
disclosures shall be subject to the provisions of Section 6.03.  LICENSEE shall
have the right to comment upon all patent office communications concerning such
patents and patent applications as well as on all proposed responses to such
communications.

     7.03 In addition, LICENSOR shall consult with patent attorneys appointed by
LICENSEE prior to taking any action that would result in the narrowing of claims
that cover the making, using, or selling of a PRODUCT, or that would otherwise
reduce the patent coverage for a PRODUCT, provided that the fees and expenses of
the appointed patent attorneys shall be paid by LICENSEE.  LICENSEE shall have
the right to assume responsibility for any PATENT or any part of a PATENT that
covers the making, using or selling of a PRODUCT and that LICENSOR intends to
abandon or otherwise cause or allow to be forfeited.

     7.04 In the event of the institution of any suit by a THIRD PARTY against
LICENSOR, LICENSEE or its sublicensees for patent infringement involving the
manufacture, use, sale, distribution or marketing of PRODUCT anywhere in the
TERRITORY, the party sued shall promptly notify the other party in writing.
LICENSEE shall have the right but not the obligation to defend such suit at its
own expense.  LICENSOR and LICENSEE shall assist one another and cooperate in
any such litigation at the other's reasonable request without expense to the
requesting party.

     7.05 In the event that LICENSOR or LICENSEE becomes aware of actual or
threatened infringement of a patent claim in a PATENT, which claim covers the
making, using, or selling of a product in the FIELD anywhere in the TERRITORY,
that party shall promptly notify the other party in writing.  LICENSEE shall
have the first right but not the obligation to bring, at its own expense, an
infringement action against any THIRD PARTY and, if required in order to bring
or maintain such action or to recover the full measure of damages, to use
LICENSOR's name in connection therewith and to include LICENSOR as a party
thereto.  If LICENSEE does not commence a particular infringement action within
ninety (90) days, LICENSOR, if LICENSEE consents, shall be entitled to bring
such infringement action at its own expense.  The party conducting such action
shall have full control over its conduct, including settlement thereof, subject
to Paragraph 7.07.  In any event, LICENSOR and LICENSEE shall assist one another
and cooperate in any such litigation at the other's reasonable request without
expense to the requesting party.

                                    Page 8
<PAGE>

     7.06 LICENSOR and LICENSEE shall recover their respective actual out-of-
pocket expenses, or equitable proportions thereof, associated with any
litigation or settlement thereof from any recovery made by any party. Any excess
amount shall be kept by the party that conducted the litigation.

     7.07 The parties shall keep one another informed of the status of and of
their respective activities regarding any litigation or settlement thereof
concerning PRODUCT, provided that no settlement or consent judgment or other
voluntary final disposition of any suit defended or action brought by one party
pursuant to this Article 7 may be entered into without the consent of the other
party if such settlement would require the non-settling party to be subject to
an injunction outside the FIELD or to make a monetary payment for which the non-
settling party is not indemnified by the settling party or would adversely
affect the non-settling party's rights under this Agreement.

8.   TRADEMARKS AND NON-PROPRIETARY NAMES
     ------------------------------------

     8.01 LICENSEE, at its expense, shall be responsible for the selection,
registration and maintenance of all trademarks that it employs in connection
with PRODUCT in the TERRITORY and shall own and control such trademarks.
Nothing in this Agreement shall be construed as a grant of rights, by license or
otherwise, to LICENSOR to use such trademarks for any purpose.

9.   TERM AND TERMINATION
     --------------------

     9.01 Unless otherwise terminated, this Agreement shall expire upon the
expiration, lapse or invalidation of the last remaining PATENT in any country of
the TERRITORY that covers the making, using, selling, or importing of PRODUCT.
Expiration of this Agreement under this provision shall not preclude LICENSEE
from continuing to market PRODUCT and to use KNOW-HOW without further payments
to LICENSOR.

     9.02 If either party fails or neglects to perform material covenants or
provisions of this Agreement and if such default is not corrected within thirty
(30) days after receiving written notice from the other party with respect to
such default, such other party shall have the right to terminate this Agreement
by giving written notice to the party in default; provided, however, that if
such default is contested in accordance with Article 14, then the termination
shall not take effect until the matter is finally resolved.

     9.03 LICENSEE may terminate this Agreement at any time and at its
discretion by giving thirty (30) days written notice thereof to LICENSOR.  Upon
any termination by LICENSOR pursuant to Section 9.02 or LICENSEE pursuant to
this Section 9.03, in addition to the provisions of Article 10 below, LICENSEE
shall return to LICENSOR any KNOW-HOW

                                    Page 9
<PAGE>

provided to LICENSEE hereunder. In addition, LICENSEE shall grant to LICENSOR a
license under LICENSEE's rights in all pre-clinical, clinical, regulatory,
manufacturing and other documentation and related know-how and patents relating
to PRODUCTS developed and/or commercialized hereunder under commercially
reasonable terms to be negotiated in good faith between the parties.

     9.04 Either party may terminate this Agreement if, at any time, the other
party shall file in any court or agency pursuant to any statute or regulation of
any state or country, a petition in bankruptcy or insolvency or for
reorganization or for an arrangement or for the appointment of a receiver or
trustee of the party or of its assets, or if the other party proposes a written
agreement of composition or extension of its debts, or if the other party shall
be served with an involuntary petition against it, filed in any insolvency
proceeding, and such petition shall not be dismissed within sixty (60) days
after the filing thereof, or if the other party shall propose or be a party to
any dissolution or liquidation, or if the other party shall make an assignment
for the benefit of creditors.

     9.05 Notwithstanding the bankruptcy of LICENSOR, or the impairment of
performance by LICENSOR of its obligations under this Agreement as a result of
bankruptcy or insolvency of LICENSOR, LICENSEE shall be entitled to retain the
licenses granted herein, subject to LICENSOR's rights to terminate this
Agreement for reasons other than bankruptcy or insolvency as expressly provided
in this Agreement.

10.  RIGHTS AND DUTIES UPON TERMINATION
     ----------------------------------

     10.01  Upon termination of this Agreement, LICENSOR shall have the right to
retain any shares of Common Stock of LICENSEE already issued to LICENSOR by
LICENSEE under this Agreement or the Stock Purchase Agreement, and LICENSEE
shall issue to LICENSOR all shares of Common Stock that may be due as of the
effective date of termination under Section 3.01.

     10.02  Termination of this Agreement shall terminate all outstanding
obligations and liabilities between the parties arising from this Agreement,
including without limitation the licenses granted in Article 2 hereof, except
those described in Paragraphs 6.02, 6.03, 6.07, 7.01, 9.01, 9.03, 11.06, 13.01
and 14.01 and Article 10, as well as any other provision which, by its terms, is
stated to survive the termination or expiration of this Agreement.  In addition,
any other provision required to interpret and enforce the parties rights and
obligations under this Agreement shall also survive, but only to the extent that
such survival is required for the full observation and performance of this
Agreement by the parties hereto.

     10.03  Termination of the Agreement in accordance with the provisions
hereof shall not limit remedies that may be otherwise available in law or
equity.

                                    Page 10
<PAGE>

11.    WARRANTIES AND REPRESENTATIONS
       ------------------------------

     11.01  LICENSOR represents and warrants that, except as listed in
Appendix G:

        11.1.1.  it has the right to enter into this Agreement;

        11.1.2. as of the EFFECTIVE DATE, to its belief and knowledge, but
without any inquiry or investigation, the claims in the PATENTS listed on
Appendix B that cover the making, using or selling of a PRODUCT are valid and
enforceable;

        11.1.3. as of the EFFECTIVE DATE, to its belief and knowledge, but
without any inquiry or investigation, there are no third party patents or other
intellectual property rights that would preclude or inhibit LICENSEE from
making, using, or selling PRODUCTS in the Field;

        11.1.4. as of the EFFECTIVE DATE, to its belief and knowledge, but
without any inquiry or investigation, there are no third party liens or other
encumbrances, including but not limited to encumbrances arising from contracts
with third parties, on the PRODUCTS or on the PATENTS listed on Appendix B for
use in the Field;

        11.1.5. it has disclosed or will timely disclose to LICENSEE all
information and data relevant to the safety of the PRODUCTS.

     11.02  Nothing in this Agreement shall be construed as a warranty that
PATENTS are valid or enforceable or that their exercise does not infringe any
patent rights of THIRD PARTIES.

     11.03  [*                    *].

     11.04  LICENSEE acknowledges that, in entering into this Agreement,
LICENSEE has independently evaluated any information supplied by LICENSOR and
related to PRODUCT and PATENTS before making its decision to enter into this
Agreement and to undertake the commitments and obligations set forth herein,
except that LICENSEE has relied upon the representations and warranties by
LICENSOR expressly recited in Section 11.01.  LICENSEE expressly acknowledges
that it is solely responsible for the development and commercialization of
PRODUCT and that, except as expressly set forth herein, LICENSOR has no
obligation to provide assistance in any manner to LICENSEE in the development
and commercialization of PRODUCT.

     11.05  LICENSEE warrants that, with respect to any sublicense which it
shall be entitled to grant under this Agreement, it shall secure all appropriate
covenants, obligations and rights from any such sublicensee to ensure that such
sublicensee can comply with all of LICENSEE' covenants and obligations to
LICENSOR under this Agreement.  LICENSEE agrees that it shall comply with all
reasonable requests from LICENSOR to use reasonable endeavors to enforce
requested provisions of such sublicense agreements.

                                    Page 11
<PAGE>

     11.06   LICENSEE shall indemnify and hold harmless LICENSOR and its
Affiliates with respect to any and all claims, suits, causes of action, damages
and costs (including reasonable attorney's fees) (hereinafter "Claims") asserted
by any Third Party against LICENSEE and/or LICENSOR and arising from any of
LICENSEE'S actions or omissions under this Agreement, including without
limitation any claims for illness, injury, death or other damage resulting from
LICENSEE or its AFFILIATES manufacture, use or sale of PRODUCT, except to the
extent:

        11.6.1. such Claims are due to the negligence or willful misconduct of
LICENSOR or to breach by LICENSOR of its representations and warranties under
Section 11.01

        11.6.2. LICENSOR fails to give LICENSEE prompt notice of such Claims,
fails to permit LICENSEE to control the defense or settlement of such Claims, or
fails to reasonably cooperate with LICENSEE in the defense of such Claims;
provided however that LICENSEE shall not settle any claim that imposes an
injunction on LICENSOR outside of the FIELD or imposes a monetary judgement on
LICENSOR for which LICENSOR is not indemnified by LICENSEE or otherwise
adversely affects LICENSOR's rights outside the FIELD.

     11.07  Immediately upon the first administration of a PRODUCT to a human in
accordance with this Agreement, and for a period of at least five (5) years
after the expiration of this Agreement or earlier termination, LICENSEE shall
obtain and/or maintain, at its sole cost and expense, product liability
insurance in amounts, which are reasonable and customary in the U.S.
pharmaceutical industry for companies that are of similar size and similarly
situated as LICENSEE.  Such product liability insurance shall insure against all
liability, including product liability, personal liability, physical injury or
property damage.  LICENSEE shall provide written proof of the existence of such
insurance to LICENSOR upon request therefor.

12.  FORCE MAJEURE
     -------------

     12.01  If the performance of any part of this Agreement by either party, or
of any obligation under this Agreement, is prevented, restricted, interfered
with or delayed by reason of any cause beyond the reasonable control of the
party liable to perform, unless conclusive evidence to the contrary is provided,
the party so affected shall, upon giving written notice to the other party, be
excused from such performance to the extent of such prevention, restriction,
interference or delay, provided that the affected party shall use its reasonable
best efforts to avoid or remove such causes of non-performance and shall
continue performance with the utmost dispatch whenever such causes are removed.
When such circumstances arise, the parties shall discuss what, if any,
modification of the terms of this Agreement may be required in order to arrive
at an equitable solution.

                                    Page 12
<PAGE>

13.  GOVERNING LAW
     -------------

     13.01  This Agreement shall be deemed to have been made in Pennsylvania and
its form, execution, validity, construction and effect shall be determined in
accordance with the laws of Pennsylvania.

14.  DISPUTE RESOLUTION
     ------------------

     14.01  Any dispute, controversy or claim arising out of or relating to this
Agreement, including termination thereof (hereinafter collectively referred to
as "Dispute") shall be attempted to be settled by the parties, in good faith, by
submitting each such Dispute to appropriate senior management representatives of
each party in an effort to effect a mutually acceptable resolution thereof.  In
the event no mutually acceptable resolution is achieved in a reasonable period
of time, then either party may submit the Dispute to binding arbitration in
accordance with the relevant rules of the American Arbitration Association and
the result of such arbitration shall be binding upon the parties and shall be
final. Any such arbitration shall take place in Philadelphia, Pennsylvania.

15.  SEPARABILITY
     ------------

     15.01  In the event any portion of this Agreement shall be held illegal,
void or ineffective, the remaining portions hereof shall remain in full force
and effect.

     15.02  If any of the terms or provisions of this Agreement are in conflict
with any applicable statute or rule of law, then such terms or provisions shall
be deemed inoperative to the extent that they may conflict therewith and shall
be deemed to be modified to conform with such statute or rule of law.

     15.03  In the event that the terms and conditions of this Agreement are
materially altered as a result of Paragraphs 15.01 or 15.02, the parties will
renegotiate the terms and conditions of this Agreement to resolve any
inequities.

16.  ENTIRE AGREEMENT
     ----------------

     16.01  This Agreement, entered into as of the date first written above,
constitutes the entire agreement between the parties relating to the subject
matter hereof and supersedes all previous writings and understandings, including
but not limited to the Confidential Information Agreement between LICENSOR and
LICENSEE dated June 16, 2001.   No terms or provisions of this Agreement shall
be varied or modified by any prior or subsequent statement, conduct or act of
either of the parties, except that the parties may amend this Agreement by
written instruments specifically referring to and executed in the same manner as
this Agreement.

                                    Page 13
<PAGE>

17.  NOTICES
     -------

     17.01  Any notice required or permitted under this Agreement shall be sent
by air mail, postage pre-paid, to the following addresses of the parties:

        LICENSEE

          To:       3-Dimensional Pharmaceuticals, Inc.
                    Three Lower Makefield Corporate Center
                    1020 Stony Hill Road
                    Yardley, PA 19067

                    Attn:  Chief Executive Officer
                    Fax No.:  267-757-7283

          Copy to:
                    Morgan, Lewis & Bockius, LLP
                    1701 Market Street
                    Philadelphia, PA  19103-2921
                    Fax No.  215-963-5299
                    Attention: Edward T. Lentz, Esq. and Linda Griggs, Esq.

          LICENSOR

          To:       GlaxoSmithKline
                    1250 Collegeville Road
                    Collegeville, PA 19426-0989

                    Attn:  Mr. Osagie Imasogie
                           V.P. and Director,
                           Genetics and Discovery Ventures
                    Fax:   610-917-4234

          Copy to:  GlaxoSmithKline
                    Corporate Law Department
                    One Franklin Plaza
                    200 North 16th Street / FP2360
                    Philadelphia, PA  19102
                    Attn:  General Counsel
                    Fax:  215-751-3935

     17.02  Any notice required or permitted to be given concerning this
Agreement shall be effective upon receipt by the party to whom it is addressed.

                                    Page 14
<PAGE>

18.  ASSIGNMENT
     ----------

     18.01  This Agreement and the licenses herein granted shall be binding upon
and inure to the benefit of the successors in interest of the respective
parties.  Neither this Agreement nor any interest under this Agreement shall be
assignable by either party without the written consent of the other; provided,
however, that either party may assign this Agreement  to (i) any AFFILIATE or
(ii) any corporation with which it may merge or consolidate, or to which it may
transfer all or substantially all of its assets , without obtaining the consent
of the other party; provided further that any such assignee shall agree to be
bound by the terms and conditions of this Agreement.  For the avoidance of
doubt, LICENSEE's obligations under the Stock Purchase Agreement and
Registration Rights Agreement shall not be affected by any such assignment.

19.  RECORDING
     ---------

     19.01  LICENSEE shall have the right, at any time, to record, register, or
otherwise notify this Agreement in appropriate governmental or regulatory
offices anywhere in the TERRITORY, and LICENSOR shall provide reasonable
assistance to LICENSEE in effecting such recording, registering or notifying.

20.  EXECUTION IN COUNTERPARTS
     -------------------------

     20.01  This Agreement may be executed in any number of counterparts, each
of which shall be deemed an original but all of which together shall constitute
one and the same instrument.

                                    Page 15
<PAGE>

     IN WITNESS WHEREOF, the parties, through their authorized officers, have
executed this Agreement as of the date first written above.

3-DIMENSIONAL PHARMACEUTICALS, INC.

BY:
    ---------------------------------

TITLE:
       ------------------------------

SMITHKLINE BEECHAM CORPORATION

BY:
    ---------------------------------

TITLE:
       ------------------------------

GLAXO GROUP LIMITED

BY:
    ---------------------------------

TITLE:
       ------------------------------

                                    Page 16
<PAGE>

                               LICENSE AGREEMENT
                             GLAXOSMITHKLINE - 3DP
                                   APPENDIX A

                   Documentation Encompassed Within KNOW-HOW
                                   Appendix A

  Documentation Encompassed Within KNOW-HOW
  -----------------------------------------

GSK agrees to supply the following documentation to the extent such information
is in its possession at the time of the Effective Date.  If electronic versions
are available, information will be supplied electronically.  If only hardcopy
information is available then hardcopy will be supplied.

  [* 2 pages have been omitted pursuant to a confidential treatment request *]

Electronic version of the Confidential Data Package

                                      A-1
<PAGE>

Appendix A continued

Documentation Encompassed Within KNOW-HOW
-----------------------------------------

The following documentation was available in the due diligence notebooks and GSK
agrees to supply this information to 3DP.

                      [*                              *]

<TABLE>
<CAPTION>
                                           INDI
        Subject         Document No.     Document/1/     Title                             Author
     <S>                <C>              <C>             <C>                               <C>
     [*         *]      [*        *]     [*        *]    [*                           *]   [*            *]
</TABLE>

   [* The entire table, consisting of 3 pages, has been omitted pursuant to
a confidential treatment request *]

                                      A-3
<PAGE>

                  [*                                      *]
<TABLE>
<CAPTION>
                                           INDI
        Subject         Document No.     Document/1/     Title                             Author
     <S>                <C>              <C>             <C>                               <C>
     [*         *]      [*        *]     [*        *]    [*                           *]   [*            *]
</TABLE>

   [* The entire table, consisting of 2 pages, has been omitted pursuant to a
                       confidential treatment request *]

                                      A-6
<PAGE>

                  [*                                      *]
<TABLE>
<CAPTION>
          Date             From             To                  Subject
     <S>                <C>              <C>                <C>
     [*         *]      [*        *]     [*        *]       [*                           *]
</TABLE>

[* The entire table, consisting of 3 pages, has been omitted pursuant to a
confidential treatment request *]

                                      A-8
<PAGE>

                  [*                                      *]
<TABLE>
<CAPTION>
                                           INDI
        Subject         Document No.     Document/1/     Title                             Author
     <S>                <C>              <C>             <C>                               <C>
     [*         *]      [*        *]     [*        *]    [*                           *]   [*            *]
</TABLE>

   [* The entire table, consisting of 5 pages, has been omitted pursuant to a
                       confidential treatment request *]

                                     A-11

<PAGE>

                         [*                             *]

<TABLE>
<CAPTION>
                                                                                           Created or Last
        Subject          Document        Format          Contents                             Modified
     <S>                <C>              <C>             <C>                               <C>
         [* *]            [*  *]         [* *]            [* *]                                 [* *]

</TABLE>

   [* The entire table, consisting of 1 page, including a portion of one
 footnote, has been omitted pursuant to a confidential treatment request *]

Notes:
1)  A single report may be reissued and appear in more than one INDI document
    files.
2)  Electronic copy not available.  Only pages or sections relevant to
    [*         *] provided.

                                     A-16
<PAGE>

                               LICENSE AGREEMENT
                             GLAXOSMITHKLINE - 3DP
                                   APPENDIX B

                            PATENTS AND APPLICATIONS

                                  U.S. PATENTS
                                  ------------

                         [*                          *]

                        U.S. PENDING PATENT APPLICATIONS
                        --------------------------------

                         [*                          *]

                                PCT APPLICATIONS
                                ----------------

                         [*                          *]

                       NON-U.S. PATENTS AND APPLICATIONS
                       ---------------------------------

  Any and all non-U.S. patents that claim priority to one or more of the U.S.
Patents, U.S. Pending Patent Applications and PCT Applications set forth above.
                    A complete list will be provided by GSK.

                                      B-1
<PAGE>

                               LICENSE AGREEMENT
                             GLAXOSMITHKLINE - 3DP
                                   APPENDIX C

                            DESCRIPTION OF COMPOUNDS

                                    AF13948
                                    -------
                                 [*         *]

                                    AF15705
                                    -------
                                 [*          *]

                                    GW350805
                                    --------
                           [*                        *]

                                    GW395058
                                    --------
                             [*                 *]

                                   C-1
<PAGE>

           STOCK PURCHASE AGREEMENT and REGISTRATION RIGHTS AGREEMENT
                             GLAXOSMITHKLINE - 3DP
                                   Appendix D

                            STOCK PURCHASE AGREEMENT

This Stock Purchase Agreement (the "Agreement") is made as of January___, 2002
                                    ---------
by and among 3-Dimensional Pharmaceuticals, Inc., a Delaware corporation
( "3DP"), SmithKline Beecham Corporation, a Pennsylvania corporation ("SBC"),
   ---                                                                 ---
and Glaxo Group Limited, a company incorporated in England and Wales ("GGL"
                                                                       ---
and, together with SBC, "GSK").
                         ---

                                WITNESSETH THAT:

WHEREAS, 3DP and GSK are entering into a License Agreement simultaneously with
the execution of this Agreement whereby GSK is granting to 3DP an exclusive
license to certain patents and know-how described in such License Agreement (the
"License");
 -------

WHEREAS, pursuant to the License Agreement and in consideration for the License,
3DP has agreed to issue shares of its common stock, par value $.001 per share
(the "3DP Common Stock"), in equal amounts to SBC and GGL in accordance with the
      ----------------
terms and conditions of this Agreement;

NOW, THEREFORE, in consideration of the mutual covenants contained herein and
other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties to this Agreement, intending to be legally
bound, hereby agree as follows:

     1.  Authorization of the Shares.  3DP has authorized the issuance and sale
         ----------------------------
to SBC and GGL of up to 2,400,000 shares of its Common Stock (the "Shares").
                                                                   ------

     2.  Purchase and Sale of the Shares.  Subject to the terms and conditions
         --------------------------------
of this Agreement and the terms and conditions of the License Agreement, and in
consideration for the grant of the License by GSK to 3DP, 3DP agrees to issue
and sell, the following number of Shares, such amount of Shares to be issued in
equal amounts to SBC and GGL:

          (a) 500,000 shares of 3DP Common Stock to be issued within five (5)
business days after the Closing Date;

          (b) [*       *] shares of 3DP Common Stock to be issued within ten
(10) days of the effective date of [*          *], i.e., within ten (10) days
of  the date on which 3DP [*         *] or to an analogous agency under the laws
and regulations of any other country;

                                  D-1
<PAGE>

          (c) [*       *] shares of 3DP Common Stock to be issued within ten
(10) days of [*          *];

          (d) [*       *] shares of 3DP Common Stock to be issued within ten
(10) days of [*          *]; and

          (e) [*       *] shares of 3DP Common Stock to be issued within ten
(10) days of [*          *].

          [*                   *].  In addition, for the purposes of this
Section 2, the terms "Product" and "IND" shall have the meanings ascribed to
                      -------       ---
such terms in the License Agreement.

          For purposes of this Agreement, the Shares to be issued pursuant to
Section 2(a) shall be referred to herein as the "Initial Shares" and the Shares
                                                 --------------
to be issued upon achievement of the milestones identified in Section 2(b), (c),
(d) and (e) shall be referred to herein as the "Contingent Shares."
                                                -----------------

          2.1  Adjustments.  If, on or prior to the issuance of any of the
               ------------
Shares, 3DP should split or combine shares of 3DP Common Stock, or pay a stock
dividend or other stock distribution in 3DP Common Stock, or otherwise change
the 3DP Common Stock into any other securities, or make any other dividend or
distribution on the 3DP Common Stock, then the number of Shares issuable will be
appropriately adjusted to reflect such split, combination, dividend or other
distribution or change.  No fractions of any Shares shall be issued pursuant to
this Agreement and the Shares issued hereunder shall be rounded up to the
nearest whole number of shares.  [*                   *].

     3.  Closing.  The issuance of the Initial Shares will occur within five
         --------
business days of the execution of the License Agreement (the "Closing Date") at
                                                              ------------
the offices of 3DP's counsel or at such other place as may be agreed upon by 3DP
and GSK.  On the Closing Date, 3DP will deliver to GSK, or a representative of
GSK, stock certificates representing the Initial Shares, each such certificate
to be registered in the name of SBC and GGL, as applicable, or in the name of a
nominee designated by SBC or GGL.  The issuance of the Contingent Shares shall
be made within ten days following the achievement of the milestones referenced
in Sections 2(b), (c), (d) and (e).  3DP's obligation to issue the Contingent
Shares will terminate upon the termination or expiration of the License
Agreement in accordance with its terms and will be conditioned on a material
breach or default not having occurred under this Agreement.

     4.  Representations, Warranties and Covenants of 3DP.  3DP hereby
         ------------------------------------------------
represents and warrants to, and covenants with, SBC and GGL, as follows:

          4.1  Organization.  3DP is duly incorporated and validly existing in
               ------------
good standing under the laws of the jurisdiction of its incorporation. 3DP has
full power and authority to own, operate and occupy its properties and to
conduct its business as presently conducted and as described in the documents
(including the exhibits thereto) filed by 3DP under the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), since the end of its most recently
                          ------------
completed fiscal year through the date

                                      D-2
<PAGE>

hereof, including, without limitation, its report on Form 10-K for the year
ended December 31, 2000, its quarterly reports on Form 10-Q for the quarters
ending September 30, 2001, June 30, 2001 and March 31, 2001 and, its current
reports on Form 8-K filed with the Securities and Exchange Commission (the
"SEC") on September 28, 2001 and January 3, 2001, (the "Exchange Act Documents")
 ---                                                    ----------------------
and is registered or qualified to do business and in good standing in each
jurisdiction in which the nature of the business conducted by it or the location
of the properties owned or leased by it requires such qualification and where
the failure to be so qualified would have a material adverse effect upon the
financial condition or results of operations of 3DP (a "Material Adverse
                                                        ----------------
Effect"), and no proceeding has been instituted in any such jurisdiction,
------
revoking, limiting or curtailing, or seeking to revoke, limit or curtail, such
power and authority or qualification.

          4.2  Due Authorization and Valid Issuance.  3DP has all requisite
               ------------------------------------
power and authority to execute, deliver and perform its obligations under this
Agreement, and the Agreement has been duly authorized and validly executed and
delivered by 3DP and constitutes a legal, valid and binding agreement of 3DP
enforceable against 3DP in accordance with its terms, except as rights to
indemnity and contribution may be limited by state or federal securities laws or
the public policy underlying such laws, except as enforceability may be limited
by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws
affecting creditors' and contracting parties' rights generally and except as
enforceability may be subject to general principles of equity (regardless of
whether such enforceability is considered in a proceeding in equity or at law).
The Shares being purchased by SBC and GGL hereunder will, upon issuance pursuant
to the terms hereof, be duly authorized, validly issued, fully-paid and
nonassessable.

          4.3  Non-Contravention.  The execution and delivery of this Agreement,
               -----------------
the issuance of the Shares to be sold by 3DP under the License Agreement and
this Agreement, the fulfillment of the terms of the Agreement and the
consummation of the transactions contemplated hereby will not: (a) conflict with
or constitute a violation of, or default (with the passage of time or otherwise)
under, (i) any material bond, debenture, note or other evidence of indebtedness,
lease, contract, indenture, mortgage, deed of trust, loan agreement, joint
venture or other agreement or instrument to which 3DP is a party or by which its
properties are bound, (ii) the charter, by-laws or other organizational
documents of 3DP, or (iii) any law, administrative regulation, ordinance or
order of any court or governmental agency, arbitration panel or authority
applicable to 3DP or its properties, except in the case of clauses (i) and (iii)
for any such conflicts, violations or defaults which are not reasonably likely
to have a Material Adverse Effect; or (b) result in the creation or imposition
of any lien, encumbrance, claim, security interest or restriction whatsoever
upon any of the material properties or assets of 3DP or an acceleration of
indebtedness pursuant to any obligation, agreement or condition contained in any
material bond, debenture, note or any other evidence of indebtedness or any
material indenture, mortgage, deed of trust or any other agreement or instrument
to which 3DP is a party or by which it is bound or to which any of the material
property or assets of 3DP is subject.  No consent, approval, authorization or
other order of, or registration, qualification or filing with, any regulatory
body, administrative agency, or other governmental body in the United States or
any other person is required for the execution and delivery of the Agreement and
the valid issuance and sale of the Shares to be sold pursuant to the Agreement,
other than such as have been

                                      D-4
<PAGE>

made or obtained, and except for any post-closing securities filings or
notifications required to be made under federal or state securities laws.

          4.4  Capitalization.  The capitalization of 3DP as of September 30,
               --------------
2001 is as set forth in the most recent applicable Exchange Act Documents,
increased as set forth in the next sentence.  3DP has not issued any capital
stock since that date other than pursuant to (a) employee benefit plans
disclosed in the Exchange Act Documents, or (b) outstanding warrants, options or
other securities disclosed in the Exchange Act Documents.  Except as set forth
in or contemplated by the Exchange Act Documents, there are no outstanding
rights (including, without limitation, preemptive rights), warrants or options
to acquire, or instruments convertible into or exchangeable for, any unissued
shares of capital stock or other equity interest in 3DP, or any contract,
commitment, agreement, understanding or arrangement of any kind to which 3DP is
a party or of which 3DP has knowledge and relating to the issuance or sale of
any capital stock of 3DP, any such convertible or exchangeable securities or any
such rights, warrants or options.  No further approval or authorization of any
stockholder, the Board of Directors of 3DP or others is required for the
issuance and sale of the Shares.  Except as disclosed in the Exchange Act
Documents, there are no stockholder agreements, voting agreements or other
similar agreements with respect to the capital stock of 3DP to which 3DP is a
party or, to the knowledge of 3DP, between or among any of 3DP's stockholders.

          4.5  Legal Proceedings.  There is no material legal or governmental
               -----------------
proceeding pending or, to the knowledge of 3DP, threatened to which 3DP is or
may be a party or of which the business or property of 3DP is subject that is
required to be disclosed and that is not so disclosed in the Exchange Act
Documents. To the knowledge of 3DP, there are no facts which, if known by a
potential claimant, governmental authority or self regulatory organization,
would give rise to a claim or proceeding which would be reasonably likely to
have a Material Adverse Effect.

          4.6  No Violations.  3DP is not in violation of its charter, bylaws,
               -------------
or other organizational document, or in violation of any law, administrative
regulation, ordinance or order of any court, self regulatory organization or
governmental agency, arbitration panel or authority applicable to 3DP, which
violation, individually or in the aggregate, would be reasonably likely to have
a Material Adverse Effect, or in default (and there exists no condition which,
with the passage of time or otherwise, would constitute a default) in any
material respect in the performance of any bond, debenture, note or any other
evidence of indebtedness in any indenture, mortgage, deed of trust or any other
material agreement or instrument to which 3DP is a party or by which 3DP is
bound or by which the properties of 3DP are bound, which would be reasonably
likely to have a Material Adverse Effect.

          4.7  Intellectual Property.  Except as specifically disclosed in the
               ---------------------
Exchange Act Documents (a) 3DP owns or possesses sufficient rights to use all
material patents, patent rights, trademarks, copyrights, licenses, inventions,
trade secrets, trade names, know-how, confidential information and other
intellectual property (collectively, "Intellectual Property") described or
                                      ---------------------
referred to in the Exchange Act Documents as owned or possessed by it or that
are necessary for the conduct of its

                                      D-5
<PAGE>

business as now conducted or as proposed to be conducted as described in the
Exchange Act Documents except where the failure to currently own or possess such
Intellectual Property would not have a Material Adverse Effect, (b) 3DP is not,
to its knowledge, infringing, and has not received any notice of, nor has any
knowledge of, any asserted infringement by 3DP of, any rights of a third party
with respect to any Intellectual Property that, individually or in the
aggregate, would have a Material Adverse Effect and (c) 3DP has not received any
notice of, or has any knowledge of, infringement by a third party with respect
to any Intellectual Property rights of 3DP that, individually or in the
aggregate, would have a Material Adverse Effect.

          4.8  Financial Statements; Accountants.  The financial statements of
               ---------------------------------
3DP and the related notes contained in the Exchange Act Documents present fairly
in all material respects the financial position of 3DP as of the dates
indicated, and the results of its operations and cash flows for the periods
therein specified, and such financial statements have been prepared in
accordance with generally accepted accounting principles applied on a consistent
basis throughout the periods specified therein, except as may be included in the
notes to such financial statements, or in the case of unaudited financial
statements, as may be permitted by the rules of the SEC for Form 10-Q under the
Exchange Act and except as disclosed in the Exchange Act Documents.  Arthur
Andersen LLP and Richard A. Eisner & Company, LLP, who 3DP expects will consent
to the inclusion in the Registration Statement of its opinion with respect to
the financial statements to be incorporated by reference from 3DP's Annual
Report on Form 10-K for the year ended December 31, 2001 into the Registration
Statement and the prospectus which forms a part thereof, are independent
accountants as required by the Securities Act and the rules and regulations
promulgated thereunder.

          4.9  No Material Adverse Change.  Except as disclosed in the Exchange
               --------------------------
Act Documents, since September 30, 2001, there has not been (a) any material
adverse change in the financial condition, or results of operations of 3DP, (b)
any material adverse event affecting 3DP, (c) any material obligation, direct or
contingent, incurred by 3DP, except obligations incurred in the ordinary course
of business, (d) any dividend or distribution of any kind declared, paid or made
on the capital stock of 3DP, or (e) any loss or damage (whether or not insured)
to the physical property of 3DP which has been sustained that is material to
3DP.

          4.10  Nasdaq Compliance.  3DP's Common Stock is registered pursuant to
                -----------------
Section 12(g) of the Exchange Act and is listed on the Nasdaq National Market of
The Nasdaq Stock Market, Inc. (the "Nasdaq National Market"), and 3DP has taken
                                    ----------------------
no action designed to, or likely to have the effect of, terminating the
registration of the 3DP Common Stock under the Exchange Act or de-listing the
3DP Common Stock from the Nasdaq National Market, nor has 3DP received any
notification that the SEC or the National Association of Securities Dealers,
Inc. ("NASD") is contemplating terminating such registration or listing.
       ----

          4.11  Reporting Status.  3DP has filed in a timely manner all
                ----------------
documents that 3DP was required to file under the Exchange Act during the 12
months preceding the date of this Agreement.  3DP's Exchange Act Documents
complied in all material respects with the SEC's requirements as of their
respective filing dates, and the information contained therein as of the date
thereof, and such information, taken as a whole as of the date hereof, did not
contain an untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein in
light of

                                      D-5
<PAGE>

the circumstances under which they were made not misleading. 3DP is eligible to
register the resale of the Shares on a registration statement on Form S-3 under
the Act.

          4.12  Listing.  3DP will comply with all of the requirements of the
                -------
NASD with respect to the issuance of the Shares and the listing thereof on the
Nasdaq National Market.

          4.13  Private Offering.  Assuming that the representations and
                ----------------
warranties of SBC and GGL set forth in Section 5.1 are accurate, the offer and
sale of Shares pursuant to this Agreement are exempt from registration under the
Securities Act.

          4.14 Reservation of Shares.  3DP shall maintain sufficient authorized
               ---------------------
but unissued shares of 3DP Common Stock to meet its obligations to deliver the
Contingent Shares pursuant to Sections 2(b), (c), (d) and (e) under this
Agreement.

          4.15 Reporting of Public Information for Rule 144.  With a view to
               --------------------------------------------
making available the benefits of Rule 144 under the Securities Act (or any
similar or successor rule which may at any time permit the sale of the Shares to
the public without registration), 3DP agrees to (i) make and keep public
information available, as those terms are defined in Rule 144 under the
Securities Act, (ii) use its best efforts to file with the SEC in a timely
manner all reports and other documents required of 3DP under the Securities Act
and the Exchange Act, and (iii) furnish to each of SBC or GGL a copy of the most
recent annual or quarterly report of 3DP, and such other reports and documents
so filed by 3DP as each of SBC or GGL may reasonably request in availing itself
of Rule 144 (or any similar or successor rule).

     5.  Representations, Warranties and Covenants of SBC and GGL.
         --------------------------------------------------------

          5.1  Accredited Investor.  Each of SBC and GGL represents and warrants
               -------------------
to, and covenants with, 3DP that: (a) it is an "accredited investor" as defined
in Regulation D under the Securities Act and is also knowledgeable,
sophisticated and experienced in making, and is qualified to make decisions with
respect to, investments in securities presenting an investment decision like
that involved in the purchase of the Shares, including investments in comparable
companies, and has had the opportunity to request, receive, review and consider
all information that it deemed relevant in making an informed decision to
purchase the Shares; (b) it is acquiring the Initial Shares identified in
Section 2(a) of this Agreement and the right to acquire the Contingent Shares
identified in Sections 2(b), (c), (d) and (e), subject to the achievement by 3DP
of the milestones identified in those subsections and pursuant to the terms and
conditions of the License Agreement, in the ordinary course of its business and
for its own account for investment only and with no present intention of
distributing any of such Shares or any arrangement or understanding with any
other persons regarding the distribution of such Shares; (c) it will not,
directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of
(or solicit any offers to buy, purchase or otherwise acquire or take a pledge
of) any of the Shares except in compliance with the Securities Act, applicable
state securities laws and the respective rules and regulations promulgated
thereunder; and (d) it has, in connection with its decision to purchase the
number of Shares set forth in Section 2 of this Agreement, relied only upon the
Exchange Act Documents, any materials requested and received pursuant to clause
(a) above and the representations and warranties of 3DP contained herein.  Each
of SBC and GGL understands that neither this issuance nor its acquisition of the
Shares has been

                                      D-6
<PAGE>

registered under the Securities Act or registered or qualified under any state
securities law in reliance on specific exemptions therefrom, which exemptions
may depend upon, among other things, the bona fide nature of its investment
intent as expressed herein.

          5.2  Authority.  Each of SBC and GGL further represents and warrants
               ---------
to, and covenants with, 3DP that (a) it has full right, power, authority and
capacity to enter into this Agreement and to consummate the transactions
contemplated hereby and has taken all necessary action to authorize the
execution, delivery and performance of this Agreement, and (b) this Agreement
and the License Agreement constitute valid and binding obligations of each of
SBC and GGL enforceable against them in accordance with their terms, except as
enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium or similar laws affecting creditors' and contracting
parties' rights generally and except as enforceability may be subject to general
principles of equity (regardless of whether such enforceability is considered in
a proceeding in equity or at law).

          5.3  No Investment Advice.  Each of SBC and GGL understands that
               --------------------
nothing in the Exchange Act Documents, this Agreement or any other materials
presented to them in connection with the purchase and sale of the Shares
constitutes legal, tax or investment advice.  Each of SBC and GGL has consulted
such legal, tax and investment advisors as it, in its sole discretion, has
deemed necessary or appropriate in connection with its purchase of Shares.

          5.4  Limitations on Resale.  Each of SBC and GGL understand that the
               ---------------------
Shares may not be transferred unless the Shares have been registered under the
Securities Act and any applicable state securities law or, in the opinion of
counsel satisfactory to the issuer, the sale or disposition of the Shares may
lawfully be made without compliance with the registration requirements of the
Securities Act.  Except with the consent of 3DP, each of SBC and GGL will not,
directly or indirectly, offer, sell, contract to sell, pledge or otherwise
dispose of any of the Initial Shares or Contingent Shares or any interests
therein, including through short sales, swaps, derivatives or other instruments
or arrangements which have the purpose or effect of transferring the risk of
ownership of such Shares (all of the foregoing referred to herein as "Transfer")
                                                                      --------
prior to the first anniversary of (x) the Closing Date in the case of the
Initial Shares or the Contingent Shares issued pursuant to Section 2(b), or (y)
the date of achievement of the relevant milestone in the case of the Contingent
Shares issued pursuant to Sections 2(c), 2(d) or 2(e) (the "Lock Up").  In
                                                            -------
addition, until January 8, 2005, in any three-month period, neither SBC nor GGL
will Transfer any of the Initial Shares or Contingent Shares in an amount of
Shares that exceeds the greater of (i) one percent of the number of shares of
3DP Common Stock outstanding as shown by the most recent report or statement
published by 3DP, or (ii) the average weekly reported volume of trading in
shares of 3DP Common Stock on the Nasdaq National Market or such other national
securities exchange as such shares may be traded, during the four calendar weeks
preceding the date of execution of the transaction, provided, however, that the
foregoing volume limitations shall not apply to any sales by SBC or GGL pursuant
to an Underwritten Offering (as that term is defined in the Registration Rights
Agreement).  Notwithstanding the limitations set forth in this Section 5.4, each
of SBC and GGL may Transfer its Shares to an Affiliate, as such term is defined
in the License Agreement.

                                      D-7
<PAGE>

          5.5  Legends. The certificates evidencing the Shares to be delivered
               --------
to each of SBC and GGL will bear restrictive legends substantially in the
following forms as long as applicable:

     THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE TRANSFERRED,
     SOLD, ASSIGNED, PLEDGED OR OTHERWISE ENCUMBERED OR DISPOSED OF, AND NO
     LIEN, CHARGE OR OTHER ENCUMBRANCE MAY BE CREATED THEREON UNLESS SUCH
     SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
     AMENDED, AND ANY APPLICABLE STATE SECURITIES LAW, OR IN THE OPINION OF
     COUNSEL SATISFACTORY TO THE ISSUER, THE SALE OR DISPOSITION THEREOF MAY
     LAWFULLY BE MADE WITHOUT COMPLIANCE WITH THE REGISTRATION REQUIREMENTS OF
     SUCH ACT.

     THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CONTRACTUAL
     RESTRICTIONS ON TRANSFER PURSUANT TO THAT CERTAIN STOCK PURCHASE AGREEMENT
     DATED JANUARY_____, 2002 (THE "AGREEMENT") BY AND AMONG THE ISSUER,
     SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED. SUCH SHARES MAY NOT
     BE TRANSFERRED, SOLD, ASSIGNED, PLEDGED OR OTHERWISE ENCUMBERED OR DISPOSED
     OF, AND NO LIEN, CHARGE OR OTHER ENCUMBRANCE MAY BE CREATED THEREON AND THE
     ISSUER SHALL NOT BE REQUIRED TO GIVE EFFECT TO ANY ATTEMPTED SALE,
     TRANSFER, ASSIGNMENT, PLEDGE OR OTHER ENCUMBRANCE EXCEPT TO THE EXTENT SUCH
     ACTIONS ARE IN COMPLIANCE WITH THE AGREEMENT.

     6.  Survival of Representations, Warranties and Agreements.
         ------------------------------------------------------
Notwithstanding any investigation made by any party to this Agreement, all
covenants, agreements, representations and warranties made by 3DP, SBC and GGL
herein will survive the execution of this Agreement, the delivery to SBC and GGL
of the Shares being purchased and the payment therefor, provided, however, that
such representations and warranties need only be accurate as of the date of such
execution and delivery as of the Closing Date.

     7.  Registration of the Shares.  The parties shall enter into a
         --------------------------
Registration Rights Agreement dated the date hereof in substantially the form
attached hereto as Exhibit A with respect to the Shares.

                                      D-8
<PAGE>

     8.  Conditions of SBC's and GGL's Obligations .  The obligations of SBC and
         ------------------------------------------
GGL under the License and this Agreement to purchase the Shares from 3DP are
subject to the fulfillment on or before the Closing Date of each of the
following conditions, any of which may be waived in writing by SBC or GGL:

          8.1  Representation and Warranties.  The representation and warranties
               -----------------------------
of 3DP contained in this Agreement shall be true and correct on and as of the
Closing Date with the same effect as though such representations and warranties
had been made as of the Closing Date, except to the extent of changes caused by
the transactions expressly contemplated herein.

          8.2  Performance of Obligations.  3DP shall have performed and
               --------------------------
complied in all material respects with all agreements, obligations and
conditions contained in the License Agreement and this Agreement that are
required to be performed or complied with by it on or before the Closing Date.

          8.3  Compliance with Law.  On the Closing Date, the issuance by 3DP of
               --------------------
the Shares and the execution of the License Agreement by SBC and GGL shall be
legally permitted by all laws and regulations to which 3DP, SBC and GGL are
subject and no preliminary or permanent injunction or other order by any court
of competent jurisdiction prohibiting or otherwise restraining such acquisition
shall be in effect.

          8.4  The License Agreement.  The License Agreement shall be in full
               ---------------------
force and effect and shall not have been terminated by any of the parties
thereto nor shall any of the parties given notice of such termination.

          8.5  Opinion of Legal Counsel.  SBC and GGL shall have received an
               ------------------------
opinion of Morgan Lewis & Bockius, LLP, counsel to 3DP, with respect to the
matters in Sections 4.1, 4.2, and 4.3 herein, dated as of the Closing Date and
in form and substance reasonably acceptable to SBC and GGL.

     9.  Conditions to 3DP's Obligations.  3DP's obligations under this
         -------------------------------
Agreement to sell and issue the Shares to SBC and GGL are subject to the
fulfillment on or before the Closing Date of each of the following conditions,
any of which may be waived in writing by 3DP:

          9.1  Representations and Warranties. The representation and warranties
               --------------------------------
of SBC and GGL contained in the License Agreement and this Agreement shall be
true and correct on and as of the Closing Date with the same effect as though
such representations and warranties had been made as of the Closing Date, except
to the extent of changes caused by the transactions expressly contemplated
herein.

          9.2.  Performance of Obligations. Each of SBC and GGL shall have
                --------------------------
performed and complied in all material respects with all agreements, obligations
and conditions contained in the License Agreement and this Agreement that are
required to be performed or complied with by it on or before the Closing Date.

                                      D-9
<PAGE>

          9.3.  Compliance with Law.  On the Closing Date, the issuance by 3DP
                --------------------
of the Shares and the execution of the License by SBC and GGL shall be legally
permitted by all laws and regulations to which 3DP and SBC and GGL are subject
and no preliminary or permanent injunction or other order by any court of
competent jurisdiction prohibiting or otherwise restraining such acquisition
shall be in effect.

          9.4.  The License Agreement.  The License Agreement shall be in full
                ---------------------
force and effect and shall not have been terminated by any of the parties
thereto nor shall any of the parties given notice of such termination.

          9.5  The Registration Rights Agreement.  The parties shall have
               ----------------------------------
executed the Registration Rights Agreement as set forth in Section 7.

     10.  Notices.  All notices, requests, consents and other communications
          -------
hereunder will be in writing, will be mailed (a) if within the United States by
first-class registered or certified airmail, or nationally recognized overnight
express courier, postage prepaid, by facsimile or e-mail, or (b) if delivered
from outside the United States, by international express courier, facsimile or
e-mail.  All such notices will be deemed given (a) if delivered by first-class
registered or certified mail, three business days after so mailed, (b) if
delivered by nationally recognized overnight carrier, one business day after so
mailed, (c) if delivered by International Federal Express, two business days
after so mailed, and (d) if delivered by facsimile or e-mail, upon electronic
confirmation of receipt and will be delivered as addressed as follows:

          (a)  If to 3DP, to:  3-Dimensional Pharmaceuticals, Inc.
                               Three Lower Makefield Corporate Center
                               1020 Stony Hill Road
                               Yardley, PA 19067

                               Attn:  David C. U'Prichard, Ph.D
                                      Chief Executive Officer
                               Fax: (267) 757-7204   ___

          (b)  With a copy to: Morgan Lewis & Bockius LLP

                    After January 18, 2002
                    ----------------------
                    111 Pennsylvania Ave., NW
                    Washington, DC 20004
                    Fax: (202) 739-3001

                                     D-11
<PAGE>

                    Attn: Edward T. Lentz, Esq. and Linda Griggs, Esq.

                    Before January 18, 2002
                    -----------------------
                    1800 M Street, N.W.
                    Washington, D.C. 20036
                    Fax:  (202) 467-7176
                    Attn: Edward T. Lentz, Esq. and Linda Griggs, Esq.

          (c)  If to the Licensors, to:
                         GlaxoSmithKline
                         1250 Collegeville Road
                         Collegeville, PA  19426-0989
                         Attn:  Mr. Osagie Imasogie
                                V.P. and Director,
                                Genetics and Discovery Ventures
                         Fax: (610) 917-4234

          (d)  With a copy to:.  GlaxoSmithKline
                                 Corporate Law Department
                                 One Franklin Plaza
                                 200 North 16th Street/FP2355
                                 Philadelphia, PA  19102
                                 Attn: General Counsel
                                 Fax:   (215) 751-3935

     11.  Changes.  This Agreement may not be modified or amended except
          -------
pursuant to an instrument in writing signed by 3DP and each of SBC and GGL.

     12.  Headings.  The headings of the various sections and subsections of
          --------
this Agreement have been inserted for convenience of reference only and will not
be deemed to be part of this Agreement and do not affect its interpretation.

     13.  Severability.  In case any provision contained in this Agreement
          ------------
should be invalid, illegal or unenforceable in any respect, the validity,
legality and enforceability of the remaining provisions contained herein will
not in any way be affected or impaired thereby.

     14.  Successors and Assigns.  This Agreement shall be binding upon and
          ----------------------
inure to the benefit of the successors in interest of the respective parties.
Neither this Agreement nor any interest under this Agreement shall be assignable
by either party without the written consent of the other; provided, however,
that either party may assign this Agreement without the written consent of the
other party to any

                                     D-11
<PAGE>

corporation with which it may merge or consolidate, or to which it may transfer
all or substantially all of its assets; provided, further, that SBC or GGL may
assign this Agreement without the written consent of 3DP to an Affiliate;
provided, further, that, in any case, any such assignee shall agree to be bound
by the terms and conditions of this Agreement.

     15.  Governing Law.  This Agreement will be governed by, and construed in
          -------------
accordance with, the internal laws of the State of Pennsylvania, without giving
effect to the principles of conflicts of law.

     16.  Entire Agreement.  This Agreement, together with the License Agreement
          ----------------
and Registration Rights Agreement, constitutes the entire agreement between the
parties relating to the subject matter hereof and no party shall be liable or
bound to the other in any manner by any warranties, representations or covenants
except as specifically set forth herein.

     17  Counterparts.  This Agreement may be executed in two or more
         ------------
counterparts, each of which will constitute an original, but all of which, when
taken together, will constitute but one instrument, and will become effective
when one or more counterparts have been signed by each party hereto and
delivered to the other parties.

                                     D-12
<PAGE>

     IN WITNESS WHEREOF the parties have executed this Agreement effective as of
the day and year first above written.

3-DIMENSIONAL PHARMACEUTICALS, INC.

BY:
    -----------------------------------

TITLE:
       --------------------------------

SMITHKLINE BEECHAM CORPORATION

BY:
    -----------------------------------

TITLE:
       --------------------------------

GLAXO GROUP LIMITED

BY:
    -----------------------------------

TITLE:
       --------------------------------

                                     D-13
<PAGE>

                         REGISTRATION RIGHTS AGREEMENT

     THIS REGISTRATION RIGHTS AGREEMENT (the "Agreement") is made and entered
into as of this ____th day of January 2002 between 3-Dimensional
Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and SmithKline
Beecham Corporation, a Pennsylvania corporation ("SBC"), and Glaxo Group
Limited, a company incorporated in England and Wales ("GGL" and, together with
SBC, the "Licensors").

                                    RECITALS

     WHEREAS, the Company and the Licensors are entering into a Stock Purchase
Agreement (the "Stock Purchase Agreement") and a License Agreement (the "License
Agreement") simultaneously with the execution of this Agreement;

     WHEREAS, pursuant to the Stock Purchase Agreement, the Company has
authorized the issuance and sale of up to 2,400,000 shares of common stock, par
value $.001 per share (the "3DP Common Stock"), in equal amounts to SBC and GGL
in accordance with the terms of the Stock Purchase Agreement and the License
Agreement; and

     WHEREAS, as a condition of entering into the Stock Purchase Agreement the
Licensors have requested that the Company extend to them certain registration
rights and other rights as set forth below.

     NOW, THEREFORE, in consideration of the mutual covenants contained herein
and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties to this Agreement, intending to be legally
bound, hereby agree as follows:

     1. DEFINITIONS.  For the purposes of this Agreement:

     "Affiliate" of any specified Person, as defined below, means any other
Person, as defined below, that, directly or indirectly, is in control of, is
controlled by or is under common control with such specified Person.  For
purposes of this definition, control of a Person means the power, direct or
indirect, to direct or cause the direction of the management and policies of
such Person, whether by contract or otherwise; and the terms "controlling" and
"controlled" have meanings correlative to the foregoing.

     "Commission" means the U.S. Securities and Exchange Commission.

     "Exchange Act" means the Securities Exchange Act of 1934, as amended, or
any successor federal statute and the rules and the regulations of the
Commission promulgated thereunder, as in effect from time to time.

                                     D-14
<PAGE>

     "Existing Holder" means each "Holder" of "the Registrable Securities, as
defined below, of 3DP as those terms are defined in the Stockholders' Agreement,
as defined below.

     "Investors" means the investors listed on Schedule 1 to the Stockholders'
Agreement, as defined below.

     "Lock Up" has the meaning set forth in Section 5.4 of the Stock Purchase
Agreement.

     "Nasdaq" means the Nasdaq National Market of The Nasdaq Stock Market.

     "Person" means an individual, partnership, limited partnership,
corporation, trust, limited liability company or unincorporated organization or
other entity or organization, including a government or agency or political
subdivision thereof.

     "Prospectus" means the prospectus (including any preliminary prospectus,
any final prospectus and any prospectus that discloses information previously
omitted from a prospectus filed as part of an effective Registration Statement,
as defined below, in reliance upon Rule 430A under the Securities Act, as
defined below) included in a Registration Statement, as amended or supplemented
by any prospectus supplement with respect to the terms of the offering of any
portion of the Registrable Shares covered by a Registration Statement, and by
all other amendments and supplements to such prospectus, including all material
incorporated by reference in such prospectus and all documents filed after the
date of such prospectus by the Company under the Exchange Act and incorporated
by reference therein.

     "Registrable Shares" means the 2,400,000 shares of 3DP Common Stock
(subject to adjustment as provided in Section 2.1 of the Stock Purchase
Agreement) that the Company has agreed to sell to the Licensors pursuant to the
terms and conditions of the Stock Purchase Agreement, excluding such shares of
3DP Common Stock (i) which have been registered and sold under the Securities
Act pursuant to an effective registration statement or (ii) that are held by the
Licensors and can be sold to the public pursuant to Rule 144 under the
Securities Act without restriction.

     "Registration Expenses" means all expenses incident to the Company's
compliance with the requirements relating to the filing of a Registration
Statement registering the Registrable Shares pursuant to this Agreement,
including all registration, filing and Nasdaq fees, all fees and expenses of
complying with securities or "blue sky" laws, all word-processing, duplicating
and printing expenses, messenger and delivery expenses, the fees and
disbursements of counsel for the Company and of its independent public
accountants, including the expenses of any special audits or "comfort" letters
required by or incident to such performance and compliance, premiums and other
costs of policies of insurance obtained by the Company against liabilities
arising out of the public offering of the Registrable Shares being registered,
but excluding fees and disbursements of counsel retained by the Licensors,
premiums and other costs of policies of insurance obtained by the Licensors or
their agents or Underwriters, as defined below, against liabilities arising out
of the public offering of the Registrable Shares being registered, any fees and

                                     D-15
<PAGE>

disbursements of Underwriters and all underwriting discounts and commissions
and transfer taxes, if any, relating to the Registrable Shares.

     "Registration Statement" means a registration statement filed under the
Securities Act, as defined below, by the Company pursuant to the provisions of
Section 2 or 3 of this Agreement, including the Prospectus contained in such
registration statement, any amendments and supplements to such registration
statement, including post-effective amendments, and all exhibits and all
material incorporated by reference into such registration statement.

     "Securities Act" means the Securities Act of 1933, as amended, or any
successor federal statute, and the rules and regulations of the Commission
promulgated thereunder, as in effect from time to time.

     "Stockholders' Agreement" means the Third Amended and Restated
Stockholders' Agreement between the Company and the Investors dated as of March
31, 2000.

     "Underwriter" means the underwriter(s) of the Registrable Shares designated
by the Licensors, with respect to a Registration Statement filed pursuant to
Section 2 or 3 of this Agreement.

     "Underwritten Offering" means an offering of shares of 3DP Common Stock,
including the Registrable Shares, by which the shares of 3DP Common Stock are
sold to an underwriter for reoffering to the public.

     2. DEMAND REGISTRATION.

     (a) REQUEST FOR DEMAND REGISTRATION.  Subject to the provisions of Section
         2(c) of this Agreement, the registration rights of the Existing Holders
         set forth in the Stockholders' Agreement and the limitations on
         transfer contained in Section 5.4 of the Stock Purchase Agreement, at
         any time after the Lock Up, the Licensors will have the right to
         require the Company to register for offer and sale under the Securities
         Act all or a portion, [*        *], of the Registrable Shares then
         outstanding.  To exercise this right, the Licensors must provide the
         Company with a joint written request specifying the number of the
         Registrable Shares that they want the Company to register and the
         Licensors' intended method(s) of distribution.  If desired, the
         Licensors will be entitled to select one or more nationally recognized
         investment banks to serve as Underwriters for an Underwritten Offering
         made pursuant to this Section 2, subject to the approval of the
         Company, which approval will not be unreasonably withheld or delayed.
         The Licensors acknowledge that the Company may include in a
         Registration Statement filed pursuant to this Section 2 shares of 3DP
         Common Stock for resale by other holders of 3DP Common Stock, including
         the Existing Holders, or for the account of the Company; provided,
         however, that if the shares of 3DP Common Stock included by the Company
         and the Existing Holders

                                     D-16
<PAGE>

         constitute at least a majority of the shares of 3DP Common Stock
         included on a Registration Statement filed pursuant to this Section 2,
         such Registration Statement will be deemed to be filed pursuant to
         Section 3 of this Agreement.

     (b)  ALLOCATION OF UNDERWRITTEN OFFERING. If the Company files a
          Registration Statement at the request of the Licensors pursuant to
          this Section 2 to register the Registrable Shares for an Underwritten
          Offering and includes in such Registration Statement additional shares
          of 3DP Common Stock for sale by the Company (the "Company Shares"),
          any of the Existing Holders (the "Existing Holders' Shares") or any
          other holders of 3DP Common Stock (the "Other Holders' Shares") and
          the total number of shares of 3DP Common Stock proposed to be included
          in such Registration Statement will, in the opinion of the Underwriter
          selected by the Licensors, exceed the maximum number of shares of 3DP
          Common Stock that can be marketed either at a price reasonably related
          to the then-current market value of the shares, or without otherwise
          materially and adversely affecting the Underwritten Offering, then the
          Company will exclude from such Underwritten Offering in such amount as
          necessary, in the opinion of the Underwriter(s), to successfully
          complete the Underwritten Offering (i) first, the Other Holders'
          Shares, if any, and (ii) second, the Registrable Shares, the Company
          Shares, and the Existing Holders' Shares, on a pro rata basis based on
          the number of shares of 3DP Common Stock sought to be included in the
          Registration Statement by the Licensors, the Company and the Existing
          Holders.

     (c)  OBLIGATION TO EFFECT DEMAND REGISTRATION.  Following receipt of any
          notice from the Licensors pursuant to Section 2(a), the Company shall
          use its reasonable best efforts to file a Registration Statement to
          register under the Securities Act, for public sale in accordance with
          the method(s) of disposition specified in such notice, the number of
          the Registrable Shares specified in such notice.  The Company shall be
          obligated to register the Registrable Shares on [*      *] in
          connection with requests made by the Licensors pursuant to Section
          2(a); provided, however, that the Licensors must make such requests on
          a joint basis and provided further, however, that such obligation to
          effect the registration shall be deemed satisfied, subject to Section
          2(d) below, only when a Registration Statement covering all of the
          Registrable Shares specified in notices received pursuant to Section
          2(a) shall have become effective.

     (d)  RIGHT TO WITHDRAW REGISTRATION STATEMENT.  The Licensors may request
          that the Company rescind or withdraw a Registration Statement filed
          pursuant to this Section 2, by giving written notice to the Company,
          with the following consequences: (i) if the Registration Statement is
          rescinded prior to being filed with the Commission, such rescinded
          Registration Statement shall not be counted as a Registration
          Statement requested pursuant to this Section 2 for purposes of Section
          2(c); and (ii) if the Registration Statement is withdrawn after being
          filed with the Commission but prior to

                                     D-17
<PAGE>

          becoming effective, such withdrawn Registration Statement will not be
          counted as a Registration Statement for purposes of Section 2(c) if
          the Licensors (A) have reimbursed the Company for all out-of-pocket
          expenses, including Registration Expenses, reasonably incurred by the
          Company with respect to such withdrawn Registration Statement or (B)
          reasonably believed that the Registration Statement contained an
          untrue statement of a material fact or omitted to state a material
          fact required to be stated therein or necessary to make the statements
          made therein not misleading, notified the Company of such belief and
          requested that the Company correct the alleged misstatement or
          omission but the Company refused to correct such alleged misstatement
          or omission.

     (e) ADDITIONAL LIMITATIONS ON DEMAND REGISTRATION.  The Company will not be
         obligated to file a Registration Statement pursuant to this Section 2:
         (i) until after 90 days after the effective date of the first
         registration statement filed by the Company at the request of the
         Existing Holders pursuant to Section 6.1 of the  Stockholders'
         Agreement (provided that such restriction shall not apply if the
         Company's obligations under Section 6.1 of the Stockholders' Agreement
         have been terminated pursuant to Section 6.13 of the Stockholders'
         Agreement); (ii) more than one time in any twelve-month period; (iii)
         if the Company has sent notice to the Licensors pursuant to Section
         3(a) of this Agreement that it proposes to file a registration
         statement to register shares of 3DP Common Stock and is diligently
         pursuing such registration; (iv) during any period in which a
         distribution of shares of 3DP Common Stock is ongoing or any other
         registration statement pursuant to which shares of 3DP Common Stock are
         to be or were sold (other than a registration statement filed for the
         offer or sale of 3DP Common Stock under a shelf registration statement
         on Form S-3 (except during a distribution of shares of 3DP Common Stock
         under such shelf registration statement), or an employee benefit plan,
         dividend reinvestment plan or rights plan or on Form S-8 or S-4 or any
         successor forms) has been filed and not withdrawn or has been declared
         effective within the prior 90 days; (v) during any period when the
         Company is precluded from selling any shares of 3DP Common Stock as a
         result of an agreement made in connection with a firm commitment
         underwriting; or (vi) during any time when the Company has determined
         in good faith that the filing of a Registration Statement would require
         the disclosure of material information which the Company has a bona
         fide reason to maintain as confidential; provided, however, that any
         such delay shall not exceed 60 days.

     (f)  EFFECTIVENESS.  The Company will use its reasonable best efforts,
          subject to receipt of all necessary information from the Licensors (or
          any Affiliate of the Licensors who is assigned registration rights
          pursuant to this Agreement), to cause any Registration Statement filed
          pursuant to this Section 2 to become effective and to maintain the
          effectiveness of any such Registration Statement to enable the
          Licensors to sell the Registrable Shares included in any such
          Registration Statement on a delayed or continuous basis as permitted
          by Rule 415 under the Securities Act, and from time to time

                                     D-18
<PAGE>

          will amend or supplement such Registration Statement and the
          Prospectus contained therein as and to the extent necessary to comply
          with the Securities Act and any applicable state securities statute or
          regulation; provided, however, that the Company will not be obligated
          to maintain the effectiveness of such Registration Statement once the
          Registrable Shares included in the Registration Statement no longer
          meet the definition of the Registrable Shares.

     3. PIGGYBACK REGISTRATION.

     (a)  REQUEST FOR PIGGYBACK REGISTRATION.  If the Company at any time
          proposes to register shares of 3DP Common Stock under the Securities
          Act for sale to the public, whether for its own account or for the
          account of other holders of 3DP Common Stock, including the Existing
          Holders, or both (other than registration statements filed for the
          offer or sale of 3DP Common Stock under an employee benefit plan,
          dividend reinvestment plan or rights plan or on Form S-8 or S-4 or any
          successor forms), each such time it will give written notice to the
          Licensors of its intention to do so.  Upon the written request of the
          Licensors, which request must (i) specify the number of the
          Registrable Shares that the Licensors want included on such
          registration statement and the intended method(s) of disposition of
          the Registrable Shares and (ii) be given to the Company within ten
          (10) calendar days of the date of the Company's notice, the Company
          will use reasonable best efforts to cause such the Registrable Shares
          to be included in the registration statement proposed to be filed by
          the Company subject to the allocation provisions set forth in
          paragraph (b) or (c) of this Section 3.

     (b)  ALLOCATION OF UNDERWRITTEN OFFERING INITIATED BY THE COMPANY.  If the
          Company initiates the filing of a registration statement for an
          Underwritten Offering and the total number of shares of 3DP Common
          Stock proposed to be included in such registration statement will, in
          the opinion of the managing underwriter(s) selected by the Company,
          exceed the maximum number of shares of 3DP Common Stock that can be
          marketed either at a price reasonably related to the then-current
          market value of the shares, or without otherwise materially and
          adversely affecting the Underwritten Offering, then the Company will
          exclude from such Underwritten Offering in such amount as necessary,
          in the opinion of the managing underwriter(s), to successfully
          complete the Underwritten Offering (i) first, the Other Holders'
          Shares, if any (ii) second, the Registrable Shares, and (iii) third,
          the Existing Holders' Shares, if any.

     (c) ALLOCATION OF UNDERWRITTEN OFFERING INITIATED BY THE EXISTING HOLDERS.
         If the Existing Holders initiate the filing of a registration statement
         for an Underwritten Offering pursuant to Section 6.1 of the
         Stockholders' Agreement and the total number of shares of 3DP Common
         Stock proposed to be included in such registration

                                     D-19
<PAGE>

         statement will, in the opinion of the managing underwriter(s) selected
         by such Existing Holders, exceed the maximum number of shares of 3DP
         Common Stock that can be marketed either at a price reasonably related
         to the then-current market value of the shares, or without otherwise
         materially and adversely affecting the Underwritten Offering, then the
         Company will exclude from such Underwritten Offering in such amount as
         necessary, in the opinion of the managing underwriter(s), to
         successfully complete the Underwritten Offering (i) first, the Other
         Holders' Shares, if any, and (ii) second, the Registrable Shares and
         the Company Shares on a pro rata basis based on the number of shares of
         3DP Common Stock sought to be included in the Registration Statement by
         the Licensors and the Company.

     4. REGISTRATION PROCEDURES.  If and whenever the Company is under an
obligation pursuant to this Agreement to use its reasonable best efforts to file
a Registration Statement for the Registrable Shares, the following provisions
will apply:

     (a)  The Company will furnish to the Licensors, at least five (5) business
          days prior to the time that the Registration Statement is declared
          effective by the Commission, a copy of the Registration Statement
          initially filed with the Commission and will furnish to the Licensors
          copies of each amendment thereto and each amendment or supplement, if
          any, to the Prospectus included therein as promptly as practicable
          after the filing thereof.

     (b)  Subject to Section 2(e) of this Agreement, the Company will use its
          reasonable best efforts to promptly take such action as may be
          reasonably necessary so that (i) the Registration Statement, when it
          becomes effective, and any amendment thereto and the Prospectus
          forming part thereof and any amendment or supplement thereto (and, in
          each case, every report or other document incorporated therein by
          reference), comply in all material respects with the Securities Act
          and the Exchange Act, as applicable, and the respective rules and
          regulations thereunder, (ii) the Registration Statement and any
          amendment thereto do not, when the Registration Statement or the
          amendment becomes effective, contain an untrue statement of a material
          fact or omit to state a material fact required to be stated therein or
          necessary to make the statements therein not misleading and (iii) the
          Prospectus forming part of the Registration Statement, and any
          amendment or supplement to such Prospectus, do not, at any time during
          any period during which the Company is required to keep the
          Registration Statement continuously effective pursuant to this
          Agreement, include an untrue statement of a material fact or omit to
          state a material fact necessary in order to make the statements
          therein, in the light of the circumstances under which they were made,
          not misleading, provided that the Licensors provide to the Company the
          information about the Licensors required to be included in the
          Prospectus.

                                     D-20
<PAGE>

     (c)  The Company will, promptly upon learning of any of the following
          events, advise the Licensors, and will confirm such advice in writing
          if so requested by the Licensors:

          (i)   when the Registration Statement and any amendment thereto have
                been filed with the Commission and when the Registration
                Statement or any post-effective amendment thereto has become
                effective;

          (ii)  of any request by the Commission for amendments or supplements
                to the Registration Statement or the Prospectus included therein
                or for additional information;

          (iii) of the issuance by the Commission of any stop order suspending
                the effectiveness of the Registration Statement or the
                initiation of any proceedings for such purpose;

          (iv)  of the receipt by the Company of any notification with respect
                to the suspension of the qualification of the Registrable Shares
                included in the Registration Statement for sale in any
                jurisdiction or the initiation of any proceeding for such
                purpose; and

          (v)   following the effectiveness of any Registration Statement, of
                the happening of any event or the existence of any facts that
                requires the making of any changes in the Registration Statement
                or the Prospectus included therein so that such Registration
                Statement and Prospectus do not contain an untrue statement of a
                material fact and do not omit to state a material fact required
                to be stated therein or necessary to make the statements therein
                (in the case of the Prospectus, in the light of the
                circumstances under which they were made) not misleading (which
                advice will be accompanied by an instruction to the Licensors to
                suspend the use of the Prospectus until the requisite changes
                have been made, which instruction the Licensors agree to
                follow). At the request of the Licensors, the Company will
                prepare a supplement or amendment to the Registration Statement
                or the Prospectus so that as of the date of such amendment or
                supplement the amended or supplemented Registration Statement
                and Prospectus do not contain an untrue statement of a material
                fact and do not omit to state a material fact required to be
                stated therein or necessary to make the statements therein (in
                the case of the Prospectus, in the light of the circumstances
                under which they were made) not misleading.

     (d) The Company will promptly notify the Licensors of its receipt of any
         notification of any stop order issued by the Commission suspending the
         effectiveness of the Registration Statement.

                                     D-21
<PAGE>

     (e)  The Company will furnish to the Licensors, without charge, at least
          one copy of the Registration Statement and any post-effective
          amendments and supplements thereto, including financial statements and
          schedules and, if the Licensors so request in writing, all reports,
          other documents and exhibits that are filed with or incorporated by
          reference into the Registration Statement.

     (f)  The Company will, during the period during which the Company is
          required to keep a Registration Statement continuously effective
          pursuant to this Agreement, deliver to the Licensors, without charge,
          as many copies of the Prospectus (including each preliminary
          Prospectus) included in the Registration Statement and any amendment
          or supplement thereto as the Licensors may reasonably request.

     (g)  Prior to any offering of the Registrable Shares pursuant to the
          Registration Statement, the Company will use reasonable efforts to (i)
          register, qualify or cooperate with the Licensors and their counsel in
          connection with the registration or qualification of such of the
          Registrable Shares for offer and sale under the securities or "blue
          sky" laws of such jurisdictions within the United States as the
          Licensors may reasonably request, (ii) keep such registrations or
          qualifications in effect and comply with such laws so as to permit the
          continuance of offers and sales in such jurisdictions for the period
          during which the Company is required to keep the Registration
          Statement continuously effective under this Agreement and (iii) take
          any and all other actions reasonably requested by the Licensors that
          are necessary or advisable to enable the disposition in such
          jurisdictions of such Registrable Shares; provided, however, that in
          no event will the Company be obligated to qualify as a foreign
          corporation or as a dealer in securities in any jurisdiction where it
          would not otherwise be required to so qualify but for this Agreement
          or file any general consent to service of process or subject itself to
          tax in any jurisdiction where it would not otherwise be required to do
          so but for this Section 4(g).

     (h)  The Company will cooperate with the Licensors to facilitate the timely
          preparation and delivery of certificates representing the Registrable
          Shares sold pursuant to the Registration Statement, which certificates
          will comply with the requirements of Nasdaq, and which certificates
          will be free of any restrictive legends and in such permitted
          denominations and registered in such names as the Licensors may
          request in connection with the sale of the Registrable Shares pursuant
          to the Registration Statement.

     (i)  In connection with an Underwritten Offering of the Registrable Shares,
          the Company will use reasonable efforts to:

          (i)  cooperate with the Licensors and their advisors in their efforts
               to conduct appropriate due diligence as is customary for a
               company of the size and character of the Company and make such
               reasonable representations and

                                     D-22
<PAGE>

                 warranties in the applicable underwriting agreement to the
                 Underwriter, in form, substance and scope as are customarily
                 made by the Company to underwriters in secondary underwritten
                 offerings of equity;

          (ii)   make available for inspection by the Licensors, the Licensors'
                 advisors, and any attorney, accountant or other agent retained
                 by the Underwriter (collectively, the "Inspectors"), all
                 pertinent financial and other records, pertinent corporate
                 documents and properties of the Company (collectively, the
                 "Records"), as shall be reasonably necessary to enable them to
                 exercise their due diligence responsibility, and cause the
                 Company's officers, directors and employees to supply all
                 information (together with the Records, the "Information")
                 reasonably requested by any such Inspector in connection with
                 the preparation of such Registration Statement. Any of the
                 Information which the Company determines in good faith to be
                 confidential, and of which determination the Inspectors are so
                 notified, will not be disclosed by the Inspectors unless (A)
                 the disclosure of such Information is necessary to avoid or
                 correct a misstatement or omission of a material fact in the
                 Registration Statement, (B) the release of such Information is
                 ordered pursuant to a subpoena or other order from a court of
                 competent jurisdiction, or (C) such Information has been made
                 generally available to the public. The Licensors and their
                 Inspectors agree that they will, upon learning that disclosure
                 of such Information is sought in a court of competent
                 jurisdiction, give notice to the Company and allow the Company,
                 at the Company's expense, to undertake appropriate action to
                 prevent disclosure of the Information deemed confidential;

          (iii)  obtain opinions of counsel to the Company (which counsel and
                 opinions (in form, scope and substance) will be reasonably
                 satisfactory to the Underwriter) addressed to the Underwriter,
                 covering such matters that the Company customarily covers in
                 opinions requested in secondary underwritten offerings of
                 equity, to the extent reasonably required by the applicable
                 underwriting agreement;

          (iv)   obtain "comfort" letters and updates thereof from the
                 independent public accountants of the Company (and, if
                 necessary, from the independent public accountants of any
                 subsidiary of the Company or of any business acquired by the
                 Company for which financial statements and financial data are,
                 or are required to be, included in the Registration Statement),
                 addressed to the Licensors (if the Licensors have provided such
                 letter, representation or documentation, if any, required for
                 such "comfort" letter to be so addressed) and the Underwriter,
                 in customary form and covering matters of the type customarily
                 covered in "comfort" letters in connection with secondary
                 underwritten offerings of Company equity;

                                     D-23
<PAGE>

          (v)  deliver such certificates as may be reasonably requested by the
               Licensors and the Underwriter, if any, including certificates to
               evidence compliance with any conditions contained in the
               underwriting agreement or other agreements entered into by the
               Company; and

          (vi) to take all other steps reasonably necessary to effect the timely
               registration of the Registrable Shares covered by a Registration
               Statement contemplated hereby.

     5. LICENSORS' AGREEMENTS.

     (a)  The Licensors agree to provide to the Company such information
          regarding the Licensors, the Registrable Shares and the Licensors'
          intended method of disposition as the Company may from time to time
          reasonably request; provided, however, that such information shall be
          used only in connection with the filing of a Registration Statement or
          as otherwise required by the Commission.  If the Registration
          Statement refers to the Licensors, the Licensors shall promptly (i)
          notify the Company of the existence of any fact of which the
          Licensors, individually or jointly, become aware or the happening of
          any event which relates to the Licensors or the distribution of the
          Registrable Shares that causes the Registration Statement to contain
          an untrue statement of a material fact or omit to state a material
          fact required to be stated therein or necessary to make any statements
          therein not misleading, or the Prospectus included in such
          Registration Statement to contain an untrue statement of a material
          fact or omit to state a material fact required to be stated therein or
          necessary to make any statements therein, in the light of the
          circumstances under which they were made, not misleading, and (ii)
          provide to the Company such information which relates to the
          Licensors' distribution of the Registrable Shares as shall be
          necessary to enable the Company to prepare a supplement or post-
          effective amendment to such Registration Statement or related
          Prospectus or any document incorporated therein by reference or file
          any other documents required so that such Registration Statement will
          not contain any untrue statement of a material fact or omit to state a
          material fact required to be stated therein or necessary to make the
          statements therein not misleading, and such Prospectus shall not
          include an untrue statement of a material fact or omit to state a
          material fact required to be stated therein or necessary to make the
          statements therein, in the light of the circumstances under which they
          were made, not misleading.

     (b)  NOTICE TO DISCONTINUE.  The Licensors agree that, upon receipt of any
          notice from the Company to discontinue using the Prospectus, the
          Licensors will promptly discontinue the disposition of the Registrable
          Shares pursuant to the Registration Statement covering such
          Registrable Shares until the Company advises the Licensors that
          dispositions

                                     D-24
<PAGE>

          pursuant to the Registration Statement can resume and it delivers to
          the Licensors copies of any required supplemented or amended
          Prospectus.

     6. INDEMNIFICATION AND CONTRIBUTION.

     (a)  Upon the registration of the Registrable Shares pursuant to Section 2
          or 3 of this Agreement, the Company will indemnify and hold harmless
          the Licensors and each Underwriter, selling agent or other securities
          professional, if any, that facilitates the disposition of the
          Registrable Shares, and each of their respective officers and
          directors and each Person who controls the Licensors, such
          Underwriter, selling agent or other securities professional within the
          meaning of Section 15 of the Securities Act or Section 20 of the
          Exchange Act (each such Person being sometimes referred to as an
          "Indemnified Person"), against any losses, claims, damages or
          liabilities, joint or several, to which such Indemnified Person may
          become subject under the Securities Act or otherwise, insofar as such
          losses, claims, damages or liabilities (or actions in respect thereof)
          arise out of or are based upon an untrue statement or alleged untrue
          statement of a material fact contained in any Registration Statement
          under which such Registrable Shares are to be registered under the
          Securities Act, or any Prospectus contained therein or furnished by
          the Company to any Indemnified Person, or any amendment or supplement
          thereto, or arise out of or are based upon the omission or alleged
          omission to state therein a material fact required to be stated
          therein or necessary to make the statements therein not misleading,
          and the Company hereby agrees to reimburse such Indemnified Person for
          any legal or other documented expenses reasonably incurred by it in
          connection with investigating or defending any such action or claim as
          promptly as practicable after such expenses are incurred; provided,
          however, that the Company will not be liable to any such Indemnified
          Person in any such case to the extent that any such loss, claim,
          damage, liability (or action or proceeding in respect thereof) or
          expense arises out of or is based upon an untrue statement or alleged
          untrue statement or omission or alleged omission made in such
          Registration Statement or Prospectus, or amendment or supplement
          thereto, in reliance upon and in conformity with written information
          furnished to the Company by such Indemnified Person or its agent(s)
          expressly for use therein; provided further, however, that the Company
          will not be liable to the extent that any loss, claim, damage,
          liability (or action or proceeding in respect thereof) or expense
          arises out of or is based upon (i) the use of any Prospectus after
          such time as the obligation of the Company to keep the same effective
          and current has expired, or (ii) the use of any Prospectus after such
          time as the Company has advised the Licensors in writing that a
          supplement thereto or a post-effective amendment to the Registration
          Statement is required; and provided further, however, that the Company
          will not be liable to any Indemnified Person to the extent that any
          loss, claim, damage, liability (or action or proceeding in respect
          thereof) or expense arises out of such Indemnified Person's failure to
          send or give a copy of the final prospectus or supplement to the
          Person asserting an untrue statement or alleged

                                     D-25
<PAGE>

          untrue statement or omission or alleged omission at or prior to the
          written confirmation of the sale of the Registrable Shares to such
          Person if such statement or omission was timely corrected in such
          final prospectus or supplement.

     (b)  The Licensors agree, as a consequence of the inclusion of the
          Registrable Shares in a Registration Statement, and each Underwriter,
          selling agent or other securities professional, if any, that
          facilitates the disposition of the Registrable Shares will agree, as a
          consequence of facilitating such disposition of the Registrable
          Shares, severally and not jointly, to (i) indemnify and hold harmless
          the Company, its directors and officers and each Person, if any, who
          controls the Company within the meaning of either Section 15 of the
          Securities Act or Section 20 of the Exchange Act, against any losses,
          claims, damages or liabilities or expenses to which the Company or
          such other Person may become subject, under the Securities Act or
          otherwise, insofar as such losses, claims, damages, liabilities (or
          actions or proceedings in respect thereof) or expenses arise out of or
          are based upon an untrue statement or alleged untrue statement of a
          material fact contained in such Registration Statement or Prospectus,
          or any amendment or supplement thereto, or arise out of or are based
          upon the omission or alleged omission to state therein a material fact
          required to be stated therein or necessary to make the statements
          therein not misleading, in each case to the extent, but only to the
          extent, that such untrue statement or alleged untrue statement or
          omission or alleged omission was made in reliance upon and in
          conformity with written information furnished to the Company by the
          Licensors, such Underwriter, selling agent or other securities
          professional or its agent expressly for use therein, and (ii)
          reimburse the Company for any legal or other expenses reasonably
          incurred by the Company in connection with investigating or defending
          any such action or claim as such expenses are incurred.

     (c)  Promptly after receipt by any Person entitled to indemnity (an
          "Indemnitee") under paragraphs (a) or (b) of this Section 6 of notice
          of the commencement of any action or claim, such Indemnitee will, if a
          claim in respect thereof is to be made against an indemnitor under
          this Section 6 (an "Indemnitor"), notify such Indemnitor in writing of
          the commencement thereof; but the omission to so notify the Indemnitor
          will not relieve it from any liability that it may have to any
          Indemnitee except to the extent of any actual prejudice.  In case any
          such action will be brought against any Indemnitee, it will notify an
          Indemnitor of the commencement thereof, such Indemnitor will be
          entitled to participate therein and, to the extent that it wishes,
          jointly with any other Indemnitor similarly notified, to assume the
          defense thereof, with counsel satisfactory to such Indemnitee, and,
          after notice from the Indemnitor to such Indemnitee of its election so
          to assume the defense thereof, such Indemnitor will not be liable to
          such Indemnitee under this Section 6 for any legal expenses of other
          counsel or any other expenses, in each case subsequently incurred by
          such Indemnitee, in connection with the defense thereof.  No
          Indemnitor will, without the written consent of the Indemnitee, effect
          the settlement or compromise of, or

                                     D-26
<PAGE>

          consent to the entry of any judgment with respect to, any pending or
          threatened action or claim in respect of which indemnification or
          contribution may be sought hereunder (whether or not the Indemnitee is
          an actual or potential party to such action or claim) unless such
          settlement, compromise or judgment (i) includes an unconditional
          release of the Indemnitee from all liability arising out of such
          action or claim and (ii) does not include a statement as to, or an
          admission of, fault, culpability or a failure to act, by or on behalf
          of any Indemnitee.

     (d)  If the indemnification provided for in this Section 6 is held by a
          court of competent jurisdiction to be unavailable to, or insufficient
          to hold harmless, an Indemnitee under paragraphs (a) or (b) of this
          Section 6 in respect of any losses, claims, damages, liabilities (or
          actions or proceedings in respect thereof) or expenses referred to
          therein, then each Indemnitor will contribute to the amount paid or
          payable by such Indemnitee as a result of such losses, claims,
          damages, liabilities (or actions or proceedings in respect thereof) or
          expenses in such proportion as is appropriate to reflect the relative
          fault of the Indemnitor and the Indemnitee in connection with the
          statements or omissions which resulted in such losses, claims,
          damages, liabilities (or actions, or proceedings in respect thereof)
          or expenses, as well as any other relevant equitable considerations.
          The relative fault of such Indemnitor and Indemnitee will be
          determined by reference to, among other things, whether the untrue or
          alleged untrue statement of a material fact or omission or alleged
          omission to state a material fact relates to information supplied by
          such Indemnitor or by such Indemnitee, and the parties' relative
          intent, knowledge, access to information and opportunity to correct or
          prevent such statement or omission.  The parties hereto agree that it
          would not be just and equitable if contribution pursuant to this
          Section 6(d) were determined solely by pro rata allocation (even if
          the Licensors or any Underwriter, selling agents or other securities
          professionals or all of them were treated as one entity for such
          purpose) or by any other method of allocation that does not take
          account of the equitable considerations referred to in this Section
          6(d).  The amount paid or payable by an Indemnitee as a result of the
          losses, claims, damages, liabilities (or actions or proceedings in
          respect thereof) or expenses referred to above will be deemed to
          include any legal fees or expenses reasonably incurred by such
          Indemnitee in connection with investigating or defending any such
          action or claim except to the extent any legal fees are incurred after
          the Indemnitor assumes the defense of the litigation as set forth in
          Section 6(c) above.  No Person guilty of fraudulent misrepresentation
          (as used in Section 11(f) of the Securities Act) will be entitled to
          contribution from any Person who was not guilty of such fraudulent
          misrepresentation.  The obligations of the Licensors and any
          Underwriter, selling agents or other securities professionals under
          this Section 6(d) to contribute will be several in proportion to the
          percentage of the principal amount of the Registrable Shares
          registered or underwritten, as the case may be, by them and not joint.

                                     D-27
<PAGE>

The obligations of the Company under this Section 6 will be in addition to any
liability which the Company may otherwise have to any Indemnitee and the
obligations of any Indemnified Person under this Section 6 of this Agreement
will be in addition to any liability which such Indemnified Person may otherwise
have to the Company.  The remedies provided in this Section 6 are not exclusive
and will not limit any rights or remedies that may otherwise be available to an
Indemnitee at law or in equity.

     7. UNDERWRITING AGREEMENT.  Notwithstanding the provisions of Sections 4
and 6 of this Agreement, to the extent that the Licensors and the Company enter
into an underwriting or similar agreement with respect to a Registration
Statement, which agreement contains provisions covering one or more issues
addressed in Sections 4 and 6, the provisions contained in such Sections
addressing such issue or issues shall be superceded with respect to such
Registration Statement by such other agreement.

      8. EXPENSES OF REGISTRATION. [*                  *].

      9. DAMAGES.  [*                    *].

     10. MISCELLANEOUS.

     (a) NOTICES.  All notices, requests, consents and other communications
hereunder will be in writing, will be mailed (a) if within the United States, by
first-class registered or certified airmail, or nationally recognized overnight
express courier, postage prepaid, by facsimile or e-mail, or (b) if delivered
from outside the United States, by international express courier, facsimile or
e-mail.  Notwithstanding anything in this Agreement to the contrary, the
Company's obligation to deliver or give notice to the Licensors shall be
satisfied by the delivery or giving of notice to SBC.  All obligations of the
Licensors to deliver or give notice to the Company shall be satisfied by the
delivery or giving of such notice by SBC and GGL jointly.  All such notices will
be deemed given (a) if delivered by first-class registered or certified mail,
three business days after so mailed, (b) if delivered by nationally recognized
overnight carrier, one business day after so mailed, (c) if delivered by
International Federal Express, two business days after so mailed, and (d) if
delivered by facsimile or e-mail, upon electronic confirmation of receipt and
will be delivered as addressed as follows:

               (i)  If to the Company, to:

                    3-Dimensional Pharmaceuticals, Inc.
                    Three Lower Makefield Corporate Center
                    1020 Stony Hill Road
                    Yardley, PA 19067
                    Attn:  David C. U'Prichard, Ph.D
                    Chief Executive Officer
                    Fax: (267) 757-7204

                                     D-28
<PAGE>

              (ii)  With a copy to:  Morgan Lewis & Bockius LLP

                    After January 18, 2002
                    ----------------------
                    111 Pennsylvania Ave., NW
                    Washington, DC 20004
                    Fax: (202) 739-3001
                    Attn: Edward T. Lentz, Esq. and Linda Griggs, Esq.

                    Before January 18, 2002
                    -----------------------
                    1800 M Street, N.W.
                    Washington, D.C. 20036
                    Fax:  (202) 467-7176
                    Attn: Edward T. Lentz, Esq. and Linda Griggs, Esq.

              (iii) If to Licensors, to:
                    GlaxoSmithKline
                    1250 Collegeville Road
                    Collegeville, PA  19426-0989
                    Attn:  Mr. Osagie Imasogie
                    V.P. and Director
                    Genetics and Discovery Ventures
                    Fax:  (610) 917-4234

               (iv) With a copy to:  GlaxoSmithKline
                    Corporate Law Department
                    One Franklin Plaza
                    200 North 16th Street/FP2355
                    Philadelphia, PA  19102
                    Attn:  General Counsel
                    Fax:  (215) 751-5349

     (b)  CHANGES.  This Agreement may not be modified or amended except
          pursuant to an instrument in writing signed by the Company and each of
          SBC and GGL.

     (c)  HEADINGS.  The headings of the various sections and subsections of
          this Agreement have been inserted for convenience of reference only
          and will not be deemed to be part of this Agreement and do not affect
          its interpretation.

                                     D-29
<PAGE>

     (d)  SEVERABILITY.  In case any provision contained in this Agreement
          should be invalid, illegal or unenforceable in any respect, the
          validity, legality and enforceability of the remaining provisions
          contained herein will not in any way be affected or impaired thereby.

     (e)  SUCCESSORS AND ASSIGNS.  This Agreement shall be binding upon and
          inure to the benefit of the successors in interest of the respective
          parties. Neither this Agreement nor any interest under this Agreement
          shall be assignable by either party without the written consent of the
          other; provided, however, that SBC or GGL may assign this Agreement
          without the written consent of the Company to any Affiliate; provided,
          further, that any such assignee shall agree to be bound by the terms
          and conditions of this Agreement.

     (f)  GOVERNING LAW.  This Agreement will be governed by, and construed in
          accordance with, the internal laws of the State of Pennsylvania,
          without giving effect to the principles of conflicts of law.

     (g)  ENTIRE AGREEMENT.  This Agreement, together with the License Agreement
          and Stock Purchase Agreement, constitutes the entire agreement between
          the parties relating to the subject matter hereof and no party shall
          be liable or bound to the other in any manner by any warranties,
          representations or covenants except as specifically set forth herein.

     (h)  COUNTERPARTS.  This Agreement may be executed in two or more
          counterparts, each of which will constitute an original, but all of
          which, when taken together, will constitute but one instrument, and
          will become effective when one or more counterparts have been signed
          by each party hereto and delivered to the other parties.

     11.  EFFECTIVENESS.  This Agreement shall become effective as of the
Closing Date, as defined in Section 3 of the Stock Purchase Agreement.  In the
event that the Stock Purchase Agreement is terminated pursuant to its terms and
the issuance of the Shares, as defined in Section 1 of the Stock Purchase
Agreement, on the Closing Date does not occur, this Agreement shall be null and
void and of no further force and effect.

                                     D-30
<PAGE>

IN WITNESS WHEREOF the parties have executed this Agreement effective as of the
day and year first above written.

3-DIMENSIONAL PHARMACEUTICALS, INC.

BY:
    ----------------------------------

TITLE:
       -------------------------------

SMITHKLINE BEECHAM CORPORATION

BY:
    ----------------------------------

TITLE:
       -------------------------------

GLAXO GROUP LIMITED

BY:
    ----------------------------------

TITLE:
       -------------------------------

                                     D-31
<PAGE>

                               LICENSE AGREEMENT
                             GLAXOSMITHKLINE - 3DP
                                   Appendix E

                               LICENSOR Services

1. Within [*                      *] following the EFFECTIVE DATE, GSK shall
   deliver to 3DP the KNOW-HOW relating to the manufacture of GW395058 by the
   processes that were used or to be used by GSK to prepare pre-clinical,
   clinical, and commercial supplies of GW395058, including but not limited to
   manufacturing protocols, operating procedures, process controls,
   environmental issues and controls, Drug Master Files, intermediates,
   reagents, drug samples, suppliers, DMPK immunoassay protocols, indirect and
   direct costs of goods, quality assurance and quality control, stability
   testing, yields, purity, impurities, by-products, and product specifications.
   GSK shall also provide final and draft reports ("as is" as of the EFFECTIVE
   DATE) of information and data related to manufacturing GW395058 to the extent
   in GSK's possession or control. GSK shall use reasonable efforts to ensure
   that the information provided under this paragraph is all such information in
   GSK's possession or control as of the EFFECTIVE DATE.

2.  Within [*               *] following the EFFECTIVE DATE, GSK shall deliver
    to 3DP KNOW-HOW comprising:

       2.1.  the documentation relating to pre-clinical studies of GW395058
             that are listed in Appendix A;

       2.2. pre-clinical and clinical development plans for PRODUCTS;

       2.3. any other information or data that is available to GSK and that is
            reasonably believed by GSK to be necessary or useful for the
            development and marketing of PRODUCTS, including but not limited to
            Project Team Meeting Minutes.

3.  For [*                     *] following the EFFECTIVE DATE, GSK shall
    provide to 3DP such additional reports, data, and records that it has in its
    possession as of the EFFECTIVE DATE and that 3DP and GSK mutually agree are
    necessary or useful for the development or commercialization of PRODUCTS.

4.  Until [*                *], GSK shall make those of its employees who have
    relevant knowledge reasonably available to 3DP for consultation concerning
    the pre-clinical development of GW395058, previous regulatory interactions
    between GSK and the FDA relating to GW395058, and manufacturing of GW395058,
    provided such consultations shall not in the aggregate exceed [*        *]
    and further provided that GSK then

                                      E-1
<PAGE>

    currently has employees who have the experience and knowledge relating to
    PRODUCTS to be able to provide such consultation.

5.  Until [*                    *], GSK shall provide to 3DP such additional
    reports, data, and records that it has in its possession as of the EFFECTIVE
    DATE and that are requested by 3DP and that are required to respond to
    inquiries by the FDA or an analogous agency outside the U.S.

6.  All requests by 3DP for reports, data, records, and consultations pursuant
    to this Appendix E shall be directed to a person or persons that GSK may
    designate for this purpose.

                                      E-2
<PAGE>

                               LICENSE AGREEMENT
                             GLAXOSMITHKLINE - 3DP
                                   APPENDIX F

                                 Press Release
<TABLE>
<CAPTION>

Corporate Contact                  Media Inquiries               Investor Inquiries
---------------------------------  ---------------------------   ------------------
<S>                                <C>                           <C>
3-Dimensional Pharmaceuticals      Noonan/Russo Communications   Rx Communications
Scott Horvitz                      Glenn Silver                  Melody Carey
VP, Finance and Administration     212-696-4455, ext. 271        917-322-2571
267-757-7208                       g.silver@noonanrusso.com      mcarey@rxir.com
horvitz@3dp.com                    ------------------------      ---------------
----------------
</TABLE>

  FOR IMMEDIATE RELEASE
  ---------------------

                    3-DIMENSIONAL PHARMACEUTICALS licenses
                       TPO Peptide from GlaxoSmithKline

                                   ---------

Yardley, PA, January 7th, 2002 - 3-Dimensional Pharmaceuticals, Inc. (Nasdaq:
DDDP) (3DP) today announced that the Company has entered into an exclusive
licensing agreement with GlaxoSmithKline (GSK), giving it worldwide development,
marketing and distribution rights to GSK's pre-IND compound GW 395058 for the
prevention and treatment of thrombocytopenia, or low blood platelet count.   GW
395058 is a pegylated synthetic thrombopoietin (TPO) mimetic peptide that
stimulates the human body to increase its production of blood platelets, which
are responsible for regulating the clotting process.

3DP's initial development focus will be on chemotherapy induced thrombocytopenia
because of the frequency with which cancer patients undergoing certain
chemotherapy regimens experience thrombocytopenia.  The condition can prolong
blood clotting times, increase the risk of bruising, and, in extreme cases,
prompt internal hemorrhaging.  These side effects frequently disrupt cancer
treatment protocols, including delays in, and the lowering of chemotherapy
dosing regimens.

"Thrombocytopenia is the unfortunate consequence of a wide range of diseases and
disease treatments," said David U'Prichard, Ph.D., Chief Executive Officer of
3DP. "We see GW 395058 as an important addition to our rapidly growing pipeline
of treatment and supportive therapies for cancer.  In addition, we believe there
could be significant upside potential from the development of GW 395058 for
various non-cancer related indications. We are pleased that we have been able to
successfully negotiate this transaction with GSK's Genetics & Discovery Ventures
Team"

                                      F-1
<PAGE>

The current standard of care for thrombocytopenia is a platelet transfusion;
however, there are a number of potentially negative side effects associated with
this procedure.   About one third of the two million platelet transfusions
administered each year in the United States are given to cancer patients, while
the remainder are given to patients with a variety of conditions including
coronary bypass and hepatic surgery, HIV/AIDS, hepatitis B and C, and idiopathic
thrombocytopenia purpura.

Under the terms of the agreement, all payments by 3DP to GSK will be made in the
form of 3DP stock.  3DP will make an initial upfront payment of 500,000 shares
and future milestone payments based on achievement of certain key development
and regulatory events.  In total, 3DP may provide 2.4 million shares to GSK.

About 3DP

3DP (http://www.3dp.com) is an integrated bio-pharmaceuticals company dedicated
to revolutionizing small molecule drug discovery and development. 3DP's
proprietary platform, DiscoverWorks, can be applied to virtually any potential
drug target.  It produces drug candidates suitable for faster development, with
fewer resources and a higher probability of success than using conventional drug
discovery methods. 3DP is developing its own drug pipeline with a strategic
focus in the therapeutic areas of oncology and metabolism, and collaborates with
other pharmaceutical companies in discovery and development.

                                     # # #

                                      F-2
<PAGE>

                               LICENSE AGREEMENT
                             GLAXOSMITHKLINE - 3DP
                                   Appendix G

                   Exceptions to Representations and Warrants

 [* 1 entire page has been omitted pursuant to a confidential treatment
                                  request *]

                                      G-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}]]